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N-Thiolated β-Lactams: Chemistry and Biology 
of a Novel Class of Antimicrobial Agents for MRSA 
 
Timothy E. Long 
 
ABSTRACT 
 
 N-Methylthio β-lactams (1) represent a promising new family of antibacterial agents whose in 
vitro activity is confined largely to Staphylococcus species, including multidrug-resistant forms of S. 
aureus. Originally developed in the 1980’s for use as synthetic intermediates, N-methylthio β-lactams have 
recently been shown in these laboratories to possess intriguing biological properties which are addressed in 
Chapters I-IV. In terms of the antibacterial activities, the structural features and species specificities 
exhibited by these compounds are unlike those of any existing family of β-lactam drugs. The lactams seem 
to exert their effects intracellularly, requiring passage of the bioactive species through the cellular 
membrane, rather than acting extracellularly on cell wall components in the manner of penicillin and 
related antibiotics. The lipophilic nature of these molecules, which lack the polar side chain functionality of 
all other microbially-active β-lactams, suggests the compounds do not target the penicillin binding proteins 
within bacterial membranes. The most active members of this β-lactam class appear to be those bearing an 
aryl substituent (Ar) at C4 of the ring. The synthesis and structure-activity relationship of these analogues is 
discussed in Chapter III. Moreover, microscopy and 3H pulse-labeling studies, which are described in 
Chapter IV, demonstrate that N-methylthio β-lactams appear to be inhibitors of protein biosynthesis. 
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CHAPTER I 
 
CLINICAL DEVELOPMENT OF  
NEW ANTI-MRSA ANTIBIOTICS 
 
1.1 Introduction 
Methicillin-resistant Staphylococcus aureus (MRSA) is a multi-drug resistant pathogen whose 
insensitivity to most antibiotics has evolved over the span of five decades. Historically, methicillin, a 
second-generation semi-synthetic penicillin, was first introduced into hospitals in 1960 in response to the 
prominence of β-lactamase producing staphylococci. However, the bacteria rapidly adapted and in 1961, 
the first MRSA strain emerged in Cairo, Egypt.1 As MRSA continues to evolve and becomes more resistant 
to current antibiotics, the need to find new therapies grows increasingly important. This chapter focuses on 
the recent progress towards the clinical development of new antimicrobial agents for MRSA. 
 
1.2 β-Lactam Antibiotics 
 
β-Lactams (Figure 1.01) remain the most widely prescribed class of antibiotics despite the 
continuous rise in resistance that forced the penicillins and cephalosporins to undergo multiple generations 
of synthetic change. S. aureus resistance to these antibacterials stem primarily from ring cleavage by β-
lactamase and modification or overproduction of the enzymes involved in cell wall biosynthesis - 
penicillin-binding proteins (PBPs).2 In recent years, structure-activity relationship (SAR) studies of 
semisynthetic cephalosporins and penems has identified chemical functionalities that enhance binding to 
low affinity transpeptidases (ie, PBP2a) and confer resistance to β-lactamase. 
 
Figure 1.01: Familes of clinically important β-lactam antibiotics.  
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1.2.1 Cephalosporins 
 
Traditional cephalosporins are poor substrates for PBP2a and are thus considered ineffective as 
anti-MRSA agents. During the 1990s, new semisynthetic analogues emerged possessing higher affinity for 
this low binding transpeptidase combined with improved stability toward β-lactamases. The cephalosporins 
have polar, lipophilic groups at C(3) and C(7) positions of the ring which were discovered to enhance 
bioactivity and chemical stability.3 Among these, MC-02479 (RWJ-5442, Essential Therapeutics/RW 
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Johnson Pharmaceutical Research Institute; Figure 1.02, Table 1.01) and BAL-5788 (BASILEA 
Pharmaceutica AG) have since advanced to clinical trials in the US and Europe, respectively. 
 
Figure 1.02: Anti-MRSA cephalosporins in clinical development.  
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 MC-02479 is a broad spectrum cephalosporin with a C(7) 4-pyridinethiol zwitterionic moiety 
contributing to the lactam's activity and solubility.4,5 MC-02479 is equipotent to vancomycin against 256 
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MRSA strains and the binding affinity for PBP2a is reportedly 43-fold greater than imipenem. SAR studies 
of the 4-pyridinethiol series also led to the discovery of MC-04546 (RWJ-333441, Essential 
Therapeutics/RW Johnson Pharmaceutical Research Institute; Figure 1.02), an analogue with enhanced 
serum stability lending to the cephem's above-average pharmacokinetic properties in rats.6 BAL-5788, the 
water-soluble prodrug of BAL-9141 (Figure 1.02), is also an efficient substrate for PBP2a and effectively 
treated MRSA-induced endocarditis in rats.7 Furthermore, it is stable to class A and C β-lactamases, which 
is attributed to the C(7) hydroxyiminoacetamido side chain.7 Other anti-MRSA cephems bearing similar 
C(3) and C(7) substituents have also been reported. Currently, CP-6679 (Meiji Seika Kaisha Ltd; Figure 
1.02) is being developed as part of an imidazothiazolium series of cephalosporins. The compound 
possesses 88-fold greater binding ability to PBP2a than imipenem but displays only modest in vitro activity 
against MRSA.8 Another clinical trial candidate is S-3578 (Figure 1.02), a unique lipophilic cephalosporin 
exhibiting low serum binding (< 25%) while maintaining the therapeutic efficacy of vancomycin in rats 
with MRSA-induced infections.9 
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 MIC90a IC50b β-lactamase stability ED50c (mg/kg) 
MC-02479 2 0.7 Stable NR 
MC-04456 ≤ 1 0.5 Stable 1.4 
BAL-9141  2 0.5 Stable 2.4 
CP-6679  12.5 5.1 NR 12 
S-3578  4 4.42 Stable  5 to 8 
BMS-247243  5 0.7 Stable 2.0 to 3.8 
NB-2001 0.5 NR Not stable NR 
Table 1.01: In vitro and in vivo activities of anti-MRSA cephalosporins in clinical 
evelopment.4-9d
 
 a
 o
aTypical MIC90 values (minimum inhibition concentration for 90% of MRSA test strains) for 
v ncomycin and ceftriaxone are 2 and > 64 µg/ml, respectively; bTypical IC50 values (concentration 
t  inhibit 50% PBP2a activity) for imipenem are > 100 µg/ml; cED50: effective dose in 50% of mice 
or rats with systemic MRSA infection; NR: not reported or could not be found in the literature.  
 
Bristol-Myers Squibb Co is investigating a thiopyridinium series of cephalosporins without a C(7) 
imino side chain.10 In lieu of an iminoacetamide group is a dichlorothiophenyl acetamide conferring 
stability toward A to D class β-lactamases.11 As an early lead compound from this series, BMS-247243 
(Bristol-Myers Squibb Co; Figure 1.02) gave rise to other potent anti-MRSA cephalosporins bearing 
similar functionalities.11,12 SAR was disclosed in recent publications and new candidates emerged for 
further pre-clinical evaluation including cephalosporins 1 and 2 (Figure 1.02) whose average PD50 in mice 
with systemic MRSA infections is 3.9 and 0.8 mg/kg, respectively.13
 
Companies such as Cubist Pharmaceuticals Inc and BASILEA Pharmaceutica AG also boast other 
anti-MRSA cephalosporins in the late stages of clinical development. CAB-175 (Cubist Pharmaceuticals 
Inc),14 an azomethine cephalosporin, is expected to begin human trials during the first half of 2003 for the 
intravenous treatment of drug-resistant bacteria. CAB-175 demonstrates bactericidal activity against MRSA 
while maintaining a similar safety profile to ceftriaxone. BAL-2057 (BASILEA Pharmaceutica AG), a 
member from a new class of narrow spectrum anti-MRSA cephalosporins, is reportedly in the final stages 
of optimization after displaying consistently high in vivo activity in animal models.15 However, no 
additional information on BAL-2057 could be obtained.  
 
Using a different chemotherapeutic approach, NewBiotics Inc is utilizing the cephalosporin NB-
2001 in an enzyme-catalyzed therapeutic activation (ECTA) method for delivering the bactericide triclosan 
upon ring hydrolysis of the inactive prodrug (Scheme 1.01).16 While extensive research on β-lactamase-
dependent prodrugs has previously been conducted,17 interest remains in ECTA as a means to circumvent 
the development of resistance in bacteria by controlled release of the active drug when the drug-resistant 
pathogen is present. 
 
 
Scheme 1.01: Enzyme-catalyzed therapeutic activation mechanism of NB-2001.16  
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1.2.2 Carbapenems 
 
Although existing carbapenems are not useful drugs for MRSA, this family of antibiotics 
continues to draw interest because of their chemical stability towards β-lactamase. During the 1990s, anti-
MRSA carbapenems18 were being developed by Merck & Co, SmithKline Beecham plc, and Wyeth-Ayerst 
Research, however, investigations of the naphthosultam penems,19 trinems,20 and THF carbapenems,21 
respectively, were discontinued or suspended by 2001. Concurrently, J-111225 (Banyu Pharmaceutical Co 
Ltd), CS-023 (Sankyo Co Ltd) and CP-6509 (Meiji Seika Kaisha Ltd) are being investigated as ultra-broad 
spectrum 1β-methyl-carbapenems possessing activity against drug-resistant staphylococci.  
 
Figure 1.03: Anti-MRSA penems in clinical development.  
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J-111225 (Figure 1.03), a pyrrolidinylthio-1β-methylcarbapenem, is a good inhibitor of PBP2a 
(IC50 = 2.5 µg/ml) which correlates well to its in vitro activity against MRSA (MIC90 = 4 µg/ml).22 The 
penem possesses a trans-hydroxyethyl side chain that imparts β-lactamase stability and a bulky lipophilic 
moiety which is understood to enhance PBP2a binding. The effectiveness of J-111225 is comparable to 
vancomycin in mice with systemic MRSA infections (ED50 = 5.83 mg/kg) and maintains good stability 
toward human renal dehydropeptidase I.23 CS-023 (Figure 1.03) is an analogous broad spectrum 
pyrrolidinylthio-1β-methylcarbapenem being investigated as a parenteral MRSA antibiotic. The drug has a 
MIC of 8 µg/ml against MRSA and an IC50 of 5.3 µg/ml to PBP2a.24 Another extensively researched 
penem is CP-5609 (Figure 1.03), a 6,7 disubstituted imidazo[5,1b]thiazole-3-yl-1β-methylcarbapenem with 
excellent affinity for PBP2a and a MIC of 4 µg/ml against MRSA.25
 
1.2.3 N-Thiolated β-Lactams 
 
N-Thiolated monocyclic β-lactams (Figure 1.04) represent a novel class of synthetic antibacterials 
whose mechanism of action is not inhibition of cell wall biosynthesis.26 Additional information on the 
biological properties of these and related molecules is presented in chapters II-IV. 
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Figure 1.04: N-Methylthio β-lactams with anti-staphylococcal properties. 
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1.3 Peptide Antibiotics 
 
1.3.1 Second Generation Glycopeptides 
 
Glycopeptides27 (Figure 1.05) embody the most successful family of MRSA antibiotics and 
remain the drugs of choice for the treatment of hospital-borne infections. Unlike β-lactam antibiotics, 
glycopeptides inhibit cell wall synthesis by forming a complex with the C-terminal D-ala-D-ala of the 
peptidoglycan crosslinkages. Although the mechanism of action was once considered unbeatable, 
glycopeptide resistance emerged during the 1980s via enzyme-dependent conversion of the terminal D-
alanines to D-lactates.28 The gene encoding resistance (vanA, vancomycin-resistance) initially evolved in 
enterococci, however, in June 2002, a S. aureus strain harboring both the mecA (methicillin-resistance) and 
vanA genes was isolated from a catheter exit site of a diabetic patient in the US.29 The recent escalation in 
glycopeptide-resistant bacteria counts has prompted researchers to investigate new semisynthetic analogues 
of vancomycin while increasing efforts to discover new natural products with enhanced bioactivity or novel 
modes of action.27,30
 
Figure 1.05: Vancomycin and teicoplanin. 
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Oritavancin (InterMune Pharm. Inc; Figure 1.06) is a semisynthetic glycopeptide prepared from a 
natural product analogue of vancomycin.31 The peptide displays good in vitro activity against MRSA 
(Table 1.02) while maintaining the efficacy of vancomycin in rabbits with MRSA-induced endocarditis.31a 
After displaying a good safety profile in humans during phase I trials, oritavancin is currently in phase III 
trials with completion and NDA filing anticipated for January 2004. Another glycopeptide in clinical trials 
is dalbavancin (Biosearch Italia SpA/Versicor Inc; Figure 1.06, Table 1.02), a semisynthetic glycopeptide 
being developed as the first once-weekly intravenous treatment for serious infections caused by Gram-
positive bacteria.32,33 Phase I trials established dalbavancin to be well tolerated in healthy individuals and 
phase II studies during which hospitalized patients with skin and soft tissue infections were administered 
the glycopeptide were reported as positive.34 Biosearch is also developing ramoplanin (Biosearch Italia 
SpA/Genome Therapeutics Corp), a lipoglycopeptide antibiotic for use as a topical treatment for nasal 
carriage of MRSA.35 However, due to the innate toxicity of ramoplanin, parenteral administration is not 
possible. 
 
Figure 1.06: Oritavancin and dalbavancin. 
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1.3.2 Lipopeptides (Daptomycin) 
 
Daptomycin (Cubist Pharmaceuticals Inc/Gilead Sciences Inc; Figure 1.07) is a naturally occuring 
lipopeptide consisting of 13 amino acids and a decanoic acyl side chain.36 The peptide displays rapid 
bactericidal activity against MRSA and the VRSA strain isolated in the US.36a,36b The mechanism of action 
for daptomycin is not entirely understood although it is known that cellular integrity is disrupted by 
insertion of the peptide into the plasma membrane.36c Daptomycin's novel mode(s) of action in bacteria 
should prevent the occurrence of cross-resistance and studies have shown the incidence of spontaneous-
resistance is below detectable levels in S. aureus.36d
 
1.3.3 Depsipeptides 
 
 Wakamoto Pharmaceutical Co Ltd is developing WAP-8294A2 (Figure 4, Table 1.02), a water-
soluble depsipeptide antibiotic produced by Lysobactor spp. WAP-8294A2 displays good in vitro activity 
against MRSA (0.78 µg/ml) and VRSA (6.25 µg/ml) while maintaining an ED50 of 0.38 mg/kg in mice 
with systemic MRSA infections.37 Shionogi & Co Ltd is also investigating two new depsipetide antibiotics 
in katanosin and plusbacin A3.38 The macrocycles inhibit the in vitro growth of MRSA at 0.39 and 1.56 
µg/ml, respectively, and unlike vancomycin, katanosin and plusbacin A3 reportedly block cell wall 
synthesis by inhibiting the formation of lipid intermediates involved in transglycosylation. In vitro studies 
have demonstrated that the incorporation of [14C]glycine is inhibited at IC50 values of 2.2 and 2.3 µg/ml 
while synthesis of nascent peptidoglycan is suppressed at IC50s of 0.8 and 0.4 µg/ml for katanosin and 
plusbacin A3, respectively.38
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Figure 1.07: Daptomycin and WAP-8294A2.  
O
NH
H
N
O
NH2
O
CO2H
NH
O
NHNH
NH2(CH2)2
i-Pr
MeN i-Pr
O
NH
O
N
H
O
HO
(CH2)3i-Pr
OHNH2
O
OH
Bn NMe
O NH
N
H
O
O
NH2(CH2)2 O
OO
N
H
O
O
 
 
daptomycin 
 
O
CH3(CH2)8 NH
NH
N
H
O
N
N
H
O
O
CO2H
N
O
NH2
Me
H
O
N
H
O
O
O
N
N
H
O
O NH
O
N
H
N
O
N
O
H
N
O
O
O
NH2
(CH2)3NH2
CO2H
Me
CO2H
HO
CO2H
Me
H
H
HH
HH
 
WAP-8294A 
 
           Table 1.02: Biological activity comparisons of oritavancin, dalbavancin and daptomycin.31-38
 MIC50a 
(µg/ml) 
MIC90a 
(µg/ml) 
MIC  
w/serumb
(µg/ml) 
Protein 
bindingc 
 (%) 
MBCd 
(µg/ml) 
Terminal 
half-lifee 
(h) 
Oritavancin  0.5 2 1-4 86-90 2 132-356 
Dalbavancin  0.13 0.25 2-4 NR 2 166-212 
Daptomycin  1 1 NR 90-94 1 8.5 
Teicoplanin  0.5 2 2 90 ≥ 2 > 35 
Vancomycin 1 2 1-2 30 2 6 
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aminimum inhibitory concentration for 50 or 90% of MRSA test strains; b50% bovine serum; c% 
human plasma protein binding; dminimum bactericidal concentration; eterminal half-life in humans; 
NR: not reported or data could not be found in the literature. 
 
 
 
 
1.4 Oxazolidinones 
 
Oxazolidinones are bacteriostatic antibiotics of Gram-positive bacteria that inhibit protein 
synthesis by binding to the 30S and 50S ribosomal subunits.39 Linezolid (Zyvox®, Figure 1.08) is the only 
oxazolidinone in clinical use, although other promising candidates have emerged and advanced to human 
trials. Currently, Versicor is investigating a thioamide series of oxazolidinones that display good in vitro 
activity against MRSA (MIC90 = 1 to 2 µg/ml).40 VRC-3783 (Pharmacia Corp/Versicor Inc; Figure 1.08) 
and VRC-4104 (Pharmacia Corp/Versicor Inc) are two promising analogues with ED50 values of 6.2 and 
3.8 mg/kg, respectively, in a mouse septicemia model.40b AstraZeneca plc was developing AZD-2563 
(Figure 1.08), an oxazolidinone with a long half-life and good activity against MRSA (MIC = 1 µg/ml), but 
development was discontinued by July 2002 for unknown reasons.41 
Figure 1.08: Linezolid, VRC-3783, and AZD-2563. 
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1.5 Quinolones, glycylcyclines and coumarin antibiotics 
 
Quinolones are bactericidal agents that act on types II (DNA gyrase, negative supercoiling) and IV 
topoisomerase (chromosome partitioning) in S. aureus.42 Several new quinolones, such as DW-116 (Dong 
Wha Pharmaceutical Industry Co Ltd; Figure 1.09),43 olamufloxacin (Hokuriku Seiyaku KK; Figure 
1.09),44 and DK-507k (Daiichi Seiyaku Co Ltd, Figure 6)45 have advanced to clinical trials after 
demonstrating strong activity against drug-resistant Gram-positive pathogens, such as MRSA (MIC90 = 
0.06, 1.56 and 0.006 µg/ml, respectively). These compounds are derived from the popular fluoroquinolone 
family possessing a C(6) fluorine atom that is known to substantially enhance bioactivity.42 Des-fluoro(6) 
quinolones are also being investigated with BMS-284756 (ganefloxacin; Bristol-Myers Squibb Co/Toyama 
Chemical Co Ltd; Figure 1.09) at the most advanced stage in clinical development for this class .46 
Ganefloxacin is completing late phase III trials in the US, Japan and Europe with an anticipated use as a 
once-daily intravenous treatment for skin and soft tissue pathogens, including MRSA and fluoroquinolone-
resistant S. aureus (MIC = ≤ 4 µg/ml).46a Non-fluorinated quinolones are also being developed as topical 
agents for SSTIs. Recently reported is T-3912 (Toyoma Chemical Co Ltd/Ferrer Internacional SA/Maruho 
KK), a 3-pyridinyl quinolone with potent in vitro activity against drug-resistant staphylococci (MIC90 = 0.2 
µg/ml).47
 
Figure 1.09: Anti-MRSA quinolones in clinical development.  
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Coumarin antibiotics are another class of topoisomerase inhibitors that selectively target DNA 
gyrase B in S. aureus.48 RU-79115 (Aventis Pharma AG; Figure 1.10), a coumarin related to novobiocin, 
displays good activity against multiple drug-resistant forms of S. aureus while maintaining a PD50 of 
1mg/kg in mice with induced systemic infections.49 Glycylcyclines, although unrelated to the coumarins, 
are also active against multi-drug resistant strains of S. aureus. Tigecycline (Wyeth Research; Figure 1.06) 
was the most developed from this class of protein synthesis inhibitors, but a policy change by the US FDA 
had forced Wyeth to delay the phase III clinical trials.50
 
Figure 1.10: Anti-MRSA coumarin and glycylcycline in clinical trials. 
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1.6 Conclusions 
 
A tremendous worldwide effort to discover new anti-MRSA antibiotics is apparent. β-Lactams 
continue to be the most heavily researched class because of their enduring ability to fight infection while 
maintaining low toxicity in humans. Semisynthetic vancomycin derivatives have also gained a great deal of 
attention due to the long-term success of glycopeptides against MRSA. However, future therapies cannot 
be devised by analogue synthesis of pre-existing antibiotics alone. Compounds with novel modes of action 
must continue to be researched and developed as S. aureus continues to evolve new mechanisms and new 
levels of resistance to current antibiotics. In chapter III-V, the synthesis and biological properties of the 
novel class anti-MRSA antibiotics called "N-methylthio β-lactams" is discussed. The structure-activity 
relationships and investigations into their unknown mode of action will be described in depth for the first 
time.     
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CHAPTER II 
 
CHEMISTRY AND BIOLOGICAL PROPERTIES  
OF N-THIOLATED β-LACTAMS 
 
2.1  Introduction 
 
 For over 60 years, the β-lactam antibiotics have served as a powerful line of defense against 
bacterial infections.51 Following the initial introduction of penicillin during World War II, a variety of other 
classes of β-lactam antibiotics were identified including the cephalosporins, penems, carbapenems, and 
monobactams (Figure 2.01).52 
 
One of the landmark discoveries in the β-lactam 
field occurred in 1981, when researchers at the Takeda 
and Squibb laboratories isolated the first classes of N-
thiolated β-lactam antibacterial agents from natural 
sources.53 The Squibb scientists coined the term 
"monobactams" in referring to these new monocyclic β-
lactams. These reports confirmed that β-lactam 
compounds do not necessarily require a conformationally 
rigid bicyclic ring system to have antibacterial 
capabilities, or the carboxylic acid moiety found in all 
other microbially-active β-lactams. These β-lactam 
compounds were the first to have a sulfur group attached 
directly to the lactam nitrogen, in the form of an N-
sulfonic acid. In this chapter, a summary of the nearly 
5000 β-lactam compounds that contain an N-sulfur 
substituent is provided. The sulfur center in these 
molecules can bear a diversity of residues and exist in a 
variety of oxidation states, as classified by the following 
five structure types (Figure 2.02). The discussion that 
follows is therefore divided into the following five 
sections: 
N
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N
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N
O
S
CO2H
X
carbapenams
N
O
monobactams
SO3H
RCONH RCONH
X
OH OH
RCONH R'
 Figure 2.01: Classes of β-lactam antibiotics. 51
 
Figure 2.02: Chemical classes of N-thiolated β-lactams. 
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2.2  N-SO2X β-Lactams 
 
Compounds within this category include the N-sulfonic acids (X=OH), N-chlorosulfonyl lactams 
(X=Cl), and N-aryloxysulfonyl or N-alkyloxysulfonyl derivatives (X=OAr or OR). Each of these will be 
discussed separatedly in this order. 
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2.2.1 N-Sulfonic Acid β-Lactams 
 
With over 3600 entries cited in the journal and patent literature, the N-sulfonic acid β-lactams 
represent the largest and most thoroughly studied class of N-thiolated β-lactams. The term "monobactam" 
is now commonly used to refer to structures containing the 2-oxoazetidine-1-sulfonic acid framework.54 
Over the past two decades, a variety of review articles have been written on the discovery and development 
of the monobactam antibiotics.55
 
The first members of this family were described in 1981 
in separate disclosures from the Takeda and Squibb 
laboratories.55b In February 1981, Takeda reported the isolation of 
two novel β-lactam natural products, sulfazecin and isosulfazecin 
(Figure 2.03), from Gram-negative Pseudomonas bacteria in soil. 
Sulfazecin was found to be active against Gram-negative bacteria 
but weakly active against Gram-positive microbes. Isosulfazecin, 
on the other hand, exhibited only weak activity against both 
Gram-negatives and Gram-positives.53a 
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A few months after the Takeda report appeared, 
Squibb53b laboratories published their findings on seven closely 
related β-lactams isolated from a diverse range of microbes, 
including Acetobacterium, Agrobacterium, Chromobacterium, 
Flexibacterium, and Gluconobacterium species. The compound 
most frequently found in these screenings, SQ 26,445, turned out 
to have a structure identical to that of Takeda's sulfazecin. A 
second lactam, SQ 26,180 seen in Figure 2.03, was also 
identified. These naturally occurring lactams proved to be highly 
stable to a wide range of β−lactamases, but had relatively weak 
antibacterial activity. These features were attributed to the low 
affinity the compounds have for the penicillin binding proteins 
(PBP’s) in bacteria.55b Their selectivity for aerobic Gram-negative 
microbes warranted further study. 
Figure 2.03: First monobactams 
discovered by American and Asian 
scientists. 55  
 
To be able to carry out detailed structure-activity studies, methods were soon developed to create 
monobactam analogues by chemically introducing or modifying the side chains on the lactam ring. The 
most common approach involves the N-thiolation of an N-unsubstituted lactam 1 with pyridine-sulfur 
trioxide complex (Scheme 2.01). This procedure, developed by the Takeda laboratories, works particularly 
well for C4 unsubstituted systems (2, R'=R"=H), giving good yields of the N-sulfonated lactam as its 
pyridinium salt.56 The salt can be readily exchanged for other cations (K+) or protonated to give the N-
sulfonic acid.  
 
Scheme 2.01: N-Sulfonation of β-lactams with pyridine-sulfur complex.56
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The N-sulfonic acid moiety can also be transferred onto the ring using the powerful sulfonating 
agent dimethylformamide-sulfur trioxide (DMF-SO3) followed by aqueous KH2PO4 workup.57 Treatment 
of this product with tetrabutylammonium bisulfate and extraction with an organic solvent enables the 
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monobactam to be obtained as its tetrabutylammonium salt.58 Alternatively, N-sulfonation can be achieved 
through a stepwise N-silylation process using trimethylsilyl chloride and triethylamine, followed by 
treatment of the resulting N-silyl lactam with trimethylsilyl chlorosulfonate ((CH3)3SiOSO2Cl) at low 
temperature.59 The silyl ester group can be hydrolyzed with KH2PO4 buffer to afford the monobactam 
potassium salt. 
 
A different strategy for making monobactams is via base-promoted cyclization of a β-
methanesulfonyloxyacyl sulfamate 3 in aqueous bicarbonate media, in which the stereochemistry at C4 
arises through an inversion process (Scheme 2.02).60
 
Scheme 2.02: Bases-promoted cyclization for synthesizing monobactams.60
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Monobactam analogues differing only in the acyl side chain can best be obtained by acylation of a 
3-amino monobactamic acid 4, as illustrated in Scheme 2.03. The acyl moiety can be introduced using an 
acyl chloride or an activated ester.61  
 
Scheme 2.03: Acylation of 3-amino monobactamic acids.61
 
        
N
O SO3
H2N R"R'
N
O SO3
N
H
R"
O
R'
4 5
Et3N-DMF
PhO
O
Cl
PhO
 
 
The preparation of the 3-amino monobactamic acid 4 proceeds via monobactam intermediates 6 
and 7 (Figure 2.04), neither of which were examined for biological activity. 
 
Figure 2.04: Intermediates used to synthesize 3-amino monobactamic acids. 
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Among the first series of synthetic monobactams studied were those whose side chains resembled 
the ones on existing β-lactam antibiotics (Figure 2.05). Thus, the phenylacetamidyl side chain of penicillin 
G gave rise to monobactams possessing a C3 phenylacetamide group (as in SQ 26,324 and SQ 81,427), 
which were found to have increased activity against Gram-positive bacteria and enhanced affinity for PBP-
1, -2, and -3. However, these compounds were still relatively weak compared to the penicillin counterpart.62  
 
Incorporation of the uriedo moiety of the penicillin, piperacillin led to monobactams having 
antibacterial activity against a broader spectrum of microbes, including β-lactamase-producing strains of 
Staphylococcus aureus.55b The most active of the synthetic derivatives came from the attachment of an 
aminothiazole alkoximino side chain found in cefotaxime, a third generation cephalosporin. One of these 
derivatives, aztreonam (SQ 26,776), showed high affinity for PBP-3 of Gram-negative bacteria.55b 
Structure-activity studies revealed that the aminothiazole oxime is responsible for aztreonam’s potent 
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activity against Gram-negative species, while the carboxylic acid on the oxime side chain enhances 
Pseudomonas activity. 
 
Figure 2.05: Synthetic monobactams with enhanced bioactivities. 55b
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Like penicillin and the other β-lactam antibiotics, the monobactams inhibit bacterial growth by 
blocking cell wall biosynthesis. The lactams act directly on the penicillin binding proteins (PBP's), a group 
of membrane-bound serine transpeptidases that catalyze cell wall crosslinking.61b  Upon binding in the 
active site, the compounds undergo β-lactam ring opening by acylating the catalytic serine hydroxyl group 
as depicted in Scheme 2.04. The PBP, giving a stable enzyme adduct that is catalytically inactive. By 
disrupting these crosslinking proteins, the β-lactams induce morphological deformities in the cell that leads 
to rupture of the bacterium. The N-sulfonic acid moiety plays a key role by activating the carbonyl of the 
monobactam ring to nucleophilic attack and ring opening in the enzyme active site. 
 
Scheme 2.04: Mechanism of β-lactam hydrolysis by serine transpeptidases. 
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The ability of the monobactams to bind selectively to the bacterial PBP's depends largely on the 
nature of the C3 and C4 side chains on the β-lactam ring. The naturally occurring monobactams possess an 
acylamido side chain and often a methoxy group at C3 of the ring. The methoxy moiety protects the ring 
from enzymatic hydrolysis by β-lactamases, but also decreases antibacterial activity. Other types of small 
polar groups at C3 also reduce antibacterial activity. Monobactams of bacterial origin do not possess C4 
side chains, but synthetic analogues that have alkyl or heteroatom-containing residues at C4 show 
significantly enhanced biological activity.62 Aztreonam (SQ 26,776) and carumonam (AMA 1080; Ro 17-
2301), two of the most active agents developed so far, have a methyl and carbamate group, respectively, at 
C4. 63  
 
Along with enhanced stability to β-lactamases, these functionalized monobactams are highly 
potent against aerobic, Gram-negative bacilli such Pseudomonas aeruginosa, Haemophilus influenzae and 
members of the Enterobacteriaceae family. Aztreonam is bactericidal in its action64 and binds selectively 
to PBP-3 of Gram-negative bacteria, resulting in the elongation of the cell and death through cell lysis. 
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However, the low affinity aztreonam has for the PBP's of Gram-positive and anaerobic microorganisms 
allows it to have a narrow spectrum of antimicrobial activity. Most commonly, the drug is used in the 
treatment of bacteremias, urinary tract infections, pelvic and intra-abdominal infections, and respiratory 
infections.65 Since its activity is selective for aerobic Gram-negative bacilli, aztreonam can be combined 
with other antibacterial agents and be used as an alternative to aminoglycosides or penicillins in penicillin-
allergic patients.  
 
 A variety of bicyclic (bridged) monobactams 8-
17 (Figures 2.06 and 2.07) have also been shown to 
serve as mechanism-based inhibitors of class C β-
lactamases, some having half-inhibition constants down 
to 10 µM-3.66 The acyl-enzyme adduct formed by these 
compounds has a half-life toward hydrolysis up to 48 
hours. This stability allowed the determination of an X-
ray structure for bridged monobactam 8 covalently 
bound via lactam ring opening to the active site serine of 
Citrobacter freundii 1203 β-lactamase. While none of 
the inhibitors possess antibacterial activity, synergistic 
effects were observed for most of the analogues when 
used in combination with ceftriaxone (a third generation 
cephalosporin) against β-lactamase-producing strains of 
Enterobacteriaceae. Thus, using a 1:4 ratio of 
drug:monobactam, the MIC's could be reduced from 128 
µg/mL (without inhibitor) to as low as 0.25 µg/mL for 
Citrobacter freundii. The compounds are much less 
effective against either class A or class B β-lactamases, and do not have significant synergies against a 
TEM-3 (class A β-lactamase)-producing strain of Escherichia coli or an 18 SH (a class C β-lactamase)-
producing strain of Pseudomonas aeruginosa. This is probably due to the limited ability of the lactams to 
permeate the outer membrane of these particular microbes.67  
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Figure 2.06: Bicyclic monobactam inhibitors 
of class C β-lactamase. 29
 
Interestingly, the disubstituted derivatives 12, 13, and 14, and BOC-protected analogue 15 offered 
no synergistic effect in combination when used in combination with a penicillin. However, lactam 17 (Ro 
48-1256) provides a good compromise between β-lactamase affinity and membrane permeability.68 
Hoffman-LaRoche AG patented a variety of related bridged monobactam derivatives 18-21 for use in 
liposome solutions as β-lactamase inhibitors.69 There has also been some interest in the development of 
monobactams as cysteine proteinase inhibitors.70
 
Figure 2.07: Bicyclic monobactams 12-21.68-70
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2.2.2 N-Chlorosulfonyl β-Lactams 
 
N-Chlorosulfonyl β-lactams have been exploited primarily as reactive intermediates in synthesis, 
and have not been studied as bioactive molecules themselves.71 This is undoubtedly due to their high 
chemical reactivity and instability in aqueous media. Scheme 2.05 depicts the standard method for 
preparing N-chlorosulfonyl lactams by a [2+2]-cycloaddition of an olefin with chlorosulfonyl isocyanate 
22,72 as shown for the conversion of vinyl acetate to 4-acetoxy lactam 23.73  
 
Scheme 2.05: Synthesis of 4-acetoxy N-chlorosulfonyl-azetidin-2-one 23.72
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The method has been applied to the synthesis of some bicyclic and multicyclic systems such as 
24-27 (Figure 2.08).74
 
Figure 2.08:  Bicyclic and multicyclic N-chlorosulfonyl β-lactams 24-27.75
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The unusual dimeric compound 28 (Figure 2.09), made by photodimerization, has been employed 
in the construction of space-separated bis-heterocycles.75
 
Figure 2.09: Dimeric N-chlorosulfonyl β-lactam 28.75  
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The N-S bond in N-chlorosulfonyl derivatives is readily cleaved by thiol nucleophiles. Thiophenol 
has been shown to reduce N-chlorosulfonyl β-lactams to give N-protio β-lactams in the presence of 
pyridine. This was demonstrated for the deprotection of 29 as seen vide infra.76  
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Figure 2.10: Deprotection of N-chlorosulfonyl β-lactams with thiophenol.76
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 Thus, while providing access to N-unsubstituted β-lactams, the inherently high reactivity of N-
chlorosulfonyl β-lactams would appear to limit their usefulness as potential therapeutic agents per se. 
 
2.2.3 N-Aryloxysulfonyl and N-Alkoxysulfonyl β-Lactams 
 
Around 30 N-aryloxy- and N-alkoxysulfonyl β-lactam derivatives have been described in the 
literature.These β-lactams are made by cycloaddition of an olefin with an aryloxy- or alkoxysulfonyl 
isocyanate 31, as illustrated in Scheme 2.06. The method is effective for the synthesis of C3 unsubstituted 
adducts such as 33-37 (see Scheme 2.06).  
 
Scheme 2.06: Synthesis of N-aryloxysulfonyl and N-alkoxysulfonyl β-lactams.43
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Starting from the cyclic enol ether, trichloroethoxy derivative 36 and aryloxy (X=H, Y=CH3; 
X=H, Y=CH3O; X=NO2, Y=H) analogues 37 have also been prepared in this manner.77 Based on published 
reports, there have not been any studies or reports on whether these compounds possess biological 
properties.  
 
2.3 N-SO2R β-Lactams 
 
Numerous articles can be found throughout the literature describing the preparation and use of N-
sulfonyl β-lactams as intermediates in synthesis. There are several common procedures for synthesizing N-
sulfonyl β-lactams. The most direct way is by treatment of an N1 unsubstituted lactam with a sulfonyl 
chloride in the presence of a base. Two examples are illustrated in Scheme 2.07.78
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Scheme 2.07: Sulfonylation of N-protio β-lactams.78
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N-Tosyl β-lactams such as 43 have also been formed by dehydrative ring closure of a sulfonamido 
carboxylic acid 42 in the presence of dicyclohexylcarbodiimide (DCC) and 4-pyrrolidinopyridine (Scheme 
2.08). This particular reaction was used in a published carbapenem synthesis.79
 
Scheme 2.08: Dehydrative ring closure of sulfonamido carboxylic acid 42.79
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Barrett demonstrated that bicyclic N-sulfonyl derivatives 45-47 could be prepared by olefin-
isocyanate cycloaddition as depicted in Scheme 2.09. None of these products were examined for biological 
activity, however.77 
 
Scheme 2.09: β-Lactam synthesis via olefin-isocyanate cycloaddition.43
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Biloski employed a different approach for closing the β-lactam ring of compound 49 as seen in 
Scheme 2.10. Here, alkenyl amide 48 underwent iodocyclization in aqueous base to afford the β-lactam 
product.80
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Scheme 2.10: β-Lactam synthesis via base-mediated iodocyclization.80
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In an isolated report, N-methanesulfonyl lactam 50 was prepared, albeit in poor yield, by a 
transition metal-mediated CO insertion of N-mesylaziridine as illustrated below (Scheme 2.11). The 
method was not extended to other sulfonyl substrates or to more complex systems, and would appear to 
be rather limited in scope.81
 
Scheme 2.11: β-Lactam synthesis via Ni-mediated CO insertion.81
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Of the nearly 600 N-sulfonyl β-lactams that have been reported, relatively few have been 
examined for biological properties. This may be related to the fact that the compounds lack the ionic 
residues needed for binding to bacterial PBP's, and consequently, should be devoid of antibacterial activity. 
However, N-arylsulfonyl β-lactams have been shown to be inhibitors of other serine proteases, including 
human leukocyte elastase (HLE).82  
 
The postulated mechanism for elastase inhibition by N-arylsulfonyl β-lactams is depicted in 
Scheme 2.12.78a The sulfonyl moiety is responsible for activating the β-lactam ring towards nucleophilic 
ring opening by a serine residue, and then after lactam ring opening, for serving as a stable leaving group to 
create an imine intermediate by loss of arylsulfinic acid. It is proposed that tautomerization of the resulting 
imine to the enamine enables a second active site nucleophile (perhaps a histidine) to add, giving a 
crosslinked adduct that is highly resistant to hydrolysis. Attempts to prove the mechanism by trapping of 
the arylsulfinic acid were inconclusive.  
 
Scheme 2.12: Proposed mechanism of N-arylsulfonyl β-lactams inhibitors of human leukocyte elastase.78a
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However, a high resolution crystal structure of a stable acyl-enzyme adduct formed between N-
arylsulfonyl lactam 51 (Figure 2.11) and elastase from porcine pancreas has been reported.83 The 
interesting feature found in the structure is that the ester functionality formed between the serine and lactam 
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moiety does not occupy the oxyanion hole in the active site. This could explain the high resistance this 
adduct has toward hydrolysis and release. 
 
Figure 2.11: N-Sulfonyl β-lactams inhibitors of porcine pancreatic elastase.78,81,83
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In addition to the N-arylsulfonyl compounds, N-acylsulfonyl lactam 52 (Figure 2.11) is also an 
inhibitor of porcine pancreatic elastase.81 The trifluoromethylsulfonyl lactam 53 (Figure 2.11), however, 
has no affect on human leukocyte elastase activity.78a Along with the elastase (serine protease) activity, 
Merck has shown interest in using N-alkylsulfonyl and N-arylsulfonyl β-lactams as anticholesteremic 
agents through their inhibition of HMG-CoA synthase.84
 
Some interesting bicyclic N-sulfonyl β-lactams have been reported as well. The N-S-fused 
bicyclic lactam 55 was prepared by oxidation of sulfenamide 54 with m-chloroperbenzoic acid (Scheme 
2.13).78b-d The compound was devoid of antibacterial activity despite its highly electrophilic β-lactam ring. 
However, the phthalimide analogue 56 (see Scheme 2.13), interestingly enough, was found to possess weak 
antibacterial activity against Staphylococcus aureus and Vibrio cholerae; the mechanism for this activity 
was not investigated. 
 
Scheme 2.13: N-S-Fused bicyclic β-lactams.78b-d
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The highly functionalized bicyclic lactams 57 and 58 (see Scheme 2.13) could likewise be 
prepared by a similar sulfoxidation of the sulfenamides. These compounds were tested for antimicrobial 
properties, but did not reveal any activity against a variety of Gram-positive and Gram-negative bacteria. 
 
2.4 N-SOR β-Lactams 
 
N-Trifluoromethylsulfinyl lactam 59 (Figure 2.12) appears to be the only example of an N-sulfinyl 
β-lactam, being found in a Merck patent on the use of substituted azetidinones as anti-inflammatory and 
anti-degenerative agents.85 However, there is no information about whether the compound possesses these 
biological properties. 
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Figure 2.12: N-Trifluoromethylsulfinyl β-lactam.85
 
N
O S
Ph
CF3
O
OCH2CH3
O
59  
 
2.5 N-SX β-Lactams 
 
 A variety of structurally interesting molecules have been described in which an S-heteromoiety is 
attached to a β-lactam nitrogen. Typically, these compounds have been isolated as synthetic intermediates 
or as unexpected reaction products. Miller developed an efficient method for preparing thiophthalimide 
analogues such as 62 and 63 (see Scheme 2.14). The procedure entails the reaction of the N-protio lactam 
with sulfur bis-phthalimide 61 in the presence of a catalytic quantity of triethylamine.86
 
Scheme 2.14: Preparation of N-phthalimidothio β-lactams.86
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The sulfur linked bis-β-lactam adduct 64 (Figure 2.13) can also be prepared using this method 
under certain reaction conditions. Phthalimide lactam 62 is presumably an intermediate of the reaction.86 
Phthalimide lactam 62 can likewise be reacted with other nitrogen nucleophiles such as morpholine to give 
derivative 65, or with benzyl alcohol in the presence of triethylamine to afford product 66 (Figure 2.13). 
No biological data was reported for any of these heterosubstituted β-lactam derivatives. 
 
Figure 2.13: Heterosubstituted N-thiolated β-lactams 64-66.56
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Miller also demonstrated that the phthalimide exchange process could be carried out using 
bisulfite anion as a means to prepare N-thiosulfuric acid derivatives such as 67 and 68 (see Scheme 2.15). 
Although only these two examples were shown, the reaction would appear to be general. Thiosulfate lactam 
68 was tested for antibacterial properties but found to be inactive, which contrasts sharply with the potent 
antimicrobial effects of the corresponding monobactam compound (the N-SO3H analogue).87 This 
confirmed the correlation between the electronegativity of the N-heteroatom of a monocyclic β-lactam and 
biological activity. Nevertheless, this dramatic difference in antibacterial activity in this case may also be 
due to differences in the way the molecules fit into the enzyme active site.88
 
Scheme 2.15: Preparation of heterosubstituted N-thiolated β-lactams via phthalimide exchange.87  
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There are only two examples of disulfide-linked β-lactams of type 69 (see Scheme 2.16), both of 
which were formed as unexpected reaction products. In the first example, dimeric lactam 71 was obtained 
by heating S-trityl lactam 70 at 75°C in the presence of cupric chloride (Scheme 2.16).89 The authors make 
no mention as to whether disulfide 71 was tested for antimicrobial activity. 
 
Scheme 2.16: Synthesis of disulfide-linked β-lactams.89
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Turos reported the formation of disulfide-linked lactam 72 by low temperature lithiation of vinyl 
iodide 54 as shown in Scheme 2.17. The reaction takes place via an initial metal-halogen exchange, 
followed by spontaneous ring-opening and dimerization. Compound 72 was screened for antibacterial 
properties, but found to be inactive against a wide variety of common Gram-positive and Gram-negative 
microbes.78c 
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Scheme 2.17: Synthesis of disulfide-linked lactam 72.78c
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2.6 N-SR β-Lactams 
 
There have been a number of studies on β-lactams having an N-sulfenyl moiety as shown in 
Scheme 2.18 for structure 74. N-Sulfenyl β-lactams can be readily obtained by thiolation of an N1 
unsubstituted lactam 73 with an appropriate sulfenylating agent and base. 
 
Scheme 2.18: Preparation of N-sulfenyl β-lactams. 
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Shah and Cama reported a procedure for placing a methylthio substituent onto a β-lactam nitrogen 
by treating the N-H precursor 75 with lithium diisopropylamide (LDA) in a mixture of 
hexamethylphosphoramide (HMPA) in tetrahydrofuran (THF) at low temperature, followed by trapping the 
amide anion with methyl methanethiolsulfonate (Scheme 2.19).90  
 
Scheme 2.19: N-Methylthiolation of β-lactams with methanethiosulfonate.90 
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N-Methylthio lactams are stable to acid and base but can be easily deprotected with a thiolate 
anion. The authors showed a selection of N-methylthio derivatives 76-82 (see Scheme 2.19) that were 
synthesized, but did not report on their biological properties. 
 
Turos has applied this same method to make N-alkylthio lactams 83-90 (Figure 2.14) for use as 
intermediates in synthesis of bicyclic β-lactams.78b-d For the N-benzylthio and N-phenylthio lactams 89 and 
90, respectively, the N-thiolation was done by trapping the amide anion with the sulfenyl chloride 
(generated from halogenation of the disulfide with chlorine gas). Similarly, researchers at Shionogi 
research laboratories prepared a series of N-methylthio lactams 91 (Figure 2.14) as intermediates in a 
carbapenem synthesis (X=F, CN, OH, O2CCH3, OSiMe2tBu, OSi(CH3)3, or I). None of these lactams 
appear to have been tested for antibacterial activity.91
 
Figure 2.14: Examples on N-methylthio monocyclic β-lactams.78b-d
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Hart introduced a procedure for preparing S-tritylated lactams via addition of an ester enolate to S-
trityl sulfenimines such as 70. This procedure favors formation of the cis β-lactam product. While the 
method works well for S-trityl lactams 70, 94, and 95, attempts to apply the reaction to S-phenyl 
sulfenimines gave the N-unsubstituted β-lactam rather than the desired N-thiolated product (Scheme 2.20).89
 
Scheme 2.20: Preparation of S-trityl β-lactams via enolate-sulfenimine addition.89
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Miller reported a mild N-thiolation procedure that made use of N-thiophthalimides 96 and catalytic 
triethylamine. The methodology allows a large assortment of organothio groups to be introduced onto the 
lactam, as illustrated in the formation of ester and carboxylic acid derivatives 97-104 (see Scheme 2.21).87 
Kilburn and colleagues recently used this method to prepare N-phenylthio lactam 105 for studies on radical 
cyclizations.92 The authors did not mention if the compound was examined for biological activity. 
 
Scheme 2.21: Sulfenylation of N-protio β-lactams with N-thiophthalimide.87,92
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As described earlier, phthalimide-containing compounds such as 62 can be used to access a range 
of other S-derivatives. Miller showed that carbon nucleophiles readily displace the phthalimide group from 
62 to deliver N-sulfenylated β-lactams 106-108 (see Scheme 2.22).87
 
Scheme 2.22: Displacement of phthalimide by a carbon nucleophile.87  
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The biological studies that have been conducted on the N-sulfenyl β-lactams described  have led to 
some surprising, and potentially important, findings. The first studies were those carried out by Miller that 
compared the synthetic N-SCH2CO2H lactams (thiamazins) made in his laboratory to their N-OCH2CO2H 
counterparts (oxamazins).87,88,93 The oxamazins are strong antimicrobial agents, but the thiamazins were 
found to be devoid of antibacterial activity. It was postulated that this remarkable difference in biological 
properties may be due to the longer N-S bond which prevents the thiamazin binding into the active site of 
the transpeptidase enzyme. Miller  has  noted that the carbonyl stretching frequencies of the active 
oxamazins are consistently 10-20 cm-1 higher than those of the inactive thiamazins, suggesting that there 
may possibly be an electronic basis for this difference as well. Miller also studied the stability of S-
thioacetic acid lactams under basic conditions, and identified three decomposition pathways (Scheme 2.23): 
(1) hydroxide ion addition to the carbonyl to give the ring-opened carboxylic acid, (2) SN2 attack at sulfur 
to cleave the N-S bond, and (3) deprotonation of the acidic carboxyl α-proton to provide the NH lactam 
through loss of the thioaldehyde. Miller determined that approximately 50% of the thiamazin is cleaved at 
the N-S bond (pathways 2 and 3) at pH 11, and the other 50% by lactam ring opening (pathway 1).88 The 
thiamazins are stable below pH 10. 
 
Scheme 2.23: Decomposition pathways of thiamazins by hydroxide ion.88
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Recently, Turos has examined N-methylthio lactams 84-91 for antibacterial activity against a 
variety of common Gram-positive and Gram-negative microorganisms. Curiously, lactam 84 was found to 
strongly inhibit Staphylococcus aureus.26a-c The N-methylthio substituent of 84 is required for biological 
activity, since the N-H and N-SO2CH3 derivatives are totally inactive. The S-benzyl compound 90 also 
demonstrates appreciable antimicrobial activity against the same microorganisms. The antibacterial 
activity of these N-alkylthio lactams is surprising, given the total absence of any ionizable ring 
functionality in the molecules (required for binding to transpeptidases) and the close similarity they have 
in structure to the inactive thiamazins (cf. Scheme 2.23). This suggests the compounds may be operating 
through a different mode of action. Further investigations into this novel family of antibacterials is 
warranted and is the focus of chapters III-V.  
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Scheme 2.24: Mechanisms of reactivity of N-thiolated β-lactams towards nucleophiles. 
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The N-methylthio β-lactams, like the thiamazins, differ from traditional β-lactams in that there are 
at least three sites vunerable to attack by a biological nucleophile. The types of nucleophilic reactions that 
could in effect provide information on the bacterial mode of action are: (1) addition to the β-lactam 
carbonyl, (2) substitution on the sulfur center, or (3) SN2 displacement at the N-methylthio carbon atom  
(Scheme 2.24). Chemical studies and investgations into the intrinsic nataure of N-methylthio β-lactams in S. 
aureus is further detailed in chapter IV  
 
Merck laboratories have conducted tests on N-trifluoromethylthio lactam 109 (Figure 2.15) against 
human leukocyte elastase; however, this lactam was found to have no inhibitory activity (IC50 = 8 
mg/mL).78a
 
Figure 2.15: N-Trifluoromethylthio β-lactam investigated by Merck laboratories.78a
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In addition to the monocyclic systems discussed above, there have been several reports of bicyclic 
compounds of this class that have the N-S bond at the site of ring fusion. The first example, N-fused β-
lactam derivative 111, was formed as an unexpected product during attempts to cyclize lactam 111 to the 
ring-closed penem (Scheme 2.25). The reaction occurs via a rearrangement process. No information was 
reported about biological testing on this adduct.94 
 
Scheme 2.25: Cyclization of 110 to the non-penem 111.94
 
 26
NH
O
S SCH3
Br
O
O
NO2
N
S
O
SCH3
OO
NO2
N S
SCH3
OO
NO2
O
LDA
CuI-SMe2
110
111  
In 1991, the Pfizer laboratories reported the synthesis of some related N-S fused lactam rings 
represented by structures 112 and 113 in studies on human leukocyte elastase inhibitors (Figure 2.16).95  
 
Figure 2.16: N-S fused bicyclic β-lactams of Pfizer.95  
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Compound  117 was synthesized by cyclizaton of lactam 116 with sulfur bis-phthalimide 61 
(Scheme 2.26). The mechanism of the ring closure involved formation of disulfide 118 and trisulfide 119 
intermediates (see Scheme 2.26), which could be isolated and independently converted to product 117 using 
triphenylphosphine. 
 
Scheme 2.26: Preparation of 117 using sulfur bis-phthalimide.95 
 
N
O
S
H
H3C
OTBDMS
OtBu
S O
116
61
Et3N, THF
N
O
H3C
OTBDMS
117
S
S
CO2tBu
 
 
N
O
S
S
S
N
O
S S
S
S
118 119
CO2tBu
CO2tBu
 
 
Alternatively, the reaction of 116 to 117 (Scheme 2.27) could be carried out using N-
chlorosuccinimide (NCS) proceeding through a sulfenyl halide intermediate 120.95 Although only one 
olefin isomer is shown for 117, the reaction in fact gave both geometric isomers which could be separated 
and independently examined for antibacterial activity.
 
Scheme 2.27: Preparation of 117 using N-chlorosuccinimide.95 
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 The Pfizer group also synthesized the six-membered ring analogue 122 through a similar 
cyclization starting from monocyclic β-lactam 121 (Scheme 2.28). Product 122 was then used to prepare 
five- membered ring lactam 117 through a sulfur extrusion process. The conversion of 122 to 117 is 
thought to proceed through a fascinating, and unexpected, rearrangement process described in the paper. 
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Scheme 2.28: Preparation of 117 using triphenylphosphine.95 
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 Both geometric isomers of ester compound 117 were found to be effective inhibitors of human 
leukocyte elastase (Ki = 1.5 µM and 4.0 µM, respectively). The sodium salt of the carboxylate, lactam 123 
(Figure 2.17) , was prepared from ester 117 and found to be devoid of antibacterial activity. Thus, to have 
elastase activity, the ester rather than the anionically-charged carboxylate group is required on these 
lactams.95
 
Figure 2.17: Human leukocyte elastase inhibitor 123. 
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 In a subsequent paper, Pfizer studied the elastase inhibitory properties of a series of related 
bicyclic lactams 124-129 (Figure 2.18), and compared their observed activities to their relative rates of 
base hydrolysis. Blocking the carbonyl with a bulky side chain as in carbonate 126 increases elastase 
inhibition while decreasing susceptibility to base hydrolysis. As anticipated, reversing the absolute 
chirality of the bicyclic ring system, as observed for lactam 127 versus 125, completely destroys the 
biological activity. The study also indicated that replacement of the ring thioether sulfur atom for a carbon 
atom as for compounds 128 and 129 slightly increases both the rate of hydrolysis of the lactam ring and 
the elastase inhibition constant Ki. The N-S linkage makes the lactam ring more susceptible to base 
hydrolysis, but does not significantly affect the elastase inhibitory ability. Thus, enhancing the reactivity of 
the β-lactam ring does not increase the compound's potency as an elastase inhibitor, suggesting that the 
rate determining step in elastase inhibition is not nucleophilic attack on the β-lactam carbonyl center (vida 
supra).96 
 
Figure 2.18: Bicyclic N-thiolated β-lactam elastase inhibitors 124-129.96
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 Turos developed a synthesis of structurally related bicyclic lactams 54 and 130 by iodocyclization 
of unsaturated N-methylthio β-lactams 84 and 85 (Scheme 2.29).78b-d Attempts to construct isopenams 131 
by halocyclization of alkenyl sulfenamide 130 were unsuccessful. 
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Scheme 2.29: Preparation of bicyclic lactams via halocyclization.78b-d
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 However, clavulanic acid-type ring systems 133, 134, and 135 were prepared from monocyclic 
N-methylthio precursor 85, 86, and 132 (Scheme 2.30). 
 
Scheme 2.30: Halocyclization of lactams 85, 86, and 132.78b-d 
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These bicyclic N-S fused compounds have a highly electrophilic β-lactam ring, yet are stable over 
a wide pH range (pH 1 to pH 10). Computational experiments indicate that they have about the same 
thermodynamic stability as the classical penicillins and penems. Ab initio calculations indicate that the β-
lactam in these N-S fused systems is slightly more twisted due to a less highly pyramidalized nitrogen 
center, and have a lower LUMO energy than that of the antibiotics. Despite the structural similarities and 
higher electrophilicities relative to the known β-lactam drugs, lactams 54, 131, 133, 134, and 135 have no 
antibacterial properties.76b,76c 
 
 
2.7 Conclusions 
 
 The discovery of the monobactams in the early 1980's opened new avenues of investigation in β-
lactam antibiotics research. This lead to exciting advances and to the introduction of aztreonam as an 
important clinical agent for control of Gram-negative bacterial infections. The interest in N-thiolated β-
lactams was further heightened in the mid-1990's with the development of N-arylsulfonyl β-lactams as 
elastase inhibitors. Most recently, the discovery that N-methylthio β-lactams have inhibitory activity 
against S. aureus by a unique mode of action, opens the door to new investigations. As such, the focus of 
the following chapters will be on the investigations into the chemical and biological properties of N-
alkylthio β-lactams. 
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CHAPTER III 
 
SYNTHESIS AND BIOLOGICAL PROPERTIES 
OF C4 ARYL SUBSTITUTED 
N-THIOLATED β-LACTAMS 
 
3.1 Introduction 
 
 As alluded to in chapters I and II, N-methylthio β-lactam 1, a synthetic precursor to the clavulanic 
acid-type ring system 2 seen below, was identified as a substance possessing specific biological activity 
against Staphylococcus aureus.78b-d Although only 8 analogues of 1 have been reported previously and the 
antimicrobial screening ad been rather limited, the novelty of this new class of antibiotics warranted their 
further investigation. This chapter examines for the first time, the structure-activity relationship (SAR) of 
N-thiolated β-lactams antibiotics containing functionalized aromatic residues at the C4 position. The 
synthesis and biological evaluation of the lactams against a panel consisting of 33 bacteria species and 10 
strains of methicillin-resistant S. aureus (MRSA) is reported. The effect on cell growth and cell survival is 
also described. The information gathered from the experiments presented in this chapter can in effect be 
applied towards the understanding of the lactam's mode of action in bacteria.  
 
Scheme 3.01: Iodocyclization of N-methylthio lactam 1. 
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3.2 Synthesis of C4 Aryl Substituted N-Thiolated β-Lactams 
 
 C4 aryl substituted β-lactams (3) were prepared by the series of reactions illustrated in Scheme 
3.01. The four stage sequence was initiated by the synthesis of N-(4-methoxyphenyl)imine (6) from aryl 
aldehyde 4 and p-anisidine. Staudinger coupling of an acid chloride (7) and imine by a formal [2+2] 
cycloaddition afforded exclusively the cis-(3S,4R)-substituted β-lactam 8 as a racemic mixture. Following 
oxidative cleavage of the p-anisyl residue by aqueous ceric ammonium nitrate, the N-protio lactam 9 was 
thiolated using readily available sulfenylating reagents to provide the N-thiolated β-lactams (3) in four 
steps. The yields of the reactions were variable depending on the substituents located at C3 and C4 positions 
of the ring and the  conditions. The following section details each reaction involved in the synthesis of  N-
thiolated β-lactams. 
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Scheme 3.02: General synthetic route to lactam 3.  
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3.2.1 Synthesis of C-Aryl(imines) 6 
 
 N-(4-Methoxyphenyl)imines (6) were prepared from the condensation of aryl aldehyde 4 and p-
anisidine (5).  Prior to the reaction, the crude p-anisidine was recrystallized in water heated to ~60oC and 
dried in vacuo.97 While most aldehydes were used without further purification, when necessary, the acid 
contaminant was removed by washing with 10% sodium bicarbonate or distilling at atmospheric pressure.97 
The synthetic protocol was identical for all the mono- and multisubstituted C-aryl(imines). The aldehyde 
and p-anisidine were dissolved in methylene chloride and stirred at room temperature for 1-2 hrs. 
Approximately 1 mg of camphorsulfonic acid (CSA) was added to the mixture and heating to reflux was 
sometimes applied to promote the condensing of the starting materials. In most instances, conversion to the 
imine was completed within 1 hr and could be followed by TLC.      
 
Scheme 3.03: Synthesis of C-aryl(imines). 
N
H
OCH3
Xn
O
SO3H
cat.
CH2Cl2, rt
O
H
Xn
+
NH2
OCH3
1:1
54 6
X = H, F, Cl, Br, I, NO2, CH3, OCH3, O2CR  
 
 In cases when the aldehydes were not commercially available, the imine precursors could be 
generated by oxidation of the corresponding benzyl alcohols using oxalyl chloride and DMSO (Scheme 
3.04).98 Aldehydes synthesized by this methodology included 2-, 3-, and 4-iodobenzaldehyde (10-12). 
 
Scheme 3.04: Swern oxidation of iodo-benzyl alcohols.  
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 Noncommercial aldeydes bearing an ester functional (13,14) were prepared by the acylation of p-
hydroxybenzaldehyde. β-Lactams generated from 13 and 14 were used to examine the in vitro performance 
of N-thiolated β-lactams possessing a lipophilic, acyloxy substituent while serving as an intermediate for 
the preparation of a p-phenol derivative.   
 
Scheme 3.05: Esterification of p-hydroxybenzaldehyde. 
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 Bis-imine 15 was synthesized by the condensation of the dialdehyde glyoxal and p-anisidine, and 
used to generate bis-β-lactam analogues. Low solubility in organic solvents, however, limited the 
usefulness of 15 as an intermediate for making β-lactams.     
 
Scheme 3.06: Synthesis of bis-imine 15. 
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3.2.2 Synthesis of N-Aryl Protected β-Lactams 6 by Staudinger Coupling 
 
 The most frequently described procedure for preparing monocyclic β-lactams is Staudinger 
coupling. This reaction involves a formal [2+2] cycloaddition of an acid chloride (5) or an activated 
carboxylic acid51c to an imine (4, eg, Schiff base), and was the methodology employed to synthesize N-aryl 
protected β-lactams 6 (Scheme 3.05).  
 
Scheme 3.07: Synthesis of N-aryl protected β-lactams by Staudinger [2+2] condensation. 
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 The mechanism of β-lactam formation in the synthesis of 6 does not entail a direct acylation of the 
imine with an acid chloride, but rather a ketene cycloaddition. The ketene forms by deprotonation of an 
activated acid with a Lewis base such as ethyldiisopropylamine. If a base is absent or added after the imine 
and acid are combined, the ketene does not form and the cycloaddition generally occurs via direct coupling 
of 4 and 5 resulting in a β-lactam with a trans configuration.51c Table 3.01 categorizes the three types of 
ketenes that undergo Staudinger coupling. The substituents of 4 and 5 ultimately determine the 
stereochemical outcome of the reaction.  Acid chlorides applied to the synthesis of 6 give rise to 
exclusively the Bose-Evans ketene which confers the cis conformation when coupled with a diaryl imine 
(4).51c This was verified for all C4 aryl analogues from the chemical shifts in the 1H NMR spectra. 
Table 3.01: Stereochemical outcome of the Staudinger reaction of ketenes and imines.51c  
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 N-Aryl imines (4) exist primarily in the E-configuration and give rise to cis β-lactams. Although 
thermodynamically less stable, kinetics allows the cis product to be generated via an anionic intermediate 
which is stabilized by the electron-rich groups of the Bose-Evans ketene. Conversely, if a Z-imine was used 
in the reaction, a trans β-lactam will result depending on the stability of the intermediate.  
 
 The stereochemical outcome of these reactions is rationalized by the pathway depicted in Scheme 
3.08. Orthogonal attack of the imine on the least hindered side of the ketene carbonyl center forms a 
zwitterionic intermediate which can (1) interconvert via the anionic intermediate, (2) revert back to the 
imine and ketene, or (3) lead to cis and trans β-lactams.  Both the β-lactam and imine can interconvert as 
well, but only if the ring opens regenerating the zwitterionic species.  
 
Scheme 3.08: Ketene-imine cycloaddition. 
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 The ketene precursors (16) were synthesized from the corresponding carboxylic acid and thionyl 
chloride. This general method was used to make acid chlorides 16 and 18. Although methoxyacetic acid 
was commercially available, acetoxyacetic acid (17) were prepared from glycolic acid and acetyl chloride 
in quantitative yield. 
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Scheme 3.09: Synthesis of acid chlorides 16 and 18.  
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 The yields of the Staudinger reaction involving acid chlorides 16 and 18 varied greatly depending 
on the acid chloride, solvent and temperature. Little variation was observed for the different imine 
derivatives or the type of base. Poor yields did however result when imine 15 was applied toward the 
syntheses of bis-β-lactam analogues. 
 
Scheme 3.10: Synthesis of bis-β-lactam from bis-imine 15. 
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 Staudinger coupling reactions typically require a tertiary amine base such as triethylamine or 
ethyldiisopropylamine (eg. Hünig's base). The latter was utilized for most reactions but could be replaced 
by triethylamine with little effect on the isolated yields. A minimum of 3 equivalents of base was needed to 
enable the reaction to go to completion. Mechanistically, the excess is required to (1) generate the ketene, 
(2) serve as a proton scavenger, and (3) act as a nucleophile (Nu-) in formation of the anionic intermediate 
(Scheme 3.06).    
 
 Toluene became the solvent of choice when yields substantially increased for reactions involving 
acid chloride 16. Another advantage the nonpolar medium offered was that the ammonium salt of 
ethyldiisopropylamine/triethylamine and sometimes the β-lactam itself were insoluble in toluene at room 
temperature. After filtration, the product could be cleanly isolated from the precipitated material or 
triturated from the concentrate of the reaction using diethyl ether or ice-cold methanol. The greatest effect 
on yield however, was the acid chloride component. Phenoxyacetyl chloride routinely gave the best yields 
followed by the methoxy- and acetoxy- counterparts. Of note, the acid chlorides and their respective 
ketenes were sensitive to heat and decomposed if the temperature was raised too high. Therefore, all 
reactions were performed at 0oC and allowed to warm to room temperature. Only in the syntheses of the 
bis-lactams analogues was reflux required, and generally gave low yields depending on the acid chloride. 
 
3.2.3 Dearylation of β-Lactams 6 with Ceric Ammonium Nitrate 
 
 Kronenthal99 reported a general method to remove the p-anisyl moiety of protected β-lactams 
using ceric ammonium nitrate (CAN) in aqueous acetonitrile. The same procedure was applied in the 
synthesis of N-methylthio β-lactams by the conversion of N-anisyl lactams 6 to N-protio lactams 9. During 
the oxidation, the electron-rich aromatic ring permits cleavage by a radical generating species such as 
CAN. The reaction proceeds through intermediate 19 (Scheme 3.11) which decomposes to the dearylated β-
lactam and benzoquinone when washed with a 5% sodium bisulfite solution.  
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Scheme 3.11: Oxidative dearylation of β-lactams 6. 
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 Deprotection of the C4 aryl analogues 6 gave low to moderate yields depending on the solubility of 
the  N-arylated β-lactam in acetonitrile. In most cases, the β-lactams did not dissolve and heating was 
required to completely solubilize the starting material. Resuspension of the heat solution in an ice water 
bath was necessary before the CAN solution could be added otherwise the reaction would fail. Most 
oxidations were complete after 30 minutes with light stirring followed by aqueous workup of the ethyl 
acetate extracts with sodium bicarbonate and sodium bisulfite.  
 
3.2.4 N-Methylsulfenylation of β-Lactams 9 
 
 Two methods were employed to incorporate the N-methylthio substituent onto the N-protio lactam 
9. Initially, the procedure reported by Shah and coworkers90 was applied toward the synthesis of 3 (Scheme 
3.12) using methylthiomesylate (20). Deprotonation of 9 with n-butyllithium at low temperature followed 
by lithium exchange with the methylthio moiety of 20 afforded the N-methylthio β-lactams in good yields. 
Methylthiomesylate was prepared by the oxidation of methyl disulfide with 30% hydrogen peroxide in 
accordance to an already established literature procedure.90   
 
Scheme 3.12: Synthesis of N-methythio β-lactams and methythiomesylate. 
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 Another method of introducing a methythio substituent was reported by Miller using N-
methylthiophthalimide (21).86  The reaction employs a mild base such as triethylamine or Hünig's base 
under reflux conditions in a low boiling, nonpolar aprotic solvent. The synthesis of 21 was carried out 
following previously described literature procedures.100 From methyl disulfide, chlorine gas was used to 
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generate the methylsulfenyl chloride in situ then cannulated into a flask containing 1 and 1.5 equivalents of 
phthalimide and triethylamine, respectively. 
  
Scheme 3.13: Synthesis of N-methythio β-lactams and N-(methyl)thiophthalimide.86,100
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 Reactions involving sulfur reagent 21 was found to be more efficient and reliable than 20 and 
became the method of choice for the N-methylthiolation of all C4 aryl β-lactams. 
 
3.3 The Structure-Activity Profiling of C4 Phenyl Analogues 
 
3.3.1 Synthesis and Microbiological Evaluation of 67-81 
 
 The SAR studies were initiated with the synthesis and microbial screening of  monosubstituted C4 
aryl β-lactams 68-81. As a control, an unsubstituted phenyl analogue (67) was included in the series for 
comparison. A diverse selection of functionalities and locations on the phenyl ring was chosen for the 
studies including: halogen (68-74), alkyl (75), ether (76), nitro (77,78), nitrile (79), and ester (80,81) 
substituents. Scheme 3.14 illustrates the synthetic route to compounds 67-81 and the intermediates involved 
in their preparation.  
 
Scheme 3.14: Synthesis of C4 phenyl analogues 67-81. 
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 A later addition to this series was a phenolic β-lactam 83 which was synthesized by the hydrolysis 
of the acrylate intermediate 66. Although p-hydroxybenzaldehyde was commercially available, the alcohol 
residue required protection for the Staudinger coupling and CAN oxidation steps. Hydrolysis of 66 afforded 
82 in quantitative yield and subsequent sulfenylation of the β-lactam gave the p-phenol analogue in two 
steps from the acrylate (Scheme 3.15).     
 
Scheme 3.15: Synthesis of C4 phenolic β-lactams from 66. 
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 A diverse panel of pathogenic and nonpathogenic bacteria representing 17 genera and 33 species 
were used in the preliminary screening. Compounds were evaluated in vitro by agar diffusion (Kirby-
Bauer) in accordance with the guidelines recommended by the National Committee for Clinical Laboratory 
Standards (NCCLS).101 Initially, the disc variation of the test was applied to assess the susceptibility. Here, 
a 6 mm cellulose disc impregnated with 20 µg of the drug was placed on an agar plate inoculated with the 
test organism. Following incubation, the zones of growth inhibition were measured to determine the 
potency of the drug after 24 hrs. Another variation which gave consistent results utilizes a well instead of a 
disc to facilitate drug diffusion. The plates were prepared by cutting 6 mm circular holes into the inoculated 
medium and applying 20 µg of the test drug in dimethylsulfoxide (DMSO) to the wells. After incubation, 
the zone diameters were measured in millimeters to ascertain the relative potency. The results of the 
susceptibility test are depicted in Table 3.03. 
 
 The β-lactams demonstrated significant inhibitory activity against Bacteroides, Bacillus, 
Micrococcus, Neisserria, Streptococcus and Staphylococcus species. Peculiarly, these six genera derive 
from four distinct taxonomic orders defined by their genetic, morphological and metabolic traits (Table 
3.02). Although nine genera in toto were found to be susceptible to the lactams, few taxonomic 
relationships could be used to ascertain the spectrum of activity. The class of bacteria that responded the 
most to the N-thiolated β-lactams was the "Bacilli" which consists of two orders: Bacillales and 
Lactobacillales. Susceptible members of this taxonomic class included species of Bacillus, Staphylococcus 
and Streptococcus. Enterococcus Lactococcus and Listeria which are also affliated with the "Bacilli" were 
mostly insensitive to the drugs, though. The sporadic activity among bacteria species suggests the 
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compounds may be acting in a different manner from traditional broad spectrum β-lactam antibiotics. 
Chapter IV further examines the metabolic relationships of these microbes and reasons for the randomness 
in the activities observed for N-thiolated β-lactam antibiotics.         
 
        Table 3.02: Comparison of microbes sensitive to N-thiolated β-lactam antibiotics. 
order genera Gram (±) morphology respiration activitya
Enterobacteriales Salmonella – rod aerobic weak 
Pasteurellales Haemophilus – rod aerobic weak 
Vibrionales Vibrio – rod anaerobic weak 
Bacillales Bacillus + rod aerobic medium 
Bacteroidales Bacteroides – rod anaerobic medium 
Lactobacillales Streptococcus + cocci anaerobic medium 
Neisseriales Neisserria – cocci aerobic medium 
Actinomycetales Micrococcus + cocci aerobic strong 
Bacillales Staphylococcus + cocci anaerobic strong 
  abased on well diffusion data: strong = >20 mm; medium = 15-20 mm; weak = <15 mm. 
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       aBacteria were obtained from various commercial mmercial sources. See pg. 87  for more information; bWell diffusioand nonco n on Mueller-Hinton agar; cWell difussion on  
Bacteria sppa                       
Table 3.03: In vitro susceptibilities of bacteria to N-methylthio β-lactams. 
 67                68 69 70 71 72 73 74 75      76 77 78 79 80 81 83 96 97 98 99 PEN CIP
Bacteroides fragalis                15 15 15 0 0 15 0 0 13 0 0  
Bacillus anthracis 21                     
                      
                    
                      
                      
                    
                     
                    
                      
 8 7 8                   
                      
 0                     
                      
  0                    
                      
                    
                      
                      
                      
                      
                  
                      
                      
             
                      
                      
                 
                    
                      
               
                      
                     
25 24 20 24 20 22 22 20 18 10 20 14 24  20 37
Bacillus cereus 18 21 20 19 18 19 19 23 18 18 10
 
15 13
 
21 19 20 12 33
Bacillus coagulans 14 20 20 20 18 13 15 22 15 13 17 0 10 0 17 14 22 27 40
Bacillus globigii 14 19 18 18 20 17 14 20 15 14 16 0 19 0 22 16 20 30 41
Bacillus megaterium 11 20 16 14 16 15 13 17 12 10
 
14 0 15 10
 
21 14 20 41 40
Bacillus subtilis 12 18 15 14 19 14 14 18 10 0 16 0 19 0 21 12 18 41
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Bacillus thuringensis 15 20 19 17 20 17 17 19 15 13 17 0 16
 
10 20 17 20 0 33
 Enterobactor cloacae 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Escherichia coli 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Haemophilus influenzae 
Klebsiella pneumoniae 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Listeria monocytogenes 
Micrococcus luteus 21 24
0
31 29 25 24 24 25 21 22 21 25 26 25 26 40
0Mycobacterium smegmatis 
Neisserria gonorrhoeaec 19 16 14 12 12 14 13 12 12
 
12
 
12 13 13 10 0
Proteus mirabilis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 18
Pseudomonas aeruginosa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Salmonella typhimurium 8 10 10 8 0 0 0 0 0 0 0 0 0 0 0 0 25
Serratia marcescens 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Staphylococcus aureus 25 26 23 24 23 27 23 24 23 28 17 15
 
14
 
16
 
21 18
 
18 25 24 23 33
Staphylococcus captitis 19 26 21 21 24 27 19 22 15 18 18 13 0 15 21 19 23 47
Staphylococcus cohnii 17 22 22 22 23 23 20 14 18 17 19 18 17 18 17 19 19 43
Staphylococcus epidermidis 31 29 25 23 30 29 23 28 25
 
20 18 20
 
20
 
20
 
20
 
17
 
20
 
24
 
25
 
23 50
Staphylococcus lentus 12 18 18 18 15 17 18 15 0 10 16 0 0 0 0 0 15 34
Staphylococcus lugdunensis 20 28 28 28 28 28 24 22 19 20 23 19 16 19 22 19 18 47
Staphylocococus saprophyticus 17 20 21
 
18
 
19 23 18 18 15 13 15 15 14
 
15 16
 
15 22 19
 
22 30
Staphylococcus simulans 14 16 0 0 18 18 18 16 14 14 12 13
 
0
 
15 0 13 21 0 20 13
Staphylococcus warneri 17 25 28 28 24 26 20 22 17 17 18 20 17 13 17 19 20 38
Staphylococcus xylosus 18
 
28
 
22 24 26 27 24
 
24 16 20
 
22 18
 
17 18
 
13 22 22 34
 Streptococcus agalactiad 0 11 0 13 15 0 0 0 14 0 11 0 15 0 14
Streptococcus pyrogenesd 14
 
11 12 14 14 14 0 0 14 0 21 14 16 10 14
Vibrio cholerae 9 10 9 0 0 12 0 0 8 0 0 0 10 0 12 17
Zone of Growth Inhibition (mm)b
        chocolate agar; dWell diffusion on tryptic soy agar. 
 
3.3.2 Structure-Activity Relationship of 67-81 and 83 Against MSSA 
 
 Based on the biological evaluation of lactams 67-81 and 83, it was evident that aromatic 
substitution is not a prerequisite for antimicrobial activity. Lactam 67 demonstrated equal or greater 
propensity to inhibit the in vitro growth of bacteria to those containing functionalized phenyl rings (68-
81,83). The influence of aromatic substitution on activity appeared to be moderate. An antagonistic effect 
was observed for analogues possessing highly polar phenyl ring residues against the 33 member panel of 
bacteria. Compounds containing powerful deactiving or activating groups such as nitro (77,78) and nitrile 
(79) or acyloxy (80,81) and hydroxy (83), respectively, were about 30% less active than 67. Although the 
reason for this anomaly is unclear, the ability for a highly polarizable aromatic ring to attenuate bioactivity 
was evident particularly against species of Bacillus and Staphylococcus.  
 
Figure 3.01: Percent relative activity of penicillin for monosubstituted analogues against methicillin-
susceptible Staphylococcus aureus (MSSA).  
 
 
 No discernable differences in bioactivity could be ascertained for compounds 68-76. These 
include derivatives that possess weak deactivating aromatic substituents like halogens (68-74) and mild-
medium activating groups such as alkyl (75) and alkoxy (76). The bacteria most susceptible were 
Staphylococcus and Micrococcus luteus. Bacillus spp. was also sensitive to the drugs though not to the 
same extent. Location and size of the aryl ring substituent had no apparent influence on biological activity. 
The expectation was that increasing ring bulk would lead to erosion of bioactivity. This however, was not 
the case for the chloro-, bromo-, and iodo-substituted lactams 68-74. As illustrated in the graph above, the 
percent activity of penicillin against methicillin-susceptible Staphylococcus aureus (MSSA; ATCC 25923) 
is nondiscrete for the haloaryl, tolyl, and methoxyphenyl derivatives. Although the zone sizes were slightly 
larger for ortho-substituted 68, 72, and 76, the minimum inhibitory concentrations (MICs) remained at or 
about 10 µg/ml for MSSA. 
 
3.3.2 Structure-Activity Relationship of 67-81 and 83 Against MRSA 
 
 Compounds 67-81 and 83 were tested against a panel of methicillin-resistant Staphylococcus 
aureus (MRSA) isolates. Eight of the ten strains were obtained from Lakeland Regional Medical Center 
and identified as USF652-659. Prior to screening, each of the Lakeland isolates was assayed for β-
lactamase activity. Using a previously described acidimetric assay to monitor the hydrolysis of penicillin 
G,102 all eight strains was verified to be β-lactamase-producing forms of S. aureus.    
 
 Table 3.04 and Figure 3.02 compare the relative effectiveness of 67-81 and 83 to inhibit the in 
vitro growth of MRSA. The glycopetide and current treatment of choice for MRSA-type infections, 
vancomycin, and penicillin were included as controls. Amazingly, the analogues retained their biological 
activity against forms of S. aureus that were resistant to penicillin. The structure-activity relationship of 67-
81 against the multi-drug resistant strains parallel those observed in the microbiological evaluation of 
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MSSA. It was apparent based on these findings that N-thiolated β-lactams are transparent to the destructive 
forces of β-lactamase (eg. penicillinases) which act to neutralize the ability of penicillins and 
cephalosporins to impede cell wall biosynthesis. In the case of benzylpenicillin, the impact of β-lactamase 
on susceptibility was quite evident for the MRSA. A 50% reduction in zone size was detected against the 
ten strains for this "activated" β-lactam antibiotic.        
 
  Table 3.04 Kirby-Bauer data for analogues 67-81 and 83 against S. aureus. 
Straina                                     
 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 83 PENc VANd
MSSA ATCC 25923  25 26 23 24 26 27 23 24 23 28 17 15 14 16 21 18 33  
MRSA ATCC 33591 20 26 26 19 29 28 25 26 17 21 17    20 14 15 20 
MRSA ATCC 43300 21 29 25 20 26 30 23 25 19 24 19    17 0 18 20 
MRSA USF652 30 30 24 26 25 34 23 27 23 29 18 17 14 17 16 14 8 19 
MRSA USF653 30 29 28 27 27 29 23 24 27 32 23 22 16 17 15 19 15 18 
MRSA USF654 26 28 22 23 26 27 21 24 23 27 20 16 12 15 20 18 10 19 
MRSA USF655 25 27 23 23 29 28 24 24 23 27 22 14 12 15 19 18 14 19 
MRSA USF656 28 29 22 25 24 29 22 25 25 28 22 18 13 16 20 19 12 21 
MRSA USF657 27 29 22 23 27 28 25 24 23 27 20 18 10 16 21 19 12 18 
MRSA USF658 26 27 19 24 20 28 23 20 22 26 21 17 12 14 19 18 19 18 
MRSA USF659 24 24 18 18 20 23 22 17 20 23 18 11 12 14 17 0 16 18 
Zone of Growth Inhibition (mm)b
         aUSF652-659 were obtained from Lakeland Regional Medical Center, Lakeland, FL. 
      bKirby-Bauer well diffusion on TSA.          
         cBenzylpenicillin potassium salt (penicillin G) 
      dVancomycin hydrochloride. 
              
 Comparison of in vitro susceptibilities of MRSA to N-methylthio β-lactams and vancomycin 
yielded promising results. In the graph below, the mean zone data of the ten MRSA isolates for compounds 
67-80 and 83 is depicted as percentage of activity relative to vancomycin. The ability to inhibit the growth 
of MRSA was greatest for analogues 67-76. The β-lactams consistently demonstrated 20-50% and 50-75% 
greater anti-MRSA activity than vancomycin and penicillin, respectively. 
 
Figure 3.02: Percent relative activity of vancomycin for monosubstituted analogues against methicillin-
resistant Staphylococcus aureus (MRSA). 
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3.3.3 Effect of Drug Amount Versus Zone Diameter 
 
 Subsequent to the screening of compounds 67-81, a series of experiments were conducted to 
calculate the optimal amount of drug needed for well diffusion measurements. The results of these studies 
are depicted in graphs of Figures 3.03 and 3.04. Plots 3.03a and b draw a comparison of the relative 
susceptibilities of MSSA and MRSA to lactam 69 and penicillin, respectively, at equimolar amounts. The 
first graph reveals a linear relationship between the µgs of lactam 69 and the zone diameter generated. 
Against MSSA (ATCC 25923), the inhibitory activity of 69 rose steadily as the amount increased from 2.8 
to 56.2 µg/well. The same trend was observed against MRSA (ATCC 43300) indicating that the compound 
retained full activity against the β-lactamase-producing strain at all drug loadings. Conversely, Figure 
3.03b illustrates that the potency of penicillin G against the drug-resistant strain was precipitously lower 
relative to the MSSA isolate. Although the antibiotic was equally effective at all concentrations for MSSA, 
no anti-MRSA activity was observed until greater than 28 µg was applied to the wells. The marked 
decrease in susceptibility was again a clear indication of the capabilities penicillinases have to neutralize 
traditional β-lactams antibiotics such as penicillin G.  
 
Figure 3.03: Equimolar drug loads versus zone of growth inhibition of (a) lactam 69 and (b) penicillin G 
against MSSA and MRSA. 
 
 
 
Figure 3.04: Equimolar drug loads versus zone of growth inhibition of lactam against (a) MSSA and (b) 
MRSA. 
 
 
  
 Figures 3.04a and 3.04b compare the performance of 69 against MSSA and MRSA to penicillin G 
and vancomycin. The first plot depicts the effectiveness of the β-lactam and penicillin G at parallel 
concentrations against MSSA. It was discovered that compound 69 produced smaller zones than penicillin 
against the non-resistant S. aureus strain up to 200 µmol-3/well (equivalent to 51.4 µg of 69, or 64 µg of 
penicillin G). The ability of penicillin to yield zone sizes >25 mm even at 10 µmol-3  was consistent with 
the lower MIC value of the antibiotic over lactam 69. As predicted, a reversal in activities occurred when 
the two drugs were screened against MRSA (Figure 3.04b). Lactam 69 demonstrated superior ability to 
inhibit the in vitro growth of the drug-resistant strain over a 10-200 µmol-3 range compared to penicillin. 
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Vancomycin also displayed less potency than 69 when greater than 75 µmol-3 of compound was applied to 
the well. 
 
3.3.4 Minimum Inhibitory Concentration (MIC)101 
  
 The lack of ionizable groups makes N-thiolated β-lactams insoluble in aqueous media, therefore 
minimum inhibitory concentrations (MIC) proved to be difficult to measure. Some lactams could be 
solubilized if a 9:1 ratio of aqueous media to dimethyl sulfoxide (DMSO) was utilized. It was reported that 
S. aureus could sustain logarithmic growth in presence of 8-10% DMSO and this was reconfirmed prior to 
the MIC determinations. Unfortunately, most of analogues could not be solubilized unless 15-25% DMSO 
was present in the growth medium.    
 
 Serial dilutions of TSB media was the initial method of choice to determine MICs though the 
results were neither consistent nor comparable to the potency levels seen with the raw data from the Kirby-
Bauer diffusion evaluation. The agar variation, however, provided dependable results that were not 
obtainable by broth dilutions of the lactams. The agar media were prepared in 48 well plates and inoculated 
by applying a 1 µl suspension of freshly prepared cultures to the well. Following a 24 hrs incubation 
period, the plates were  examined for growth. The lowest concentration to inhibit the visual growth of 
bacteria was recorded as the MIC. The MIC values for lactam 68 against MSSA (ATCC 25923) was 10 
µg/ml.  Though penicillin G (<1 µg/ml) was superior to 68, the antibiotic did not retain the same 
effectiveness against the MRSA isolates. The MICs to inhibit 90% of the MRSA strains (MIC90) was >125 
µg/ml for penicillin G in comparison to 8 µg/ml for compound 68.          
 
3.3.5 In Vitro Activity in Blood Serum 
 
 The ability of  a pharmacological agent to retain its antibacterial properties in blood serum is an 
important attribute if the drug were to be used clinically. Growth studies designed to examine the chemical 
stability of the N-thiolated β-lactams in the presence of serum were performed against MRSA. The graphs 
in Figure 3.05 depict the efficacy of 68 to inhibit the in vitro growth of S. aureus over 24 hrs in the 
presence of serum. Bacterial growth was monitored during the course of the study by optical density of the 
cultures at 630 nm.   
 
Figure 3.05: Growth studies of MRSA with and without blood serum.   
 
 
 
 It was apparent based on these studies that the chemical components of blood serum did not affect 
the lactam's ability to hinder microbial growth. Figure 3.05a and 3.05b are plots of the growth study 
performed in Mueller-Hinton broth (MHB) in the presence or absence of blood serum. In the antibiotic-free 
media (DMSO only), a steady progression of cellular growth was observed over 24 hrs for S. aureus. 
Conversely, bacteria viability was abruptly halted in the presence of lactam 68 at 1x MIC (8 µg/ml) after 1 
hr. Over 6 hrs, the drug uniformly stunted microbial growth in the serum and serum-free MHB. These data 
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suggest that the in vitro half-life (t½) of lactam 68 with serum extends beyond 6 hrs. Between 6 and 24 hrs 
though, both media were equally turbid to the control (DMSO only) suggesting that the t½ is less than 24 
hrs. It was postulated based on these finding that N-thiolated β-lactams could be bacteriostatic antibiotics. 
Intrinsically, the drugs may not be capable of causing cell death but act in a manner that suppresses growth 
until drug levels were low enough for the bacteria to reproduce. The next section further examines the 
nature of N-thiolated β-lactams to affect the viability of bacteria. 
 
3.3.6 Time-Kill Studies       
 
  Antibiotics can be categorized by the way they affect the viability of bacteria.  Classification  as a 
bacteriostatic or bacteriocidal agent can provide insight on the pharmacokinetic properties such as effective 
dosage. Additional information on the cellular target of a new antibiotic can be extracted from the intrinsic 
nature of other known drugs. Apropos those antibiotics that inhibit protein synthesis (ie, chloramphenicol) 
or secondary metabolites (ie, sulfa drugs) have been historically considered bacteriostatic agents whereas 
those that disrupt the cell wall (ie, penicillin) or directly damage DNA (ie, metronidazole) are bactericidal.  
 
Figure 3.06: Time-kill studies of 68 against (a) MSSA and (b) MRSA. 
 
 
 
 The effect of N-thiolated β-lactams on cell survival was examined by monitoring the growth of 
bacteria at high drug concentrations. Early logarithmic phase cultures of S. aureus were used in the study 
and growth was measured by viable cell counts. Figures 3.06a and 3.06b depicts cell survival  for MSSA 
and MRSA, respectively, when cultured in the absence or presence of lactam 68 over a 2 hr time frame. In 
the absence of lactam 68, MSSA and MRSA grew logarithmically; in the presence of 68, bacterial growth 
was immediately halted. While reproduction ceased at the MIC level of the lactam as well as at 10x MIC, 
the number of viable cells remains constant throughout the duration of the experiment. Consequently, 
bacteria growth was clearly inhibited by lactam 68, but little to no decrease in cell population was 
observed. These data provide substantial evidence that even at high drug concentrations, N-methylthio β-
lactams are bacteriostatic agents toward staphylococci. 
 
3.4 Multihalogenated Phenyl Analogues and Their Biological Activities 
 
3.4.1 Synthesis of Multihalogenated Phenyl Analogues   
 
 Follow up studies on the structure-activity relationships of C4 phenyl analogues were conducted to 
examine the effect of multisubstitution and lipophilicity on the bioactivity of N-thiolated β-lactams. Ergo 
the multihalogenated analogues 96-99 were prepared (Scheme 3.16) in the same manner that was 
previously described in Section 3.2. The aldehydes  employed to make the pentafluoro- (84), dichloro- 
(97,98), and tricholorophenyl (99) N-(methoxyphenyl)imines were obtained from commercial sources. 
Staudinger coupling followed by anisyl removal and N-thiolation of the protio β-lactams 92-95 with N-
(methyl)thiophthalimide (21) gave 96-99 for screening.  
 
 
 
 44
Scheme 3.16: Synthesis of multihalogenated N-thiolated β-lactams. 
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3.4.2 Antimicrobial Activity of Multihalogenated Phenyl Analogues 
 
 Multihalogenated β-lactams 96-99 demonstrated comparable bioactivities to the monosubstituted 
analogues 68-74 (Table 3.02). The spectrum of activity was again narrow which included species of 
Bacillus, Micrococcus, and Staphylococcus. The multichlorinated lactams 97-99 were equipotent to their 
monosubstituted counterparts 68-70 against MSSA and MRSA. The di- and trisubstituted analogues 
displayed about 70% the activity of penicillin against MSSA (Figure 3.07a) and 20-40% greater potency 
against 10 strains of MRSA than vancomycin (Figure 3.07b).  
 
Figure 3.07: Percent activities of lactams 96-99 against (a) MSSA and (b) MRSA.  
 
 
 
 Surprisingly, both forms of S. aureus were least susceptible to the pentafluorinated derivative 96. 
It was postulated before these results that the added hydrophobicity by the fluorine atoms would confer 
enhanced bioactivity to the β-lactams. Lipophilic substances have been known to permeate cell membranes 
amid greater efficiency thus increasing the intracellular bioavailibilty of the drug. This was clearly not the 
case for lactam 96. Though the reason for the attenuation of potency is unknown, it is possible that 
repulsive forces evoked by the electronegativities of the fluorine atoms could decrease recognition and 
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binding of the lactam to the biological target. However, other explanations can also be put forth. More on 
the mechanism of action and reactivity of N-thiolated β-lactams will be discussed in chapter IV.      
 
3.5 N-Sulfenylated Analogues and Their Biological Activities 
 
 Based on the data gathered from the microbial screening of 67-81, 83, and 96-99, it was apparent 
that functionalization of the aryl ring will not improve the in vitro performance of the β-lactams. Though 
few structure-activity relationships could be established from the aryl substituted series, it was believed that 
modification of the sulfur-bearing substituent could have the greatest impact on biological activity. This 
section examines the antimicrobial properties of N-thiolated β-lactams having different sulfenyl 
substituents attached to the ring.  
 
3.5.1 Synthesis of N-Sulfenylated Analogues 
 
 A series of 10 other sulfenyl analogues was synthesized using N-thiolating reagents 94-99.100 As 
described in Section 3.2.4, the N-thiophthalimides were prepared via chlorination of the corresponding thiol 
or disulfide to generate the sulfenyl chloride in situ. The volatile liquid was then canulated into a flash 
containing phthalimide and triethylamine. The reactions were performed neat for 1 hr in an ice bath   
(Scheme 3.17). Reagents 94-99 were then recrystallized from methanol and used without further 
purification. 
  
Scheme 3.17: Synthesis of N-thiophthalimide reagents 94-99.100 
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 N-Sulfenylated derivatives of the alkynyl lactam 1 were the first to be synthesized and evaluated 
for antimicrobial activity. Compounds 101-106 were prepared from 100 by base-promoted thiolation using 
the corresponding N-thiophthalimide (94-99) (Scheme 3.18). 
 
Scheme 3.18: Synthesis of N-sulfenyl analogues 101-106. 
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 Sulfenylated analogues of 67 were also synthesized from the phenyl-substituted lactam 49 using 
N-thiophthalimides 94-97 (Scheme 3.19). 
 
Scheme 3.19: Synthesis of N-sulfenyl analogues 107-110. 
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3.5.2 Antimicrobial Susceptibilities to Lactams 101-109 
  
 A structure-activity profile could be established for β-lactams possessing larger sulfur-bearing 
substituents. The alkynyl and phenyl analogues, 101-106 and 107-109, respectively, were screened against 
a panel of bacteria that were known to be susceptible to this drug class. In comparison to the N-methylthio 
β-lactams 1 and 67, a 5-40% reduction in the zone diameter was detected for 101-109.  The reduced  
bioactivity was observed against species of Staphylococcus, M. luteus, and N. gonorrhoeae (Table 3.05). It 
became evident from the data that increasing the sulfur bulk decreased the biological activity of the β-
lactams. This was again somewhat surprising since the hydrophobicity rose without augmenting the in vitro 
performance of the lactam. Presumably, the sulfur moiety which is the most labile group on the molecule, 
has direct involvement in the mode of action. Increasing the size of groups on sulfur could hinder the attack 
of a biological nucleophile or reduce the binding capabilities of the lactam to its cellular target.    
 
              Table 3.05: Kirby-Bauer data for analogues 1, 67, and 101-109. 
Species/Straina                          
  1 67 101 102 103 104 105 106 107 108 109 PENc VANd
MSSA  ATCC 25923  27 25 23 17 15 12 15 15 21 21 16 33  
MRSA USF652 31 30 28 18 15 12 17 18 21 24 18 8 19 
MRSA USF653 30 30 27 20 15 10 16 18 25 24 15 15 18 
MRSA USF654 28 26 23 16 16 12 14 17 18 20 15 10 19 
MRSA USF655 27 25 24 17 17 13 14 15 20 22 16 14 19 
MRSA USF656 30 28 24 18 15 12 15 17 20 20 14 12 21 
MRSA USF657 28 27 25 16 15 12 14 18 17 20 14 12 18 
MRSA USF658 27 26 24 18 18 13 15 18 21 22 17 19 18 
MRSA USF659 24 24 22 16 15 13 16 18 20 20 15 16 18 
S. epidermidis 30 31 23 18  10 16 14 27 25 0 50  
S. saprophyticus 22 22 18 15  10 0 13 16 19 10 30  
S. simulans 21 14 15 15  10 8 12 11 18 0 13  
M. luteus 23 21 24 23  13 15 17 21 16 16 40  
N. gonorrhoeae 13 14 10 8  0 0 0 13 25 0 0  
                        aUSF652-659 were obtained from Lakeland Regional Medical Center, Lakeland, FL.  
                bKirby-Bauer well diffusion on TSA.          
                        cBenzylpenicillin potassium salt (penicillin G)
                        dVancomycin hydrochloride. 
 
 N-Ethylthio lactams (101, 107) and the N-butylthio lactam 108 were the most active members 
from the series of sulfenyl analogues. Compared to 1 and 67, the compounds were slightly less active 
against MSSA but more active than the benzyl (103), phenyl (104), and cyclohexyl (105) analogues (vide 
infra). A linear relationship was established between the bulk of the S-substituent and the observed 
biological activity. In general, the performance of the β-lactams declined as the length of the hydrocarbon 
Zone of row h Inhibition (m )b  G t m
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chain on sulfur increased. The addition of a heteroatom-containing side chain also had an antagonist effect 
on the anti-staphylococcal activity of β-lactam 106. The reason why the β-mercaptoethanol (106) lactam 
was 30% less active to the mercaptoethane (101) lactam is not yet known.  
 
Figure 3.08: Comparison of anti-MSSA activities of lactams 101-109 to penicillin G. 
 
 
 
 The structure-activity relationship observed for lactams 101-109 against MRSA was similar to the 
profile seen vida supra for the susceptible-form of S. aureus. The size of the S-substituent once again had 
the greatest impact on biological activity. All compounds appeared stable to β-lactamase given that no 
alteration of the antibacterial properties was detected. Most possessed between 90 and >100% the 
inhibitory activity than vancomycin though remained less potent than 1 and 67 against eight strains of 
MRSA (Figure 3.09). 
 
Figure 3.09:  Anti-MRSA activity comparison of 101-109. 
    
 
 
3.6 Antibacterial Activity of Heterosubstituted N-Thiolated β-Lactams 
 
 Attempts to make heterosubstituted N-thiolated β-lactams (113) were performed by a substitution 
reaction involving (2-oxo-1-azetidinyl)-thiophthalimides (112). As described in chapter II, 112 has been 
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reported to react with nucleophilic substances such as benzyl alcohol, morpholine, and sodium bisulfite to 
generate 113 in good yields (Scheme 3.20).86  
 
Scheme 3.20: Synthesis of heterosubstituted N-thiolated β-lactams. 
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 Prior to the synthesis of the heterosubstituted N-thiolated β-lactams, N,N'-thiobisphthalimide (111) 
was prepared from the treatment of phthalimide with sulfur monochloride in dry DMF (Scheme 3.21).103  
 
Scheme 3.21: Synthesis of N,N'-thiobisphthalimide (111). 
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 The o-chlorophenyl β-lactam 53 and 111 were refluxed in chloroform (Scheme 3.22) and the 
progress of the reaction was monitored by TLC. Following the disappearance of starting material, the 
product was purified by silica gel chromatography. Surprisingly, the product of the reaction was not 115  
but the dimerized β-lactam 116 depicted in Figure 3.10.  
 
Scheme 3.22:  Reaction of 53 with N,N'-thiobisphthalimide (111). 
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Figure 3.10: Thiolated bis-β-lactam dimers 116 and 117. 
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 The desired intermediate was generated when the m-bromophenyl β-lactam 118 and 111 were 
reacted without heating (Scheme 3.23). 
 
Scheme 3.23: Synthesis of N-phthalimidothio β-lactam 119. 
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 In accordance to the previously described procedure, a 200% mole equivalent of the amine 
nucleophiles, morpholine and diisopropylamines were reacted with 119 at 0−25°C  in attempt to generate 
the heterosubstituted N-thiolated β-lactams 120 and 121 (Scheme 3.24). However, the TLC indicated after 
24 hrs that a reaction had not occurred. Heat was next applied and only then was the starting material 
consumed. Although 119 reacted under reflux, the product that formed was again a β-lactam dimer (117). 
 
Scheme 3.24: Reaction of 119 with morpholine and diisopropylamine. 
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 With the understanding that elevated temperature could not be used for the substitution reactions, 
other types of nucleophiles were attempted such as sodium methoxide and isopropanol. However, once 
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again the desired product (122,123) from the displacement of phthalimide was not formed. Either starting 
material or the N-protio β-lactam (118) resulted from the reaction (Scheme 3.25) 
 
Scheme 3.25: Reaction of 119 with sodium methoxide and isopropanol. 
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 The heterosubstituted β-lactams 116, 117 and 119 were tested for biological activity against 
MSSA and MRSA. Surprisingly, the compounds were found to possess some antimicrobial properties (see 
Table 3.05). Although the lactams were less potent than penicillin for MSSA, they were approximately 
equal to vancomycin in efficacy against MRSA (Figure 3.11). These results contradict previous findings 
that increasing the molecular bulk on sulfur diminishes the activity of the β-lactam (see Section 3.5). To the 
contrary, 116, 117 and 119 were more effective at eliciting an antimicrobial response than the phenyl 
(104,109), benzyl (103), and cyclohexyl (105) S-substituted analogues. Though the reason for this remains 
unclear, it is postulated that the sulfur of the heterosubstituted N-thiolated β-lactams is more electrophilic 
with a second nitrogen bound, making it more reactive, and thus more susceptible, to attack by a biological 
nucleophile.  
 
Figure 3.11: Comparison of anti-MSSA and anti-MRSA activities 116, 117, and 119.  
 
 
 
3.7 Additional N-Thiolated β-Lactam Analogues Probed For Biological Activity 
 
 Other N-methylthio β-lactam analogues were synthesized and probed for antibacterial activity that 
did not fit in the series of compounds described in Sections 3.2-3.5. Among these was 127 which contained 
a 2-thiophene substituent instead a phenyl group at the C4 position of the ring (Scheme 3.26). The lactam 
was synthesized by the methodologies previously discussed and tested by well diffusion. The results are 
depicted in Table 3.05. Analysis of the zone data revealed that a C4 phenyl ring is not a requirement for 
antibacterial activity. Lactam 127 was equipotent to the most active N-methylthio β-lactams despite lacking 
a 6-carbon member aryl substituent. These data also suggest that other heterocycles could be placed at C4 of 
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the β-lactam and still retain biological activity. Synthesis of a 2-furan and 2-pyridine analogue was 
attempted, though, both decomposed during the CAN reaction.        
 
Scheme 3.26: Synthesis of 2-thiophene β-lactam 127. 
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 Alternative substituents at the C3 position of the β-lactam were examined for their influence on the 
biological properties (Scheme 3.27). Phenoxy (134) and acetoxy (135,137) derivatives were prepared from 
the corresponding acid chlorides (18,129) and tested by well diffusion. It was apparent from the zone data  
that the larger substituents at C3 do not enhance the efficacy of the lactams (Table 3.06). In particularly, the 
phenoxy analogue of 68 displayed 45% reduced activity with the added molecular bulk.  
 
Scheme 3.27: Synthesis of lactams 134, 135, and 137. 
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 With the implication that increasing the size of the C3 substituent leads to erosion of bioactivity, a 
substituent smaller that methoxy was incorporated and tested against the same bacteria panel. The group 
assigned to the position was a hydroxy which was generated by hydrolysis of the acetoxy group in lactam 
139 (Scheme 3.28). The zone data revealed that the hydroxy analogue 141 was about 25% less effective 
than the methoxy derivative 67 at inhibiting the growth of S. aureus (see Tables 3.03, 3.05).  
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Scheme 3.28: Synthesis of C3 hydroxy substituted analogue. 
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 Based on the Kirby-Bauer data, it appeared that the antibacterial properties are influenced by the 
bulk and polarity of the substituent located at the C3 position of the β-lactam. In this regard, it was 
hypothesized that MeO ≥ AcO > OH > PhO is the order by which the substituents affect the biological 
activity of N-methylthio β-lactams. 
 
                    Table 3.06: Disc diffusion data for various N-thiolated β-lactams. 
Species/Straina                    
 116 117 119 127 134 135 137 141 PENc VANd 
MSSA ATCC 25923  20 15 18 27 15 15 22 19 33  
MRSA USF652 18 21 18 28 18 15 22 15 8 19 
MRSA USF653 19 20 20 28 15 11 25 23 15 18 
MRSA USF654 19 20 22 27 15 11 20 18 10 19 
MRSA USF655 17 19 18 29 14 12 19 20 14 19 
MRSA USF656 18 19 19 28 16 14 23 19 12 21 
MRSA USF657 19 19 20 26 13 11 21 19 12 18 
MRSA USF658 18 16 15 26 15 14 21 18 19 18 
MRSA USF659 18 19 20 24 16 11 20 15 16 18 
S. epidermidis    28 16 16 26  50  
S. saprophyticus    20 14 13 19  30  
S. simulans    0 13 0 13  13  
M. luteus    15 20 20 20  40  
N. gonorrhoeae    11 7 10 15  13  
        aUSF652-659 were obtained from Lakeland Regional Medical Center, Lakeland, FL. 
       bKirby-Bauer well diffusion on TSA.          
                      cBenzylpenicillin potassium salt (penicillin G) 
                      dVancomycin hydrochloride. 
 
3.8 Antifungal Properties of N-Thiolated β-Lactams 
 
 N-Thiolated β-lactams demonstrated unique antifungal properties against two members of the 
genus Candida. The compounds were tested by well diffusion on yeast-nitrogen base agar at 50 µg 
quantities. As a control, clotrimazole at the same amount was tested as a gauge for percent activity. The 
antifungal performance for various N-methylthio β-lactams is depicted in the charts below. Against C. 
albicans and C. tropicalis, a discernable structure-activity profile could be established for the C4 phenyl 
substituted analogues. This contrasted the SAR studies for bacteria where few correlations could be 
detected. 
 
 The most apparent relationship that could be ascertained for lactams possessing anti-Candida 
properties was that they all contained a haloaryl residue. The phenyl (67), tolyl (75), and 2-nitrophenyl (77) 
were completely devoid of activity suggesting that ring substitution has a critical role in drug delivery or in 
binding to the biological target. The position of the halogen appeared to have little effect on the in vitro 
perfomance of the lactam. The monosubstituted β-lactams were equally effective when the halogen was 
located ortho, meta, or para, although the m-chorophenyl analogue (70) was oddly found to be inactive 
against both Candida species (Figures 3.12, 3.11).  
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 Figure 3.12: Comparision of antifungal activities against C. albicans. 
 
 
  
 Another effect that was not observed against bacteria was the enhancement of biological activity 
when the aryl ring contained multiple chlorine atoms. The efficacy of the 97 and 99 to inhibit fungal 
growth was 15-40% greater than the monosubstituted lactams 68 and 69.  
 
Figure 3.13: Comparision of antifungal activities against C. tropicalis. 
 
 
 
 N-Sulfenylated β-lactams 101-109 were also screened against the Candida species and as 
expected, the activity diminished when the size of the S-substituent increased (data not shown).  
 
3.9 Antiviral Properties of N-Thiolated β-Lactams 
 
 In collaboration with Professor Erik De Clercq's laboratory114 at the Rega Institute for Medical 
Research in Leuven, Belgium, the antiviral properties of lactams 1, 69, and 75 were assessed in preinfected 
human HeLa (cervix carcinoma), HEL (human embroyonic lung), and Vero (African green monkey 
kidney) cell cultures. Prior to screening, cytotoxicity measurements were determined for the 3 cell lines and 
recorded as the minimum cytotoxic concentration to induce microscopic alterations in normal cell 
morphology (MCC). The antiviral performance of the antibiotics were subsequently assayed and expressed 
as the minimum concentration to reduce cytopathogenicity by 50% (MIC50).  
 
 The antiviral activitites of the β-lactams against vesicular stomatitis (rhabdovirus), coxsackie 
(enterovirus), and respiratory syncytial virus (pneumovirus) in HeLa cells is shown in Table 3.07. For 
comparison, the antivirals brivudin (nucleoside mimic), (S)-DHPA (S-adenosylhomocysteine hydrolase 
inhibitor), and the ribavarin (reverse transcriptase inhibitor) were included as controls. None of the lactams 
 54
demonstrated inhibitory activities against the 3 viruses. Compounds 1, 69,  and 75 were ineffective at 
subtoxic concentrations greater than 80 µg/ml in HeLa cells whose MCC  value was >400 µg/ml. 
 
                       Table 3.07: Cytotoxicity and antiviral activity of N-methylthio β-lactams 
                        1, 69, and 75 in HeLa (cervix carcinoma) cell cultures. 
Compound   MIC50b  
 MCCa Vesicular Coxsackie Respiratory 
  stomatitis virus Virus B4 syncytial virus 
1 400 >80 >80 >80 
69 400 >80 >80 >80 
75 400 >80 >80 >80 
Brivudin >400 >80 >80 >80 
(S)-DHPA >400 >80 >80 >80 
Ribavirin >400 >80 >80 >80 
                       aminimum cytotoxic concentration (µg/ml); bminimum inhibitory concentration (µg/ml). 
 
 Similarly, herpes simplex virus-1 (HSV-1, strain KOS), HSV-1 (strain TK- KOS ACVr), HSV-2 
(strain G), vaccinia virus, and vesicular stomatitis virus were insensitive to N-methylthio β-lactams at 
concentrations >16 µg/ml in HEL cells (Table 3.08). In Vero cells, the compounds were also inactive 
against parainfluenza type 3 virus, reovirus type 1, Sindbis virus, Coxsackie B4 virus, and Punta Toro virus 
at MICs >16 µg/ml (Table 3.09).                       
 
              Table 3.08: Cytotoxicity and antiviral activity of N-methylthio β-lactams 1, 69, and 75  
               in HEL (Human Embryonic Lung) cell cultures. 
Compound       MIC50
b   
 MCCa  HSV-1  HSV-1 TK- HSV-2 Vaccinia Vesicular 
    (KOS)  KOS ACVr  (G) virus stomatitis virus 
1 ≥16 >16 >16 >16 >16 >16 
69 ≥16 >16 >16 >16 >16 >16 
75 ≥16 >16 >16 >16 >16 >16 
Brivudin >400 0.0256 80 >400 3.2 >400 
Ribavirin >400 >400 >400 >400 16 240 
ACG >400 0.384 9.6 0.384 >400 >400 
DHPG >100 0.0038 0.48 0.0064 >100 >100 
                        aminimum cytotoxic concentration (µg/ml);  bminimum inhibitory concentration (µg/ml). 
 
           Table 3.09: Cytotoxicity and antiviral activity of N-methylthio β-lactams 1, 69, and 75 in  
           Vero cell cultures. 
Compound       MIC50b     
 MCCa Parainfluenza-3  Reovirus-1 Sindbis Coxsackie Punta Toro 
    virus   virus virus B4 virus 
1 400 >80 >80 >80 >80 >80 
69 400 >80 >80 >80 >80 >80 
75 80 >16 >16 >16 >16 >16 
Brivudin >400 >400 >400 >400 >400 >400 
(S)-DHPA >400 48 48 >400 >400 >400 
Ribavirin >400 80 9.6 >400 >400 16 
                   aminimum cytotoxic concentration (µg/ml); bminimum inhibitory concentration (µg/ml). 
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CHAPTER IV 
 
MODE OF ACTION OF  
N-THIOLATED β-LACTAMS 
 
4.1 Introduction 
 
 Antibiotics can be grouped by at least 3 classification schemes: (1) narrow-spectrum vs. broad-
spectrum, (2) bacteriostatic vs. bactericidal, and (3) intracellular vs. extracellular. In chapter III, N-thiolated 
β-lactams were identified as bacteriostatic agents possessing a narrow range of activity which implied that 
the biological target is internalized. Cytostatic agents usually evoke arrest of intracellular processes 
involving biosynthetic pathways through enzyme or secondary metabolite modification. Conversely, 
antibiotics whose function is to weaken the outer periphery of cells (eg, cell wall and plasma membrane) 
are in most cases, cytocidal (Table 4.01). Based on the attributes of existing antibacterials, N-thiolated β-
lactams were believed to act in a different manner from traditional β-lactam antibiotics. The studies 
presented in this chapter examine the lactam's effect on cellular processes in S. aureus in an effort to define 
the mechanism of action.    
 
Table 4.01: Important classes of antibiotics and there respective intrinsic characteristics. 
 representative bacteri- activity cellular cell process 
 member(s) ostatic, cidal spectrum target affected 
I. extracellular      
   a) β-lactams penicillins -cidal broad transpeptidase cell wall 
 cephalosporins     
      
   b) glycopeptides vancomycin, -cidal narrow crosslinkages  cell wall 
 teicoplanin   in cell wall  
      
   c) polymyxins polymyxin B -cidal narrow phospholipids plasma 
        membrane 
      
   d) bacitracin bacitracin A -cidal narrow lipid carrier  cell wall 
II. intracellular      
   a) quinolones Cipro® -cidal broad topoisomerase DNA synthesis 
       
   b) ansamycins Rifadin® -cidal broad RNA mRNA synthesis 
 (rifampicin)   polymerase  
      
   c) macrolides erythromycin -ostatic narrow 50S ribosome translocation 
      
   d) aminoglycosides streptomycin, -cidal broad 16S rRNA initiation 
 gentamicin     
      
   e) tetracycline minocylin -ostatic broad 30S ribosome tRNA binding 
      
   f) chloramphenicol Chloromycetin® -ostatic broad peptidyl tRNA 
       transferase charging 
        
    g) oxazolidinone Zyvox® -ostatic narrow 50S ribosome initiation 
      
4.2 Probing the Modes of Action  
 
 There are at least 3 types of reactions that can occur between N-methylthio β-lactams and a 
biological nucleophile (Nu-) (Scheme 4.01). For the β-lactam class of molecules, it is naturally assumed that 
nucleophilic addition occurs on the carbonyl center of the ring. As in the case of penicillins and 
cephalosporins, a serine residue within the active site of cell wall peptidases adds to the lactam, disabling 
the enzyme. Chemical studies of N-thiolated β-lactams have shown, however, the ring to be less prone to 
nucleophilic ring opening such as hydrolysis, therefore other types of reactivity were considered.      
 
Scheme 4.01: Possible reactions of N-thiolated β-lactams.        
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 Whereas the least reactive substituents are located at the C3 (-OR) and C4 (-Ar) positions of the β-
lactam, the sulfenyl moiety is the most vulnerable to nucleophilic attack. Alkylation is one manner by 
which the cellular target might be chemically altered by the S-methyl residue. Most alkylating drugs react 
with nucleotides to inhibit DNA replication or compromise the integrity of the super helices. Examples of 
DNA alkylating agents include leinamycin and mitomycin. The S-methyl moiety could as well transfer to 
the target to induce an inhibitory response. These 3 pathways will be discussed in sections 4.2-4.4 
presenting the evidence for or against each reaction type. 
 
4.3 N-Thiolated β-Lactams as Acylating Agents 
 
  Deactivation of the penicillin-binding proteins (eg, transpeptidase), is the only mechanism for 
which β-lactam antibiotics are known to eradicate bacteria. A serine residue in the active site of the PBPs 
adds to the carbonyl center of penicillins and cephalosporins, forming a stable ester linkage (Scheme 4.02). 
The addition reaction occurring on the hydroxyl of serine is enhanced by ring strain and a carboxylic acid 
moiety located in proximity to the β-lactam carbonyl. Situated at the β-C of the lactam nitrogen, the acid 
functionality increases the electrophilicity of the carbonyl carbon.51 Repositioning or eliminating the 
carboxylate negates the ability of the antibiotics to irreversibly bind to the PBPs.   
 
Scheme 4.02: Acylation of penicillin-binding proteins (HO-PBP), a serine hyrdrolase, by penicillin.51  
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 The lack of an acid functionality in the N-methylthio β-lactams suggests that attack on the 
carbonyl carbon does not occur. Chemical studies of lactam 68 (Figure 4.01) in buffered media verified the 
ring's stability towards equimolar amounts of potassium hydroxide and serine. In addition, the compound 
was unreactive to commercial β-lactamases (eg, serine hydrolases from B. subtilis) and did not thwart the 
enzyme's ability to hydrolyze penicillin G to the corresponding β-amino acid. However, to prove 
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unequivocally that the N-thiolated β-lactam was not inhibiting the PBPs, light and electron microscopy 
were used to probe for damage or thinning of the cell wall in S. aureus treated with high concentrations of 
lactam 68.  
 
Figure 4.01: N-Protio β-lactam 53 and N-methylthio β-lactam 68.  
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Section 4.3.1 Scanning Electron Microscopy 
 
 Scanning electron microscopy (SEM) is a technique that can be used to examine cell morphology 
at >10,000 magnification. Bacteria exposed to antibiotics that disrupt the cell wall (ie, β-lactams) or 
cytoplasmic membrane (ie, polymyxins) can be observed by SEM for physiological damage elicited by the 
drugs. Cultures of S. aureus inoculated with lactam 68 and penicillin G were inspected by SEM for changes 
in cell size and appearance in comparison to a culture with no antibiotic. The samples were prepared from 
Kirby-Bauer diffusion plates by incision of the agar along the outer zones where bacterial growth is 
inhibited and sublethal doses of the drugs are present.  The advantage of preparing the samples from agar 
cultures as opposed to broth is that a concentration gradient is produced as the antibiotics difuse through the 
solid media, allowing microscopic examination among a range of exposure amounts.            
 
Figure 4.02: Scanning electron microscopy of S. aureus cultured with (a) no antibiotic, (b) lactam 68, and 
(c) penicillin G. 
 
 
 
 Results of the electron microscopy experiments are depicted in Figure 4.02a-c. The first image 
portrays the appearance of S. aureus grown with no antibiotic present. In its natural state, staphylococci 
grow to about 1 µm in diameter and reproduce in clusters of spherical-shaped cells. Cultures treated with 
lactam 68 also resembled S. aureus in its natural state, appearing spherical and uniform with no apparent 
deformities. When exposed to penicillin G, though, the bacteria were no longer uniform in size and shape 
(Figure 4.02c). The cocci appeared wrinkled, concaved, and often sheared resulting from deterioration of 
the cell wall. This was the first substantial evidence that N-thiolated β-lactams do not inhibit bacterial 
transpetidases nor cause rupturing of the cytoplasmic membrane in staphylococcus.   
Section 4.3.2 Light Microscopy 
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 The inhibition of cell wall biosynthesis in Gram-positive bacteria can be detected by standard light 
microscopy. Using the Gram-stain technique, bacteria are able to be distinguished by the thickness (eg, 
crosslinked peptidoglycan content) of their cell walls. The appearances of S. aureus exposed to (a) no 
antibiotic, (b) lactam 68, and (c) penicillin G after staining is shown below. In its natural state, 
staphylococcus produces a thick cell wall which retains the crystal-violet stain upon decolorization with 
95% ethanol (Figure 4.03a). When the bacterium is treated with a peptidase inhibitor, though, the Gram 
stain is lost due to thinning of the peptidoglycan shell. The staphylococci appear pink or red under the light 
microscope as a result. Figure 4.03c reveals the effect of penicillin G on the assimilation of the bacterial 
cell wall. The vast majority of cells manifested the staining characteristics of Gram-negative bacteria as a 
consequence of diminished peptidoglycan incorporation. The limited number of staphylococci that did 
retain the Gram stain in all probability came from the original inoculum before exposure to penicillin G. 
Mature bacteria with intact cell walls are not affected by β-lactam antibiotics and can be Gram stained. 
 
Figure 4.03: Light microscopy of S. aureus exposed to (a) no antibiotic, (b) lactam 68, and (c) penicillin G.  
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(a) (b) (c) 
  
 The effect on cell wall synthesis when S. aureus was treated with lactam 68 is shown in Figure 
4.03b. It was quite apparent that all of the bacteria had completely intact cell walls. The staphylococci 
retained the crystal-violet stain indicating a high level of incorporated peptidoglycan. Based on these 
findings, it was concluded that N-thiolated β-lactams do not inhibit the formation of bacterial cell walls. 
 
4.3.3 Model Membrane Studies
 
  While N-thiolated β-lactams do not appear to inhibit formation of the cell wall, further proof was 
needed to establish that the compounds are not extracellular antibiotics. Microscopy experiments revealed 
that lactam 68 does not cause staphylococcal cells to rupture due to deterioration of the cell wall or plasma 
membrane. Additional evidence, however, was sought to confirm that the integrity of the plasma membrane 
was not being altered by the compounds. 
 
 The lipophilic nature of N-thiolated β-lactams might confer "detergent-like" properties enabling  
incorporation into biological membranes. To determine if lactam 68 can destabilize a phospholipid bilayer, 
model studies were performed in collaboration with Dr. Pavel Grigoriev105 on black lipid membranes (eg, 
poreless membranes) prepared from commercially available long chain fatty acids in a nonpolar medium. 
Incorporation was monitored by electrical conductance of the lipid bilayers; increased conductivity and 
subsequent disintegration of the bilayer signified a disturbance in the membrane. 
 
 For the initial study, conductivity measurements indicated that lactam 68 at concentrations up to 
15 µg/ml (0.06 µM from a DMSO stock solution) did not have an effect on the stability of the bilayer. 
These findings demonstrate that the lactam did not actively absorb into the interface of the hydrophobic 
membrane. Poron formation, the cause for the observed changes in conductance, would have resulted if 
absorption had occurred. Lactam 68 was also assayed with a membrane containing model channels 
(porons) formed by amphotericin B. A change in conductance was observed for this anion-selective, porous 
bilayer, though, further experiments were needed to confirm these results. In addition, this ongoing 
collaboration will next examine the effect N-thiolated β-lactams possessing longer alkyl side chains for 
added lipophilicity.  
      
4.4 N-Thiolated β-Lactams as Alkylating Agents    
 
 The ability of lactam 68 to function as a biological alkylator was next examined. Most antibiotics 
from the family of bioalkylating drugs have nucleic acids as a common cellular target. Hence, 
investigations of the methylation pathway focused on the interaction of N-thiolated β-lactams with 
supercoiled DNA and their effect on DNA strand replication.    
 
 Consideration of the alkylation mechanism derived from the in vivo use of methionine in cells to 
alter the structure and function of proteins, nucleic acids, and phospholipids. Scheme 4.03 depicts the 
manner in which substrates are methylated by methionine in bacteria. Enzyme-dependent sulfenylation of 
adenosine with L-methionine generates S-adenosylmethionine which selectively dealkylates in the presence 
of a methyl transferase and complimentary substrate.    
    
Scheme 4.03: Methylation of a nucleophilic substrate from the conversion of L-methionine to S-
adenosylmethionine. 
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 The clinical application of DNA alkylators is in cancer chemotherapy. Leinamycin107 and 
mitomycin C are examples of antitumor drugs which alkylate guanosine residues in helical DNA  (Scheme 
4.04). Chemical modification of DNA bases can lead to strand breakages with apoptotic consequences. 
With the possibility that N-thiolated β-lactam could be a new member in the drug family of DNA alkylating 
agents, the anticancer properties of the compounds were investigated by researchers at H. Lee Moffitt 
Cancer Research Institute. 
 
Scheme 4.04: Alkylation of guanosine by leinamycin and mitomycin C. 
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4.4.1 Anticancer Properties of Lactam 6826d 
 
 N-Methylthio β-lactam 68 demonstrated unique anticancer properties against human leukemic and 
solid tumor cell lines. In Jurkat T (leukemia) cells, the lactam was found to inhibit cellular mitosis and to 
induce apoptosis through (1) p38 mitogen-activated protein (MAP) kinase activation, (2) mitochondrial 
cytochrome c release, and (3) caspase activation. Activation of apoptosis was measured by the proficiency 
of caspase-3 to cleave poly(ADP-ribose) polymerase (PARP) in lysed Jurkat T cell extracts following 
treatment with lactam 68 (50 µM). Apoptotic commitment was observed after 4 hrs of exposure based on 
the fragmentation of PARP to p38. At this point, the ratio of viable to nonviable cells was 5:1. After 24 hrs, 
the nonviable population increased to 60% as determined by a trypan blue exclusion assay.         
 
 A rise in the S-phase population was also detected for Jurkat T cells treated with lactam 68. Pulse-
labeling experiments with 3H-thymidine confirmed that cells stalled in the S-phase had reduced DNA 
replicating abilities. TUNEL assays further revealed that the attenuation of DNA biosynthesis was due to 
strand breakages occurring prior to the attainment of S-phase.  
 
4.4.2 DNA Cleavage Experiment 
 
               Though substantial anticancer properties were demonstrated by lactam 68, it was unknown if the 
reduced viability of the cancer cells was instigated by chemical modification of DNA. Further experiments 
were required to verify if N-thiolated β-lactams are functional as nucleotide alkylators. A cell-free study 
was performed to detect whether a plasmid treated with an N-methylthio β-lactam could cause strand 
breakage or reduced torsion of supercoiled DNA. Plasmid pBR322 (0.5µg; Sigma Biochemicals) was 
incubated with lactam 68 at 37°C in sodium phosphate buffer (50 mM; pH 7.2) for 24 hrs and analyzed for 
fragmentation or linearization by agarose gel electrophoresis containing 1% ethidium bromide.  
 
Figure 4.04: Supercoiled DNA treated with 
lactam 68 at 5-100 µM. Plasmid pBR322 (0.5µg) 
was incubated with lactam 68 at 37°C in sodium 
phosphate buffer (50 mM, pH 7.2) for 24 hrs and 
analyzed by agarose gel electrophoresis 
(ethidium bromide staining). Lane 1: marker. 
Lane 2: pBR322. Lane 3: pBR322 + DMSO. 
Lane 4. pBR322 + 5 µM 68. Lane 5: pBR322 + 
10 µM 68. Lane 6: pBR322 + 25 µM 68. Lane 7: 
pBR322 + 50 µM 68. Lane 8: pBR322 + 100 µM 
68. Lane 9: marker. 
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 The initial study examined the effect of lactam 68 on DNA integrity at elevated concentrations (5-
100 µM). Results of this experiment are depicted by the gel in Figure 4.04. In lanes 2 and 3, two bands 
were observed for the plasmid in the absence of lactam 68. With the supercoiled pBR322 giving rise to the 
denser band, a weak band of relaxed or "nicked" DNA was formed by the electrical current and passage 
through the gel. Lanes 3-8 contained plasmid samples treated with various concentrations of lactam 68. It 
was evident that the compound did not cause fragmentation or relaxation of the super helix. The bands 
were equivalent in location and illumination to those observed for the untreated plasmids (lanes 2,3) thus 
indicating that chemical modification of the DNA did not occur with 5-100 µM of the lactam present. 
 
Figure 4.05: Supercoiled DNA treated with 
lactam 68 in the presence of thiols. Plasmid 
pBR322 (0.5µg) was incubated with lactam 68 
at 37°C in sodium phosphate buffer (50 mM, pH 
7.2) for 24 hrs and analyzed by agarose gel 
electrophoresis (ethidium bromide staining). 
Restriction digests conducted with EcoR1 were 
performed at 37°C for 1 hr. Lane 1: pBR322 + 
100 µM 68. Lane 2: pBR322 + 100 µM 
glutathione. Lane 3: pBR322 + 100 µM 
glutathione + 100 µM 68. Lane 4: pBR322 + 
100 µM DTT. Lane 5: pBR322 + 100 µM DTT + 100 µM 68. Lane 6: pBR322 + 100 µM 2-
mercaptoethanol. Lane 7: pBR322 + 100 µM 2-mercaptoethanol + 100 µM 68. Lane 8: linearized pBR322 
(EcoR1digest). Lane 9: pBR322 + EcoR1 + 100 µM 68. Lane 10: pBR322 + DMSO. Lane 11: pBR322 + 
EcoR1 + DMSO. 
 
 DNA alkylators are often in a prodrug form requiring chemical or enzymatic activation before the 
nucleotide addition can occur. Leinamycin, for example, is transformed into a potent alkylating antibiotic 
by a thiol-mediated reaction with cysteine or glutathione.109 Cells susceptible to leinamycin possess thiol-
rich intracellular environments which may also be needed for N-thiolated β-lactams to alkylate its cellular 
target. A second study was performed to examine the stability of plasmid pBR322 (5 µM) after treatment of 
lactam 68 (100 µM) with various thiols (100 µM) (Figure 4.05). In lane 1, the plasmid following 24 hr 
exposure to lactam 68 is shown. As expected, the supercoil did not relax or linearized with the antibiotic 
present. DNA samples loaded in lanes 2-7 were incubated with glutathione (lane 2,3), dithiotreitol (DTT; 
lane 4,5), or β-mercaptoethanol (lane 6,7) as possible activators of 68. Samples with lactam also added, are 
located in lanes 3,5, and 7. After 24 hrs, the superhelix of the DNA appeared unaltered by the combination 
of 68 and equimolar amounts of glutathione, DTT, or β-mercaptoethanol. The bands of lanes 2-7 were 
comparable in illumination and location to the antibiotic-free plasmid loading (lane 10). 
 
 To verify the cleavability of the plasmid, pBR322 was linearize with the endonuclease, EcoR1 
(Sigma Biochemicals). Samples containing the digested DNA are located in lanes 8 and 11. A loading 
comprised of lactam 68 and EcoR1 was applied to lane 9 to establish if the compound could function as an 
endonuclease inhibitor. Not surprisingly, linearization of the supercoil DNA was unhindered by the N-
methylthio β-lactam. 
 
4.4.3 Pulse-Labeling Studies of DNA Replication
 
  Disruption of the super helix by chemical modifications of nucleotide bases can cause the arrest 
of DNA replication. To further substantiate that N-thiolated β-lactams are not alkylating drugs or affect 
nucleotide assimilation into double-stranded DNA, pulse-labeling experiments with 3H-thymidine were 
performed to monitor DNA replication in bacteria.110 Protocols of the labeling experiment were as follows: 
cultures of S. aureus grown to early logarithmic phase (104 cfu/ml) were inoculated with 3H-thymidine (3 
µCi/ml) and lactam 68 (20 µg/ml in DMSO from a 1 mg/ml stock; 2x MIC), penicillin G (2 µg/ml; 2x 
MIC), or the inhibitor of DNA replication, ciprofloxacin (30 µg/ml; 2x MIC). A sample containing only 
DMSO (20µl/ml) was used as a control in the study. Aliquots of 50 µl were removed at the appropriate 
time intervals and precipitated in trichloroacetic acid (TCA). Incorporation was measured by scintillation 
counts following filtration of the TCA precipitated material on glass fiber filters.  
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 The labeling experiments revealed that lactam 68 has no effect on DNA replication in 
staphylococcus (Figure 4.06). Figure 4.06a depicts thymidine incorporation as a percent of the control for 
the three antibiotics. As expected, ciprofloxacin (CIP) was the most potent, inhibiting 65% of thymidine 
utilization after 30 mins. Conversely, with lactam 68 and penicillin G (PEN) present, ≥90% of the 
nucleotide was converted into DNA. The plot in Figure 4.06b further details the rate of thymidine uptake 
over a period of 1 hr. Again, ciprofloxan caused almost a complete and immediate cessation of DNA 
replication in S. aureus. Lactam 68 appeared not to affect thymidine incorporation up to 30 mins. 
Afterwards, the utilization began to temper most likely due to the halt of bacterial reproduction (see Section 
3.3.5 for growth studies).  
  
Figure 4.06: Thymidine incorporation in S. aureus. 
  
 
 
4.5 N-Thiolated β-Lactams as Thiolating Agents 
 
  N-Thiolated β-lactams were discovered to have similar sulfenylating properties to the sulfur 
transfer reagent (20, 21) involved in their preparation. An adjacent electronegative atom enhances the 
electrophilicity and vulnerability of the sulfurs toward nucleophilic attack (Scheme 4.05). Chemical studies 
of lactam 68 revealed that the most reactive substances towards 68 are those containing a sulfhydryl group. 
In buffered media, the S-methyl was rapidly cleaved by cysteine, glutathione (GSH), 1,4-dithio-treitol 
(DTT), and β-mercaptoethanol. 
 
Scheme 4.05: Electrophilic sulfenylation of nucleophiles. 
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4.5.1 Enzyme-Binding Properties of N-Thiolated β-Lactams 
 
 Based on the preceding investigations, N-thiolated β-lactams appear to inhibit staphylococcal 
growth by S-methyl transfer to an unidentified protein or metabolite. Chemical studies involving lactam 68 
and the 20 L-amino acids comprising proteins revealed that cysteine is the only component of proteins that 
reacts with the lactam under physiological conditions. The products of the reaction were presumably S-
methyl-cystine (142) and N-protio lactam 53 as depicted below. 
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Scheme 4.06: Reaction of cysteine and lactam 68.    
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 To evaluate the in vitro effect of cysteine on the anti-staphylococcal properties of N-thiolated β-
lactams, equimolar amounts of the cysteine-containing tripeptide, glutathione (see Scheme 4.06) and lactam 
68 were added to the same well in a Kirby-Bauer diffusion experiment. Following overnight incubation, the 
plate inoculated with S. aureus was examined for growth inhibition. A zone of inhibition was absent for the 
well containing lactam 68 and glutathione. The antagonistic effect conferred by the tripeptide could explain 
the selectivity observed in the activity spectrum of N-methylthio β-lactams.     
 
 To further substantiate the neutralizing effect of 
glutathione, a plate was prepared with a 1 mg reservoir of 
the tripeptide located at the center and three surrounding 
wells containing 20 µg of the monochlorophenyl N-
methylthio β-lactams 68-69 (Figure 4.07). The ability of 
glutathione to protect the bacteria from the antibiotics was 
again clearly evident by the presence of concaved zones 
between the glutathione- and lactam-containing wells. At 
the dimpled region of the zones, the concentration of 
glutathione was sufficient to deactivate the lactams 
allowing proliferation of the staphylococci. The protective 
role of glutathione likely explains the bacterial selectivity 
of the antibiotics. Species demonstrating the highest 
sensitivity to the lactams may have thiol-deficient 
intracellular environments. To determine if a correlation 
between the sulfhydryl content and biological activity 
exists, thiol concentrations in susceptible and 
nonsusceptible bacteria were measured.            
Figure 4.07: Antagonist effect of 
glutathione (GSH) on the anti-MSSA 
properties of  N-thiolated β-lactams.  
 
 
4.5.2 Thiol Determination in Bacteria 
 
 The concentration of sulfhydryl-containing molecules in bacteria was quantitated with Ellman's 
reagent, 5,5'-dithiobis(2-nitrobenzoic acid).111 The reaction between the reagent and the thiol extracts 
results in cleavage of the disulfide bond and generation of the fluorophore, 2-nitro-5-thiobenzoate anion 
(Scheme 4.07). Optical density measurements (OD412) were then taken of the samples and used to calculate 
the relative amount of thiols contained in the cells. 
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Scheme 4.07: Reaction of Ellman's reagent and a thiol.111a  
 
S
S
NO2
O2N
COO
COO
S
RSS
NO2
O2N
COO
COO
+
Ellman's reagent 2-Nitro-5-thiobenzoate anion
(fluorescence-active)
RSH
 
 
 The intracellular sulfhydryl content of eight bacterial species with known susceptibilities to N-
methylthio β-lactam 68 is depicted in Table 4.02. It was evident from the data that the thiol levels in 
bacteria were inversely proportional to the sensitivities the organisms displayed toward the antibiotic 
(Figure 4.08). The greatest concentration was discovered in E. coli which has been recognized in a 
previous report as a bacterial species maintaining a thiol-rich intracellular environment to guard against 
oxidants.# N-Thiolated β-lactams are entirely devoid of microbiological activity against E. coli and these 
data suggests that the microbe is protected by its proficiency to produce low molecular weight thiols.     
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   ∆A Co (mM) zone (mm) 
Bacillus anthraces 0.239 0.04 25 
Staphylococcus aureus 0.288 0.04 28 
Bacillus megaterium 0.312 0.05 21 
Bacillus cereus 0.412 0.07 20 
Bacillus subtilis 0.475 0.08 19 
Bacillus globigii 0.566 0.09 20 
Bacillus niger 0.569 0.09 19 
Escherichia coli 1.098 0.18    0 
Table 4.02: Correlation between relative intracellular thiol 
levels and susceptibility to lactam 68. 
 
 Susceptible bacteria were found to have ≤50% the total thiol content in E. coli. The lowest 
amounts were found in B. anthraces and S. aureus who also displayed the highest sensitive to lactam 68. 
Additional species of Bacillus that displayed susceptibilities were also low producers of sulfhydryl 
compounds, although, the levels were slightly higher than those observed for B. anthraces and S. aureus. 
The zone sizes were smaller for these bacteria as well, with the implication that the elevated thiol content  
was responsible for reduced bioactivity.  
 
Figure 4.08: Zone diameter of lactam 68 compared to relative thiol levels in select bacteria. 
 
 
 Though a correlation between sulfhydryl content and susceptibility to N-methylthio β-lactams 
could be established, the selectivity in all likelihood involves other factors. The existence, amount, and 
accessibility of the biological target(s) are additional factors that would influence the antimicrobial potency 
of the lactams 
 
4.5.4 1H NMR Studies 
 
 NMR studies were conducted to verify that the N-protio lactam is the only byproduct between the 
interaction of N-methylthio β-lactams and staphylococcal cells. The product was recovered by ethyl acetate 
extraction of an overnight broth culture of S. aureus inoculated with lactam 68. The extracts were 
combined, concentrated, and analyzed by NMR. The 1H NMR spectrum of the crude isolated residue 
revealed the clean formation of the N-protio β-lactam 53 as represented by the broad singlet positioned at 
6.97 ppm (Figure 4.09b). The loss of the S-methyl substituent was also confirmed by the absence the 
methyl proton which would give rise to a signal at 2.41 ppm (Figure 4.09a).  
 
 Although no attempts were made to identify the location of thio- transfer, the evidence from this 
and prior experiments suggest that the S-methyl is cleaved by a protein or metabolite following entry of the 
β-lactams into the cytoplasm. The N-protio lactam byproduct is  subsequently secreted into the extracellular 
environment where in itself does not possess antibacterial properties. Further studies involving 
fluorescently-labeled or radiolabeled N-thiolated β-lactams are needed, however, to verify this proposed 
mechanism.  
 
Figure 4.09: 1H NMR spectrums of (a) lactam 68 prior to inoculation of S. aureus and (b) lactam 68 
following inoculation of S. aureus.        
  
 
 
 
4.6 Effects of Lactam 68 on Gene Expression 
 
4.6.1 Introduction 
 
 Gene expression is a biological process targeted by many families of antibiotics including: 
tetracyclines, macrolides, aminoglycosides, streptogramins, and oxazolidinones (see Table 4.01). In most 
cases, drugs that affect transcription or translation are bacteriostatic suggesting that one of these processes 
may be subject to inhibition by N-thiolated β-lactams. To test this hypothesis, incorporation of 3H-uridine 
and 3H-isoleucine into RNA and proteins, respectively, was measured in a broth culture of S. aureus treated 
with lactam 68. 
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4.6.2 Pulse-Labeling Studies of RNA Assimilation
 
 RNA labeling studies110 with 3H-uridine were conducted to assess the influence of lactam 68 on 
transcription in S. aureus. Cultures were grown to early logarithmic phase (104 cfu/ml) and inoculated with 
3H-uridine (3 µCi/ml) and lactam 68 (20 µg/ml in DMSO from a 1 mg/ml stock; 2x MIC), penicillin G (2 
µg/ml; 2x MIC), or an inhibitor of RNA synthesis, rifampicin (2 µg/ml; 2x MIC). A sample containing 
only DMSO (20 µl/ml) was used as a control in the study.   
 
 Figure 4.10 compares uridine uptake in cultures treated for 30 mins with the 3 antibiotics. As 
expected, penicillin G had only a moderate effect on RNA assembly into polynucleotide chains. The slight 
decrease was probably due to reduced cell counts associated with the bactericidal nature of the antibiotic. 
Conversely, rifampicin (RIF) clearly impacted the proficiency of S. aureus to transcribe RNA. The 
nucleotide usage was less than 20% of the control with the culture containing the RNA synthesis inhibitor.  
 
 Lactam 68 was also found to modulate uridine incorporation though not to the extent of 
rifampicin. After 30 mins, the nucleotide usage was 50% of the control suggesting that transcription may 
not be the primary process targeted by the lactam. Frequently, inhibition of a single biosynthetic pathway 
will hinder subsequent cellular processes by a negative feedback mechanism. These responses are observed 
in bacteria exposed to translation inhibitors. When protein synthesis stalls, the cell recognizes the 
accumulation of aminoacyl-tRNA and activates a feedback inhibitor to disable DNA replication, RNA 
synthesis, and peptidoglycan incorporation into cell walls. This was observed in S. aureus for 
chloramphenicol which obstructed RNA synthesis after 10 mins of exposure to the peptidyl transferase 
inhibitor (data not shown).  
 
Figure 4.10: Uridine incorporation in S. aureus. 
 
 
 
4.6.3 Pulse-Labeling Studies of Protein Synthesis 
 
 To determine if the primary role of growth inhibition by N-thiolated β-lactams is as a transcription 
inhibitor, the rate of protein synthesis was monitored by the uptake of 3H-isoleucine.110 The experiments 
were conducted in the same manner previously described in Section 4.3.3. An overnight culture of S. 
aureus was grown to early logarithmic phase (104 cfu/ml) and inoculated with 3H-isoleucine (5 µCi/ml). A 
larger amount of the radiolabeled amino acid was required because of its lower utility compared to the 
DNA and RNA precursors. Isoleucine is 1 of 20 amino acids comprising proteins therefore the probability 
of its incorporation is less than thymidine and uridine. The cultures were then treated with lactam 68 (20 
µg/ml in DMSO from a 1 mg/ml stock; 2x MIC), penicillin G (2 µg/ml; 2x MIC), or the translation 
inhibitor, chloramphenicol (30 µg/ml; 2x MIC). A sample containing only DMSO (20µl/ml) was once 
again used as a control.   
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Figure 4.11: Isoleucine incorporation in S. aureus. 
  
 
 
 Figures 4.11a and 4.11b compare the relative rates that mRNA was translated in the presence of 
lactam 68, penicillin G, and chloramphenicol (CHL). Penicillin G and chloramphenicol weakly inhibited 
protein synthesis in S. aureus after 30 mins compared to lactam 68 (Figures 4.11a)  Based on these results, 
it was clearly evident that the lactam is a more powerful inhibitor of translation than transcription. The plot 
of Figures 4.11b further elaborates the propensity of the antibiotic to curtail polypeptide formation. For the 
initial 10 mins of the experiment, a linear progression of isoleucine incorporation was observed for the 
culture containing lactam 68. Afterwards, a large dissension in protein synthesis was detected. Neither in 
the  DNA or RNA incorporation studies was such a dramatic decline observed. Moreover, cultures treated 
with the lactam demonstrated a steady increase of thymidine and uridine incorporation that eventually 
leveled off over time. It was apparent from these results that the primary mode of action of N-thiolated β-
lactams is to impede protein synthesis while transcription appears to be interrupted as a consequence of the 
translation blockage. 
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CHAPTER V 
 
DISCUSSION, CONCLUSIONS, 
AND FUTURE DIRECTIONS 
 
 
5.1 Discussion and Conclusions 
 
5.1.1 Introduction 
 
 Over the past 50 years, thousands of β-lactam antibiotics have been discovered in nature and 
through synthetic means. The biological target common to all members in this chemical class of 
antimicrobials has been the membrane-bound transpeptidases and DD-carboxypeptidases. These enzymes, 
collectively referred to as penicillin-binding proteins (PBPs), recognize traditional β-lactam antibiotics (ie, 
penicillins and cephalosporins) as the D-ala-D-ala residues in peptidoglycan (Figure 5.01).55 In 
misrepresenting the normal substrates of PBPs, these antibacterials bind irreversibly, disabling the 
enzymes. Chemical structure comparison would suggest that N-methylthio β-lactams (3) do not react with 
the peptidases of bacterial cell walls (Figure 5.01). They lack the D-ala-D-ala backbone and additional 
binding motifs required for reactivity with the PBPs.  
 
Figure 5.01: Chemical structures of penicillin and N-methylthio β-lactams.   
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 Scientists have historically used the β-lactams discovered in nature as models to create analogs 
with enhanced potency and expanded activity spectrums. Seldom have researchers strayed from the concept 
that β-lactams must bind to a peptidase to function as an antibacterial. N-Methylthio β-lactams are the first 
novel design of a β-lactam having antimicrobial properties while not possessing PBP-binding capabilities. 
With an apparent intracellular mode of action, their activity spectrum contrasts to that of traditional β-
lactam antibiotics amid the inclusion of yeast and cancer.       
 
5.1.2 Narrow vs. Broad Spectrum 
 
 A narrow range of microbes demonstrated in vitro susceptibility to the inhibitory effects of N-
methylthio β-lactams. As illustrated in Table 5.01, bacterial species very sensitive to the lactams were 
represented by 3 genera: Bacillus, Micrococcus, and Staphylococcus. The vast majority of bacteria were not 
susceptible indicating high selectivity among the 48 species that were screened. The sporadic activity 
displayed by N-thiolated β-lactams is unusual for an antimicrobial agent. Most antibiotics in clinical use 
possess broad spectrum activities despite being reserved for certain bacterial pathogens.  
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Table 5.01: Susceptibility comparison of N-methylthio β-lactams 67-81, 83, and 97-99. 
Bacteria          Zone of Growth Inhibition (mm)   
(Species:Strains) Gram (±) >30 21-30 15-20 <15  0 
Bacteriodes sp. (1:1) -   X X X 
Bacillus spp. (7:7) +  X X X  
Enterobacter sp. (1:1) -     X 
Enterococcus spp. (6:6) +    X X 
Escherichia sp. (1:3) -     X 
Fusobacterium spp. (6:16)112 -     X 
Haemophilus sp. (1:3) -    X  
Klebsiella sp. (1:1) -     X 
Lactococcus sp. (1:1) +    X X 
Listeria sp. (1:2) +    X X 
Micrococcus sp. (1:1) + X X    
Mycobacterium sp. (1:1) -     X 
Neiserria sp. (1:2) -   X X X 
Peptostreptococcus sp. (1:1)112 +     X 
Porphyromonsa (1:2)112 -     X 
Proteus sp. (1:1) -     X 
Pseudomonas sp. (1:1) -     X 
Salmonella sp. (1:1) -    X X 
Serratia sp. (1:1) -     X 
Sporobolomyces sp. (1:1)113 -     X 
Staphylococcus spp. (10:21) + X X X X X 
Streptococcus spp. (2:2) +   X X X 
Vibrio sp. (1:2) -    X X 
susceptibilities    medium weak none   high 
 
 Broad spectrum antibacterials kill or inhibit a wide range (ie, genera) of Gram-positive and Gram-
negative microbes exposed to the drugs. Antibiotics in clinical use that have been classified as broad 
spectrum include: aminoglycosides (ie, streptomycin, gentamicin), tetracyclines (ie, doxycycline), semi-
synthetic penicillins (ie, ampicillin, amoxicillin), 2nd and 3rd generation cephalosporins, monobactams (ie, 
aztreonam), carbapenems (ie, imipenem), macrolides (ie, erythromycin), most quinolones (ie, 
ciprofloxacin), chloramphenicol, cycloserine, sulfonamides, and many others. Narrow spectrum 
bacteriocidal or bacteriostatic therapeutics are selective for either Gram-positive or Gram-negative bacteria. 
Glycopeptides (ie, vancomycin, teicoplanin), natural and semi-synthetic penicillins (ie, penicillin G), and 
oxazolidinones are used clinically to treat Gram-positive bacterial infections whereas polymyxin (ie, 
colisitin) and nalidixic acid are mainly effective for Gram-negative bacteria. N-Methylthio β-lactams 
appear to have a limited spectrum of activity similar to the glycopeptides. Although they possess dissimilar 
modes of action and cytotoxicities, N-methylthio β-lactam and glycopeptide antibiotics both inhibit the 
growth of Gram-positive bacteria deriving from the "Bacilli" class of medically important pathogens.  
 
5.1.3 Bioactivity Spectrum 
 
 N-Methylthio β-lactams demonstrated a unique bioactivity spectrum that was distinct from any 
pre-existing class of drugs. Inhibitory effects were observed against bacterial, fungal, and cancer cells but 
lacking for viruses. In bacteria, the most susceptible cell-types to N-methylthio β-lactams were Gram-
positive. Gram-negative species displayed little or no sensitivities to the lactams with the exception of 
Neisserria gonorrhoeae which had modest susceptibility towards the antibiotic. Clearly though, the 
bacterial species most affected by the lactams derived from the genera of Staphylococcus. A broad range of 
bioactivities was achieved by the drugs against 10 species of staphylococci. MSSA, MRSA, S. epidermidis, 
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and S. lugdunensis were consistently the most susceptible; S. lentus and S. simulans were consistently the 
least susceptible. The lactams were also effective against some species of Bacillus, most notably B. 
anthracis whose pathogenesis causes anthrax disease. The greatest surprise, though, were the bioactivities 
observed against eukaryotes, particularly yeast and cancer cells. Until the discovery of N-methylthio β-
lactams, never have antifungal or anticancer properties been observed for a member from the β-lactam class 
of antibiotics. Moreover, their ability to obstruct the viability of eukaryotic pathogens further substantiates 
that the PBPs are probably not the primary biological target in bacteria. The potential therapeutic use of N-
methylthio β-lactams for treating mycosis and carcinoma warranted additional screening which are 
presently ongoing.    
 
5.1.4 Structure-Activity Relationship  
 
 Few structure-activity relationships were established for the N-thiolated β-lactam analogues. In 
bacteria, changes to the N1, C3, and C4 substituents did not expand the activity spectrum nor enhance the in 
vitro performance of the lactams against a particular class or species. Increasing polarity or lipophilicity, 
though, reduced biological activity for bacteria susceptible to the lead compound, lactam 1 (Figure 5.02). 
Analogues which demonstrated the greatest potency contained a C4 aryl ring functionalized by a weak 
activating or deactivating group such as methyl or chlorine, respectively. The monochlorinated lactam 68 
(Figure 5.02) gave the best overall activity against bacteria, yeast, and cancer. Analogues with multiple 
chlorine atoms, however, were the most effective inhibitors of yeast proliferation. Di- and trichlorinated 
lactams demonstrated 15-40% greater activity than 68 and clotrimazole.  
 
Figure 5.02: Structure of N-methylthio β-lactams 1 and 68.  
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5.1.5 Mechanism of Action 
 
 N-Methylthio β-lactams appear to inhibit protein synthesis as their primary mode of action. 
Substantiating this hypothesis were the results gathered from multiple chemical and biological experiments. 
Chemical studies demonstrated that the carbonyl carbon and the S-methyl carbon of the thiolated lactams 
are least vulnerable to nucleophilic attack which was an observation also reported for the thiamazins# 
(Figure 5.03). As illustrated in Figure 5.04, antibiotics that perform via an acylating (ie, penicillin) or 
alkylating (ie, mitomycin C) mechanism possess an electropositive center (δ+) at the sites of reactivity 
conferred by neighboring electronegative atoms. In the case of N-methylthio β-lactams, the highly 
activated, electron-deficient sulfur center is the most reactive part of the molecule due to the adjacent amide 
functional (Figure 5.04). For this reason, the ability of the lactams to acylate or alkylate cellular 
components in bacteria was considered remote.         
 
 Microscopy and DNA studies further validated the proposed chemical mechanism by 
demonstrating that the lactams do not inhibit cell wall synthesis through acylation of bacterial PBPs or 
alkylation of supercoiled DNA thereby causing linearization or disrupting DNA replication. Intracellular 
transfer of the S-methyl substituent appears to be the means which the viability of bacteria, yeast, and 
cancer cells is reduced. In bacteria, though, the lactams seem to have a cystostatic effect on growth which 
implies that the primary process targeted by the compounds is protein synthesis. 
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Figure 5.03: Reaction of thiamazins at pH 11.88 
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Figure 5.04: Site of nucleophilic attack on electropositive centers of 3 antibiotics: penicillin, mitomycin C, 
and N-methylthio β-lactam 68.  
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 The vast majority of bacteriostatic antibiotics are inhibitors of gene expression including: 
aminoglycosides, tetracyclines, macrolides, and oxazolidinones. These antibacterials operate by slowing 
cell proliferation allowing time for the natural defenses of the body to eradicate the infectious bacteria. 
Reproduction and other biosynthetic processes in bacteria are usually suppressed when gene expression is 
blocked. This was observed in the incorporation studies with lactam 68 which showed that inhibition of 
protein synthesis in staphylococci caused a 50% reduction in RNA synthesis. Future studies will be 
dedicated to determining the precise stage at which protein assimilation is interrupted.   
 
5.2 Future Directions 
 
5.2.1  Structure-Activity Relationship 
 
 To help define the intracellular target of N-methylthio β-lactams, several key investigations were 
attempted or are, at present, being conducted. Additional SAR studies were performed to determine if the 
β-lactam ring was required for bioactivity. Methylthiomesylate (20) and N-(methylthio)phthalimide (21) 
(Figure 5.05) were the initial compounds screened but found to be devoid of antistaphylococcal properties.  
Other molecules analogous to C4 aryl substituted N-methylthio β-lactams were, however, desired to 
ascertain if the azetidinone was a prerequisite for activity.   
 
Figure 5.05: Methylthiomesylate (20) and N-(methylthio)phthalimide (21). 
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 Preparation of azetidines from N-arylated and N-protio β-lactams were the first compounds 
pursued in these studies. A general method of reducing the carbonyl carbon of β-lactams was reported by 
Ojima114 using monochlorohydroalane (AlH2Cl). As depicted in Scheme 5.01, the metal hydride was 
generated in situ from the reduction of aluminum trichloride with lithium aluminum hydride. N-Anisyl 
lactam 90 was then added to the stirring solution of AlH2Cl and the mixture was refluxed for 4 hrs. 
Following aqueous workup, azetidine 143 was isolated as a yellow oil in quantitative yield.  
 
Scheme 5.01: Reduction of N-arylated β-lactam 90 to azetidine 143.  
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 Attempts to deprotect azetidine 143 with cerium ammonium nitrate were unsuccessful. The 
dearylated azetidine could not be obtained from the reaction as a result of oxidative decomposition. Efforts 
to reduce the carbonyl carbon of N-protio β-lactams with AlH2Cl also failed; 1H NMR spectra of the 
reaction following workup confirmed the presence of unconverted starting material.   
 
Scheme 5.02: Reduction of N-arylated β-lactam 90 to azetidine 143.  
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 Despite the failed attempts to make N-methylthio azetidines, additional types of N-containing 
rings were explored. Azetidine-2-thiones (eg, thiolactams) were successfully prepared from C4 aryl-
substituted β-lactams using 2,4-bis(4-methoxyphenyl)-1,3-dithiadiphosphonate-2,4-disulfide (Lawesson's 
reagent).115 Lawesson's reagent (143) was synthesized by refluxing anisole and phosphorous pentasulfide in 
a 10:1 ratio (Scheme 5.03).116 After 6 hrs, the yellow precipitate was filtered, washed with 
chloroform/ether, and dried in vacuo at room temperature to prevent polymerization of the reagent.  
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Scheme 5.03: Preparation of Lawesson's reagent.  
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 N-Aryl protected β-lactam 40 was then subjected to the thionation conditions using Lawesson's 
reagent (Scheme 5.04). Compounds 40 and 143 were stirred at approximately 50oC for 4 hrs followed by 
silica gel chromatography to give thiolactam 144 as a yellow solid. With the β-lactams proving stable to the 
reaction conditions, N-protio β-lactams 53 and 54 were converted to their respective thiolactams 144 and 
145. Attempts to prepare N-methylthio thiolactams were, however, unsuccessful.    
 
Scheme 5.04: Synthesis of thiolactams 144-146. 
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 Other analogous compounds that were explored included 2-methylene azetidines. Previously, 
these vinylogous carbamates have been generated from thiolactams either by an Eschenmoser sulfide 
contraction,117 thio-Reformasky,118 or thio-Wittig reaction.119 Eschenmoser's method has been the most 
widely used and was first attempted on the N-arylated thiolactam 147 (Scheme 5.05). Ethyl bromoacetate 
and 147 were stirred at room temperature to generate the thioalkyliminium salt 148 as an intermediate (not 
isolated).117c After 1 hr, triphenylphosphine was added to induce the sulfide contraction whereby, 
eliminating sulfur. However, the vinylgous amide 149 was not obtained, presumably due to ring strain or 
insufficient nucleophilicity of the thiocarbonyl.     
 
Scheme 5.05: Attempted synthesis of 2-methylene azetidines from thiolactam 147 via Eschenmoser sulfide 
contraction.  
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 The thio-Reformansky was then tried with ethyl bromozincacetate on the N-protio thiolactam 146 
(Scheme 5.06).118 Again, the reaction produced unsatisfactory results. Conversion to the vinylogous 
azetidine was also attempted with ethyl diazoacetate and the stabilized ylide, 
(carbmethoxymethylene)triphenyl phosphine, but the desired product was not obtained (Scheme 5.06).  
 
Scheme 5.06: Unsuccessful syntheses of vinylogous azetidines from N-protio thiolactams. 
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 Previous reports119b have shown that thiolactams require an electron-withdrawing group on the 
amide nitrogen for the thiocarbonyl to have sufficient reactivity to nucleophilic attack. A common 
substituent allocated to the nitrogen atom of the thiolactam which can later be removed with hydrofluoric 
acid is an alkoxycarbonyl. Apropos, N-protio lactam 145 was acylated with di-tert-butylcarbonyl anhydride 
in the presence of catalytic base to generate N-Boc thiolactam 153 in quantitative yield (Figure 5.07). The 
thio-Wittig reaction was then attempted on the Boc activated compound, however, only starting material 
was recovered after 24 hr of reflux in benzene. 
 
Scheme 5.07: Unsuccessful attempts to synthesize vinylogous azetidines from N-Boc thiolactams. 
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 Synthesis of an open ring S-methyl amide was also attempted via the sulfenylation of amide 155, 
prepared from the reaction of benzyl amine and methoyxacetyl chloride (Scheme 5.08). The sulfenamide 
156, a compound analogous to N-methylthio β-lactam 67, could not be obtained from 155 using N-
methylthiophthalimide (21).       
 
Scheme 5.08: Unsuccessful synthesis of noncyclic thioamide 156.  
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5.2.2 Elucidation of the Biological Target 
 
 Elucidation of the biological target is the primary focus of current investigations. To ascertain the 
cellular binding site of the lactams, the S-methyl residue will be labeled with tritium which can be tracked 
inside the bacteria. The proposed synthetic route to the radiolabeled lactam is depicted in Scheme 5.09. 
Thioacetic acid (157) is alkylated with commercially available [3H]methyl iodide then subsequently 
cleaved by mesyl chloride (158) under basic conditions to provide [3H]methylthiomesylate (159). 
Afterwards, the mesylate shall be used to sulfenylate lactam 53 to give the [3H]N-methylthio β-lactam for 
the probing studies.     
  
Scheme 5.09: Proposed synthetic route to [3H]-labeled lactam 160.  
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 The [3H]S-methyl will be traced by fractionation of S. aureus into its subcellular components 
following treatment with 168. The flow diagram in Figure 5.04 depicts the manner by which the 
fractionation will proceed.120 A 108 cfu/ml suspension of S. aureus in buffer will be treated with the 
[3H]lactam for 30 mins. The labeled cells are then harvested, lysed, and fractioned by chemical means 
(Figure 5.04). Radiation levels will next be measured to determine if the S-methyl is bound to a metabolite, 
RNA, DNA, a protein, or a lipid. Afterwards, the fraction(s) containing the label can be further analyzed to 
resolve the molecular size of the biological target. 
 
 
 
 
 
 
 
 76
Figure 5.06: Cell fractionation of S. aureus.  
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  In conclusion, this thesis has traced the development of the project from a curious and unexpected 
discovery of an N-methylthio β-lactams having antibacterial properties to a potentially valuable class of 
new antibiotics. The remaining research and the focus of current investigations is to design additional 
analogues with enhanced potency (eg, lower MICs) and greater stability to glutathione. Furthermore,  
experiments to identify the cellular target will continue to be conducted to validate the novelty of these 
antibiotics and bring them to the forefront as a new weapon for the treatment of MRSA. 
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CHAPTER VI 
 
MATERIALS AND METHODS 
 
6.1. Synthetic Procedures 
 
All reagents needed for the synthesis of N-thiolated β-lactams were purchased from Sigma-Aldrich 
Chemical Company and used without further purification. Solvents were obtained from Fisher Scientific 
Company. Products purified by flash chromatography used J.T. Baker flash chromatography silica gel (40 
µm). NMR spectra were recorded in CDCl3. 13C NMR spectra were proton decoupled, but not fluorine 
decoupled, therefore, some signals in the spectra are split by J C-F-coupling.  
 
6.1.2 Preparation of N-Anisylimines 
 
N-Anisylimines (6): Aldehyde (1 mmol), p-methoxyaniline (1 mmol), and 1 mg camphorsulfonic acid 
(cat.) were dissolved in dichloromethane and stirred at room temperature for 1 hr. Afterwards, an 
appropriate amount of magnesium sulfate was added and the mixture was filtered. The solvent was then 
removed in vacuo and purified by silica gel chromatography or recrystallized from methanol.  
 
N
H
OCH3
Xn
O
SO3H
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CH2Cl2, rt
O
H
Xn
+
NH2
OCH3
1:1
54 6
X = H, F, Cl, Br, I, NO2, CH3, OCH3, O2CR  
 
6.1.3 Preparation of Acid Chlorides 
 
Methoxyacetyl chloride (18): To a 250 ml flame dried round bottom flask containing methoxyacetic acid 
(31.38 g, 0.35 mol) was added thionyl chloride (41.4 g, 0.35 mol) dropwise while stirring for 0.5 hr at 0°C. 
The ice bath was remove and the mixture reacted for 12 hr at 30°C. The pale yellow solution was then 
distilled to provide pure acid chloride (bp 112-113 °C). 
 
OH
O
H3CO +     SOCl2 Cl
O
H3CO
16
0oC
then heat  
 
Acetoxyacetyl chloride (18): To a 250 ml round bottom flask containing glycolic acid (10 g, 0.13 mol) 
was added acetyl chloride (20 g, 0.26 mol) dropwise at 0°C. The ice bath was removed and the resulting 
slush dissolves within 30 min after the acetyl chloride addition. After 1 hr, a white precipitate forms. 
Benzene (50 ml) was added and the reaction stirred for an additional 12 hr. The solid was then filtered and 
washed with benzene and ice cold methanol to give pure product 17 in 80% yield (mp 62-63°C). 
Afterwards, thionyl chloride (31.8 g, 0.24 mol) was added dropwise at 0°C to a 250 ml flask containing 
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acid 17 (24.6 g, 0.24 mol) while stirring. The ice bath was then removed and the resulting slush was stirred 
overnight at 30°C. After 12 hr, the liquid was distilled in vacuo to give the acetoxyacetyl chloride in 60% 
yield from glycolic acid.  
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6.1.4 Preparation of N-4-Anisyl Azetidin-2-ones 
 
N-4-Anisyl azetidin-2-ones (6): Imine (1 mmol) and N,N-ethyldiisopropylamine (3 mmol) or  triethyl 
amine (3 mmol) were added to a 250 ml round bottom flask containing dry dichloromethane or toluene (50 
ml per g of imine) and the mixture was chilled in an ice bath to 0°C. Acid chloride (1.1 mol) in dry toluene 
(50 ml per g acid) was added dropwise (5 ml per min) to the stirring solution. Following addition of the 
acid chloride, the flask was removed from the ice bath and the reaction monitored by thin layer 
chromatography.  After 1 hr, the solution was gently heated overnight if imine was still present. The 
solvent was then removed in vacuo and the crude product was redissolved in ethyl acetate.  After dH2O 
extraction, the organic layer was dried with magnesium sulfate, filtered, and the crude material was 
concentrated in vacuo. Diethyl ether or methanol was then added and the solution chilled to precipitate the 
β-lactam. When silca gel chromatography was required for purification, separation was achieved with ethyl 
acetate and hexanes mixtures. 
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(±)-(3S,4R)-4-(phenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (37): white solid; mp 168-170  
°C; 1H NMR (250 MHz, CDCl3): 7.33-7.16 (m, 5H), 7.19 (d, 2H, J = 9.0 Hz), 6.71 (d, 2H, J = 9.0 Hz), 5.11 
(d, 1H, J = 4.8 Hz), 4.74 (d, 1H, J = 4.8 Hz), 3.66 (s, 3H), 3.11 (s, 3H);  13C NMR (63 MHz, CDCl3): 
δ 163.7, 156.3, 133.3, 130.5, 128.5, 118.7, 114.3, 84.8, 61.8, 58.4, 55.4. 
 
(±)-(3S,4R)-4-(2-chlorophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (38): white solid; mp 
183-184 °C; IR (neat) 1747 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.43 (d, 1H, J = 7.4 Hz), 7.29-7.19 
(m, 5H), 6.80 (d, 2H, J = 9.0 Hz), 5.61 (d, 1H, J = 4.8 Hz), 4.89 (d, 1H, J = 4.8 Hz), 3.73 (s, 3H), 3.27 (s, 
3H); 13C NMR (63 MHz, CDCl3): δ 163.6, 156.4, 133.2, 131.2, 130.3, 129.6, 128.9, 127.0, 118.6, 114.1, 
84.9, 59.1, 58.8, 55.4. 
 
(±)-(3S,4R)-4-(3-chlorophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (39): white  solid; mp 
189-191 °C; 1H NMR (250 MHz, CDCl3): δ 7.28-7.21 (m, 4H), 7.17 (d, 2H, J = 8.9 Hz), 6.72 (d, 2H, J = 
9.0 Hz), 5.09 (d, 1H, J = 4.7 Hz), 4.74 (d, 1H, J = 4.7 Hz), 3.68 (s, 3H), 3.15 (s, 3H); 13C NMR (63 MHz, 
CDCl3): δ 163.5, 156.4, 134.5, 132, 130.3, 129.3, 128.8, 118.7, 114.3, 84.7, 61.1, 58.5, 55.4. 
 
(±)-(3S,4R)-4-(4-chlorophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (40): white  solid; mp 
136-138 °C; IR (neat) 1731 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.28-7.21 (app m, 4H), 7.17 (d, 
2H, J = 8.9 Hz), 6.72 (d, 2H, J = 9.0 Hz), 5.09 (d, 1H, J = 4.7 Hz), 4.74 (d, 1H, J = 4.7 Hz), 3.68 (s, 3H), 
3.15 (s, 3H) 2.39 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 163.5, 156.4, 134.5, 132.0, 130.3, 129.3, 128.8, 
118.7, 114.3, 84.7, 61.1, 58.5, 55.5. 
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(±)-(3S,4R)-4-(4-bromophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (41): white  solid; mp 
154-156 °C; 1H NMR (250 MHz, CDCl3): δ 7.45 (d, 2H, J = 8.4 Hz), 7.23-7.14 (AB m, 4H) 6.73 (d, 2H, J 
= 9.0 Hz), 5.01 (d, 1H, J = 4.7 Hz), 4.75 (d, 1H, J = 4.8 Hz), 4.79 (d, 2H, J = 4.7 Hz), 3.66 (s, 3H), 3.16 (s, 
3H); 13C NMR (63 MHz, CDCl3): δ 163.5, 156.4, 132.5, 131.8, 130.3, 129.6, 122.7, 118.7, 114.4, 84.7, 
61.2, 58.5, 55.4. 
 
(±)-(3S,4R)-4-(2-iodophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (42): white solid; mp 130-
132 °C; 1H NMR (250 MHz, CDCl3): δ 7.84 (d, 1H, J = 7.8 Hz), 7.28-7.15 (m, 4H), 7.00  (t, 1H, J = 7.8 
Hz), 6.76  (d, 2H, J = 9.0 Hz), 5.40 (d, 1H, J = 4.8 Hz), 4.84 (d, 1H, J = 4.8 Hz), 3.69 (s, 3H), 3.24 (s, 3H); 
13C NMR (63 MHz, CDCl3): δ 163.5, 156.4, 139.4, 135.4, 130.3, 130.1, 128.9, 128.3, 118.7, 114.4, 98.5, 
84.8, 66.1, 59.4, 55.4. 
 
(±)-(3S,4R)-4-(3-iodophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (43): white solid; 1H 
NMR (250 MHz, CDCl3): δ 7.67 (s, 1H), 7.62 (d, 1H, J = 8.0 Hz), 7.29 (d, 1H, J = 7.7 Hz), 7.17 (d, 2H, J = 
9.0 Hz), 7.04 (t, 1H, J = 7.8 Hz), 6.73 (d, 2H, J = 9.0 Hz), 5.02 (d, 1H, J = 4.8 Hz), 4.73 (d, 1H, J = 4.8 
Hz), 3.68 (s, 3H), 3.16 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 137.8, 136.8, 130.3, 118.7, 114.4, 84.4, 61.0, 
55.4.  
 
(±)-(3S,4R)-4-(2-methylphenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (45): white  solid; mp 
132-134 °C; IR (neat) 1734 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.23-7.08 (m, 6H), 6.75 (d, 2H, J = 
8.9 Hz), 5.31 (d, 1H, J = 4.9 Hz), 4.82 (d, 1H, J = 4.9 Hz), 3.69 (s, 3H), 3.20 (s, 3H) 2.39 (s, 3H); 13C NMR 
(63 MHz, CDCl3): δ 163.9, 156.3, 135.8, 131.3, 130.7, 130.4, 128.1, 127.1, 126.1, 118.7, 114.3, 84.4, 60.0, 
55.4. 
 
(±)-(3S,4R)-4-(2-methoxyphenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (46): white solid; mp 
117-118 °C; IR (neat) 1743 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.23 (m, 3H), 7.13 (app d, 1H, J = 
7.0 Hz), 6.85 (t, 2H, J = 6.85 Hz), 6.73 (d, 2H, J = 9.0 Hz), 5.52 (d, 1H, J = 4.8 Hz), 4.76 (d, 1H, J = 4.8 
Hz), 3.85 (s, 3H), 3.67 (s, 3H), 3.16 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 164.0, 157.3, 156.2, 130.7, 
129.3, 128.2, 121.4, 120.6, 118.7, 114.3, 110.2, 85.8, 58.6, 56.4, 55.4 (d). 
  
(±)-(3S,4R)-4-(2-nitrophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (47): white  solid; mp 
143-145 °C; 1H NMR (250 MHz, CDCl3): δ 8.16 (app d, 1H, J = 9.1 Hz), 7.54-7.37 (ABm, 3H), 7.22 (d, 
2H, J = 9.0 Hz), 6.78 (d, 2H, J = 9.0 Hz), 5.82 (d, 1H, J = 5.1 Hz), 4.95 (d, 1H, J = 5.1 Hz), 3.71 (s, 3H), 
3.30 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 164.3, 156.6, 148.1, 133.9, 130.6, 130.4, 129.3, 129.0, 125.4, 
118.5, 114.5, 85.5, 59.6, 59.5, 55.4. 
 
(±)-(3S,4R)-4-(3-nitrophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (48): yellow solid; 1H 
NMR (250 MHz, CDCl3): δ 8.27 (s, 1H), 8.22 (d, 1H, J = 8.2 Hz), 7.72 (d, 1H, J = 7.7 Hz), 7.56 (d, 1H, J = 
7.9 Hz), 7.22 (d, 2H, J = 9.0 Hz) 6.79 (d, 2H, J = 9.0 Hz), 5.30 (d, 1H, J = 4.8 Hz), 4.87 (d, 1H, J = 4.8 
Hz), 3.74 (s, 3H), 3.25 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 163.3, 156.6, 148.3, 136.0, 133.9, 129.9, 
129.7, 123.7, 123.7, 123.0, 118.6, 114.5, 84.8, 60.8, 58.7, 55.4.   
 
(±)-(3S,4R)-4-(4-cyanophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (49): white solid; mp 
138-139°C; 1H NMR (250 MHz, CDCl3): δ 7.60 (d, 2H, J = 8.1 Hz), 7.43 (d, 2H, J = 8.1 Hz), 7.13 (d, 2H, J 
= 8.9 Hz), 6.72 (d, 2H, J = 8.9 Hz), 5.18 (d, 1H, J = 4.6 Hz), 4.79 (d, 2H, J = 4.7 Hz), 3.67 (s, 3H), 3.16 (s, 
3H); 13C NMR (63 MHz, CDCl3): δ 163.1, 156.6, 139.2, 132.3, 130.0, 128.7, 118.6, 118.4, 114.5, 112.5, 
85, 61.1, 58.7, 55.4.   
 
(±)-(3S,4R)-4-(4-hexanoyloxyphenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (50): white  solid; 
mp 91-93 °C; 1H NMR (250 MHz, CDCl3): δ 7.40 (d, 2H, J = 8.4 Hz), 7.26-7.24 (m, 4H), 7.11 (d, 2H, J = 
8.3 Hz), 6.78 (d, 2H, J = 8.4 Hz), 5.17 (d, 1H, J = 4.6 Hz), 4.80 (d, 1H, J = 4.7 Hz), 3.74 (s, 3H), 3.12 (s, 
3H), 2.54 (t, 2H, J = 7.5 Hz), 1.74 (app q, 2H), 1.23 (m, 4H), 0.82 (app t, 3H); 13C NMR (63 MHz, CDCl3): 
δ 172.1, 163.6, 156.3, 150.9, 130.7, 130.4, 128.9, 121.8, 118.7, 114.3, 84.7, 61.2, 58.4, 55.4, 34.4, 31.2, 
24.5, 22.3, 13.9. 
(±)-(3S,4R)-4-(4-propenoyloxyphenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (51): white 
solid; mp 93-94 °C; 1H NMR (250 MHz, CDCl3): δ 7.36 (d, 2H, J = 8.5 Hz), 7.20 (d, 2H, J = 7.0 Hz), 7.11 
(d, 2H, J = 8.5 Hz), 6.72 (d, 2H, J = 9.0 Hz), 6.53 (d, 1H, J = 17.3 Hz), 6.24 (dd, 1H, J = 17.3, 10.4 Hz), 
6.00 (d, 1H, J = 10.3 Hz), 5.13 (d, 1H, J = 4.7 Hz), 4.74 (d, 1H, J = 4.7 Hz), 3.67 (s, 3H), 3.14 (s, 3H); 13C 
NMR (63 MHz, CDCl3): δ 164.2, 163.6, 156.4, 150.7, 132.8, 130.9, 130.4, 129.0, 127.7, 121.7, 118.7, 
114.3, 84.8, 61.2, 58.5, 55.4. 
 
(±)-(3S,4R)-4-(2,4-dichlorophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (89): white solid; 
mp 124-126 °C; 1H NMR (250 MHz, CDCl3): δ 7.41 (s, 1H), 7.19-7.15 (m, 4H), 6.76 (d, 2H, J = 8.9 Hz), 
6.78 (d, 2H, J = 9.0 Hz), 5.52 (d, 1H, J = 4.8 Hz), 4.83 (d, 1H, J = 4.9 Hz), 3.70 (s, 3H), 3.26 (s, 3H); 13C 
NMR (63 MHz, CDCl3): δ 163.5, 156.5, 134.7, 133.8, 130.1, 129.9, 129.8, 129.4, 127.4, 118.6, 114.5, 84.5, 
59.2, 58.3, 55.4. 
  
(±)-(3S,4R)-4-(2,6-dichlorophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (90): crystal; mp 
172-174 °C; 1H NMR (250 MHz, CDCl3): δ 7.34 (d, 1H, J = 7.3 Hz), 7.20-7.10 (m, 4H), 6.73 (d, 2H, J = 
8.9 Hz), 5.93 (d, 1H, J = 4.9 Hz), 4.87 (d, 1H, J = 4.9 Hz), 3.67 (s, 3H), 3.24 (s, 3H); 13C NMR (63 MHz, 
CDCl3): δ 163.2, 156.4, 136.2, 131.1, 130.9, 129.9, 128.6, 117.8, 114.4. 
 
(±)-(3S,4R)-4-(2,3,5-trichlorophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (91): white solid; 
IR (neat) 1756 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.46 (app s, 1H), 7.23 (d, 2H, J = 8.9 Hz), 7.15 
(app s, 1H), 6.83 (d, 2H, J = 8.9 Hz), 5.57 (d, 1H, J = 4.9 Hz), 4.91 (d, 1H, J = 4.9 Hz), 3.76 (s, 3H), 3.36 
(s, 3H); 13C NMR (63 MHz, CDCl3): δ 163.4, 156.7, 135.2, 134.0, 133.2, 130.0, 129.9, 129.8, 127.0, 118.5, 
114.6, 84.9, 59.5, 59.2, 55.4. 
 
(±)-(3S,4R)-4-(2-thiophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (125): white solid; mp 
150-153 °C; 1H NMR (250 MHz, CDCl3): δ 7.27 (m, 3H), 7.12 (d, 1H, J = 2.8 Hz), 6.97 (dd, 1H, J = 4.9, 
3.7 Hz), 6.73 (d, 2H, J = 9.0 Hz), 5.40 (d, 1H, J = 4.5 Hz), 4.76 (d, 1H, J = 4.6 Hz), 3.68 (s, 3H), 3.24 (s, 
3H); 13C NMR (63 MHz, CDCl3): δ 163.2, 156.4, 136.5, 130.4, 127.7, 126.8 (d), 125.9, 118.8 (d), 114.3, 
84.9, 58.6, 57.7, 55.4.   
 
6.1.5 Dearylation of N-Anisyl Azetidin-2-ones 
 
Dearylated azetidin-2-ones (9): To a solution of N-anisyl β-lactam 6 (1 mmol) in acetonitrile (25 ml) at 0 
°C was added 25 ml of an aqueous solution of ammonium cerium (IV) nitrate (3 mmol) over 5 min. The 
reaction was stirred for 25 min then quenched with 50 ml of water. The solution was extracted 3x with 
ethyl acetate (25 ml) and the combined organic layers were washed twice with aqueous 5% sodium 
bicarbonate, once with aqueous 5% sodium bisufite, and once with brine. Follwing treatment with 
magnesium sulfate and filtration, the solvent was removed in vacuo and the crude material was purified by 
silica gel chromatography. 
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(±)-(3S,4R)-4-(phenyl)-3-(methoxy)azetidin-2-one (52): white solid; mp 68-70 °C; 1H NMR (250 MHz, 
CDCl3): δ 7.31-7.19 (m, 4H), 6.47 (bs, 1H), 4.76 (d, 1H, J = 4.6 Hz), 4.67 (dd, 1H, J = 4.5, 2.8 Hz), 3.11 (s, 
3H); 13C NMR (63 MHz, CDCl3): δ 168.3, 134.2 (d), 129, 128.5, 86.5, 58.2, 57.5. 
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(±)-(3S,4R)-4-(2-chlorophenyl)-3-(methoxy)azetidin-2-one (53): white solid; mp 94-95 °C; IR (neat) 
3275 cm-1 (N-H), 1770 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.47 (d, 1H, J = 6.7 Hz), 7.39-7.27 (m, 
3H), 6.97 (bs, 1H), 5.25 (d, 1H, J = 4.5 Hz), 4.83-4.82 (app m, 1H), 3.26 (s, 3H); 13C NMR (63 MHz, 
CDCl3): δ 168.5, 133.7, 133.1, 132.9, 129.2, 128.2, 126.9, 86.9, 59.0, 55.9.  
 
(±)-(3S,4R)-4-(3-chlorophenyl)-3-(methoxy)azetidin-2-one (54): white solid; mp 110-111 °C; IR (neat) 
3196 cm-1 (N-H), 1762 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.30-7.20 (m, 4H), 6.58 (bs, 1H), 4.76 
(d, 1H, J = 4.5 Hz), 4.69-4.67 (app m, 1H), 3.13 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 168.1, 137.9, 
129.6, 128.5, 127.7, 125.8, 86.7, 58.3, 57.6. 
 
(±)-(3S,4R)-4-(4-chlorophenyl)-3-(methoxy)azetidin-2-one (55): white solid; mp 121-123 °C; 1H NMR 
(250 MHz, CDCl3): δ 7.36-7.27 (m, 4H), 6.86 (bs, 1H), 4.82 (d, 1H, J = 4.5 Hz), 4.72-4.70 (m, 1H), 3.15 
(s, 3H); 13C NMR (63 MHz, CDCl3): δ 168.1, 134.2, 129.0, 128.5, 86.6, 58.2, 57.5. 
 
(±)-(3S,4R)-4-(4-bromophenyl)-3-(methoxy)azetidin-2-one (56): white solid; mp 65-67 °C; 1H NMR 
(250 MHz, CDCl3): δ 7.45 (d, 2H, J = 8.4 Hz), 7.19 (d, 2H, J = 7.9 Hz), 6.39 (bs, 1H), 4.76 (d, 1H, J = 4.5 
Hz), 4.70 (app m, 1H), 3.13 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 168.4, 149.6, 134.7, 131.4, 129.3, 
122.3, 116.1, 86.4, 58.2, 57.6. 
 
(±)-(3S,4R)-4-(2-iodophenyl)-3-(methoxy)azetidin-2-one (57): white solid; mp 133-138 °C; IR (neat) 
3227 cm-1 (N-H), 1761 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.77 (d, 1H, J = 8.0 Hz), 7.35-7.33 (m, 
2H), 6.99 (dd, 1H, J = 8.0, 4.4 Hz), 6.16 (bs, 1H), 5.02 (d, 1H, J = 4.5 Hz), 4.79 (dd, 1H, J = 4.5, 3.4 Hz), 
3.23 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 168.0, 139.2, 137.9, 129.8, 128.2, 98.2, 86.8, 62.7, 59.3. 
 
(±)-(3S,4R)-4-(3-iodophenyl)-3-(methoxy)azetidin-2-one (58): brown solid; mp 63-65 °C; 1H NMR (250 
MHz, CDCl3): δ 7.64-7.60 (m, 2H), 7.28 (d, 1H, J = 7.6 Hz), 7.06 (t, 1H, J = 7.7 Hz), 6.37 (bs, 1H), 4.73-
4.68 (m, 2H), 3.14 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 167.9, 138.0, 137.4, 136.5, 130.0, 129.9, 94.2, 
86.7, 58.4, 57.4. 
 
(±)-(3S,4R)-4-(2-methylphenyl)-3-(methoxy)azetidin-2-one (60): brown solid; mp 110-111 °C; 1H NMR 
(250 MHz, CDCl3): δ 7.35-7.32 (m, 1H), 7.19-7.11 (m, 3H), 6.53 (bs, 1H), 4.98 (d, 1H, J = 4.7 Hz), 4.77 
(dd, 1H, J = 4.6, 3.1 Hz), 3.19 (s, 3H), 2.26 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 168.8, 135.6, 134, 
130.1, 127.8, 126.1, 126, 86.1, 58.3, 55.7, 19.1. 
 
(±)-(3S,4R)-4-(2-methoxyphenyl)-3-(methoxy)azetidin-2-one (61): brown solid; mp 81-86 °C; 1H NMR 
(250 MHz, CDCl3): δ 7.33-7.19 (AB m, 2H), 6.97-6.94 (app t, 1H), 6.82 (d, 1H, J = 8.2 Hz), 6.15 (bs, 1H), 
5.17 (d, 1H, J = 4.6 Hz), 4.72 (dd, 1H, J = 4.6, 3.1, Hz), 3.79 (s, 3H), 3.16 (s, 3H); 13C NMR (63 MHz, 
CDCl3): δ 168.9, 156.9, 128.9, 127.4, 124.2, 120.5, 109.9, 86.7, 58.6, 55.3, 53.5. 
 
(±)-(3S,4R)-4-(2-nitrophenyl)-3-(methoxy)azetidin-2-one (62): white solid; mp 153-150 °C; 1H NMR 
(250 MHz, CDCl3): δ 8.12 (d, 1H, J = 8.1 Hz), 7.64-7.56 (m, 2H), 7.47-7.42 (m, 1H), 7.09 (bs, 1H), 5.50 
(d, 1H, J = 4.7 Hz), 4.89-4.86 (m, 1H), 3.26 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 168.8, 147.7, 134.0, 
132.7, 128.7, 125.1, 87.2, 59.5, 56.6. 
 
(±)-(3S,4R)-4-(3-nitrophenyl)-3-(methoxy)azetidin-2-one (63): white solid; mp 87-90 °C; 1H NMR (250 
MHz, CDCl3): δ 8.17-8.14 (m, 2H), 7.67 (d, 1H, J = 7.5 Hz), 7.67 (t, 1H, J = 7.8 Hz), 6.47 (bs, 1H), 4.93 
(d, 1H, J = 4.5 Hz), 4.67 (app m, 1H), 3.17 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 168.0, 148.2, 138.2, 
133.7, 129.4, 123.4, 122.6, 86.8, 58.5, 57.3. 
 
(±)-(3S,4R)-4-(4-cyanophenyl)-3-(methoxy)azetidin-2-one (64): brown oil; 1H NMR (250 MHz, CDCl3): 
δ 7.67 (d, 2H, J = 8.2 Hz), 7.50 (d, 2H, J = 8.3 Hz), 6.88 (bs, 1H), 4.94 (d, 1H, J = 4.8 Hz), 4.81 (dd, 1H, J 
= 4.5, 2.9 Hz), 3.20 (s, 3H). 
 
(±)-(3S,4R)-4-(4-hexanoyloxyphenyl)-3-(methoxy)azetidin-2-one (65): white solid; mp 58-60 °C; 1H 
NMR (250 MHz, CDCl3): δ 7.39 (d, 2H, J = 8.5 Hz), 7.10 (d, 2H, J = 8.5 Hz), 6.33 (bs, 1H), 4.84 (d, 1H, J 
= 4.5 Hz), 4.76 (dd, 1H, J = 4.5, 2.8 Hz), 3.17 (s, 3H), 2.55 (t, 2H, J = 7.5 Hz), 1.78-1.72 (m, 2H), 1.42-
1.36 (m, 4H), 0.93 (t, 3H, J = 6.8 Hz); 13C NMR (63 MHz, CDCl3): δ 172.7, 171.6, 168.5, 151.1, 133.6, 
129.2, 121.9, 87.0, 60.8, 58.5, 57.9, 34.7, 31.6, 31.6, 25.0, 22.7, 21.4, 14.6, 14.3. 
 
(±)-(3S,4R)-4-(4-propenoyloxyphenyl)-)-3-(methoxy)azetidin-2-one (66): white solid; mp 94-96 °C; 1H 
NMR (250 MHz, CDCl3): δ 7.33 (d, 2H, J = 8.4 Hz), 7.09 (d, 2H, J = 8.4 Hz), 6.55 (d, 1H, J = 17.3 Hz), 
6.26 (dd, 1H, J = 17.3, 10.4), 6.00 (d, 1H, J = 10.4 Hz), 4.78 (d, 1H, J = 4.5 Hz), 4.68-4.66 (m, 1H), 3.11 
(s, 3H); 13C NMR (63 MHz, CDCl3): δ  168.0, 164.5, 150.5, 133.2, 132.9, 128.8, 127.7, 121.5, 116.0, 86.6, 
58.2, 57.5. 
 
(±)-(3S,4R)-4-(4-hydroxyphenyl)-3-(methoxy)azetidin-2-one (82): Acrylate β-lactam (99 mg, 0.4 mmol) 
was dissolved in 4 ml of methanol in a 3-neck flask and place in a 0oC ice bath. A potassium hydroxide 
(44.8 mg, 0.8 mmol) dissolved in 4 ml of a 50% methanol solution was added dropwise over 1 min and 
allow to stir for an additional 15 min . The reaction was quenched with 10 ml of dH2O and the red solution 
was extracted 3x with 10 ml of ethyl acetate. The organic layer was dried with sodium sulfate then 
concentrated in vacuo. The product was recrystallized from chloroform giving a brown solid in 84% yield. 
mp 174-179 °C; IR (neat) 3330 cm-1 (O-H), 1729 cm-1 (C=O); 1H NMR (250 MHz, DMSO-d6) δ 7.38 (bs, 
1H), 8.43 (bs, 1H), 7.03 (d, 2H, J = 8.8 Hz), 6.66 (d, 2H, J = 8.5 Hz), 4.60 (d, 1H, J = 4.5 Hz), 4.55 (dd, 
1H, J =  4.5, 2.3 Hz), 2.89 (s, 3H); 13C NMR (63 MHz, DMSO-d6): δ 167.9, 157.4, 129.1, 127.5, 115.2, 
86.5, 57.4, 56.4. 
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(±)-(3S,4R)-4-(2, 3, 4, 5, 6-pentafluorophenyl)-3-(methoxy)azetidin-2-one (92): pale solid; mp 153-155 
°C; 1H NMR (250 MHz, CDCl3): δ 6.64 (s, 1H), 5.19 (d, 1H, J = 4.7 Hz), 4.86 (dd, 1H, J = 4.6, 2.0 Hz), 
3.42 (s, 3H).  
 
(±)-(3S,4R)-4-(2,4-dichlorophenyl)-3-(methoxy)azetidin-2-one (93): pale solid; mp 114-116 °C; IR 
(neat) 3196 cm-1 (N-H), 1762 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.39-7.35 (m, 2H), 7.26 (app d, 
1H, J = 9.3 Hz), 6.85 (bs, 1H), 4.82-4.78 (app m, 1H), 3.26 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 168.7, 
134.8, 133.9, 132.8, 129.6, 127.7, 87.3, 59.6, 55.9. 
 
(±)-(3S,4R)-4-(2,3,5-trichlorophenyl)-3-methoxyazetidin-2-one (95): white solid; mp 163-166 °C; 1H 
NMR (250 MHz, CDCl3): δ 7.39 (s, 1H), 7.30 (s, 1H), 6.82 (bs, 1H), 5.15 (d, 1H, J = 4.6 Hz), 4.82-4.79 
(m, 1H), 3.28 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 168.1, 137.5, 133.8, 133.1, 129.6, 129.5, 126.6, 87.0, 
59.5, 56.3. 
 
(±)-(3S,4R)-4-(2-thiophenyl)-3-methoxyazetidin-2-one (126): white solid; mp 85-88 °C; 1H NMR (250 
MHz, CDCl3): δ 7.35 (d, 1H, J = 5.0 Hz), 7.11 (d, 1H, J = 3.0 Hz), 7.05-7.02 (m, 1H), 6.49 (bs, 1H), 5.12 
(d, 1H, J = 4.3 Hz), 5.12 (dd, 1H, J = 4.0, 2.8 Hz), 3.28 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 167.6, 
139.2, 126.9, 126.7, 126.3, 86.6, 58.4, 54.0. 
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6.1.6 Preparation of Sulfur-Transfer Reagents 
 
Methyl methanethiolsulfonate (20): Methyl disulfide (14.1 g, 160 mmol) was dissolved in 60 ml of 
glacial acetic acid and place in an ice water bath. Hydrogen peroxide (34 g of 30% solution) was added 
slowly to the mixture without stirring over 20 min. The solution was stirred for an additional 30 min at 
room temperature then slowly warmed to 50°C for 2 hr to destroy the excess peroxide. After testing for the 
presence of peroxide by starch-iodide paper, the glacial acetic acid was removed under vacuum. The 
residue was treated with 50 ml of sat. sodium bicarbonate and extracted with ethyl acetate. After drying 
over anhydrous magnesium sulfate, the solvent is removed and the yellow oil distilled. bp 60-70°C (0.3 
torr); 1H NMR (250 MHz, CDCl3): δ 2.65 (s, 3H), 3.22 (s, 3H). 
 
CH3
S
S
CH3
glacial AcOH
30% H2O2
0oC to RT
S
O
O
SCH3 CH3
20  
N-(Organothio)phthalimide: In dry benzene containing thiol (1 mmol) or disulfide (1 mmol), chlorine gas 
(2 mmol in benzene) was added dropwise at 0°C while stirring. After 1 hr, the sulfenyl chloride solution 
was canulated into a flask containing phthalimide (1 mmol) and N,N-ethyldiisopropylamine (1.5 mmol) 
then stirred for an additional 2 hr. Afterwards, the solid material was filtered, wash with water and n-
heptane, and recrystallized from methanol to give N-(organothio)phthalimide in good yields.     
 
NH
O
O
1. Cl2, PhH, 0oC
, Et3N
2.
R"SH
or
R"SSR"
NSR"
O
O
 
 
6.1.7 Preparation of N-Thiolated Azetidin-2-ones 
 
N-Thiolated azetidin-2-ones (3): To a solution of 9 (1 mmol) in dry THF at -78 °C was added n-
butylithium (1.1 mmol). After 30 min, methyl methanethiosulfonate 20 (1 mmol) was added and the 
mixture was stirred for 12 hr with warming to room temperature. The mixture was poured into 5% aqueous 
ammonium chloride and extracted 3x with dichloromethane. The organic layers were dried with 
magnesium sulfate, filtered, and concentrated in vacuo. Flash chromatography of the crude material with 
ethyl acetate/hexanes mixtures gave N-methylthio β-lactams 3. 
 
N
O H
R'O H H
Xn
N
O SCH3
R'O H H
Xn
CH3SSO2CH3 
20
n-BuLi, THF
-78oC
9 3  
 
N-Thiolated azetidin-2-ones (3): Lactam 9 (1 mmol) and N-(organothio)phthalimide (1 mmol) were 
dissolved in dry benzene with a catalytic amount of ethyldiisopropylamine. Following reflux for 1 hr, the 
mixture was concentrated in vacuo and the residue was purified by silica gel chromatography to give the N-
methylthio β-lactams 3. 
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(±)-(3S,4R)-4-(phenyl)-3-methoxy-1-(methylthio)azetidin-2-one (67): white solid; mp 51-54 °C; 1H 
NMR (250 MHz, CDCl3): 7.31 (m, 5H), 4.76 (d, 1H, J = 4.9 Hz), 4.72 (d, 1H, J = 4.9 Hz), 3.08 (s, 3H), 
2.29 (s, 3H).  
 
(±)-(3S,4R)-4-(2-chlorophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (68) white crystal; mp 71-73 
°C; IR (neat) 1756 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.35 (d, 1H, J = 7.4 Hz), 7.24 (m, 3H), 5.29 
(d, 1H, J = 4.9 Hz), 4.80 (d, 1H, J = 4.9 Hz), 3.16 (s, 3H), 2.40 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 
170.4, 133.8, 131.4, 129.6, 128.9, 126.8, 86.7, 62.7, 58.9, 21.8. 
 
(±)-(3S,4R)-4-(3-chlorophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (69): white crystal; mp 73-75 
°C; IR (neat) 1740 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.30-7.29 (m, 3H), 7.21 (s, 1H), 4.73 (app s, 
2H), 3.14 (s, 3H), 2.33 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 170.6, 136.1, 134.8, 130.1, 129.5, 129.4, 
127.4, 87.0, 66.0, 58.9, 22.6. 
 
(±)-(3S,4R)-4-(4-chlorophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (70): white crystal; mp 62-66 
°C; IR (neat) 1751 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.33 (d, 2H, J = 8.5 Hz), 7.25 (d, 2H, J = 
8.5 Hz), 4.73 (app s, 2H), 3.13 (s, 3H), 2.31 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 170.2, 134.9, 130.2, 
128.6, 86.5, 65.5, 58.4, 22.1. 
 
(±)-(3S,4R)-4-(4-bromo-phenyl)-3-methoxy-1-(methylthio)azetidin-2-one (71): white solid; mp 80-83 
°C; IR (neat) 1761 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.48 (d, 2H, J = 8.1 Hz), 7.18 (d, 2H, J = 
8.4 Hz), 4.72 (app s, 2H), 3.13 (s, 3H), 2.31 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 170.6, 133.0, 132.0, 
131.0, 123.5, 86.9, 66.0, 58.9, 22.6. 
 
(±)-(3S,4R)-4-(2-iodophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (72): white crystal; mp 62-65 °C; 
IR (neat) 1756 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.80 (d, 1H, J = 7.8 Hz), 7.30 (t, 1H, J = 7.5 
Hz), 7.15 (t, 1H, J = 8.0 Hz), 7.00 (t, 1H, J = 7.5 Hz), 5.09 (d, 1H, J = 5.0 Hz), 4.80 (d, 1H, J = 4.8 Hz), 
3.82 (s, 3H), 2.41 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 170.7, 139.9, 136.2, 130.6, 129.3, 128.6, 99.8, 
87.1, 70.4, 59.6, 22.2. 
 
(±)-(3S,4R)-4-(3-iodophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (73): white crystal; mp 97-99 °C; 
IR (neat) 1745 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.65 (m, 2H), 7.27 (d, 1H, J = 7.7 Hz), 7.08 (t, 
1H, J = 8.0 Hz), 4.73-4.67 (AB m, 2H), 3.13 (s, 3H), 2.32 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 170.6, 
138.4, 138.2, 136.4, 130.5, 128.5, 94.5, 87, 65.8, 58.3, 22.6. 
 
(±)-(3S,4R)-4-(4-iodophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (74): white solid; mp 102-105 
°C; IR (neat) 1766 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.65 (d, 2H, J = 8.3 Hz), 7.03 (d, 2H, J = 
8.3 Hz), 4.70 (app s, 2H), 3.10 (s, 3H), 2.29 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 170.1, 137.5, 133.2, 
130.7, 94.9, 86.4, 65.6, 58.4, 22.1. 
 
(±)-(3S,4R)-4-(2-methylphenyl)-3-methoxy-1-(methylthio)azetidin-2-one (75): white solid; mp 80-81 
°C; IR (neat) 1745 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.27-7.21 (m, 4H), 5.11 (d, 1H, J = 5.0 Hz), 
4.85 (d, 1H, J = 5.0 Hz), 3.21 (s, 3H), 2.45 (s, 3H), 2.37 (s, 3H).  
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(±)-(3S,4R)-4-(2-methoxyphenyl)-3-methoxy-1-(methylthio)azetidin-2-one (76): white solid, mp 120-
123°C; 1H NMR (250 MHz, CDCl3): δ 7.27-7.24 (app m, 1H), 7.19-7.15 (m, 1H), 6.95 (t, 1H, J = 7.5 Hz), 
6.86 (d, 1H, J = 8.2 Hz), 5.27 (d, 1H, J = 4.9 Hz), 4.72 (d, 1H, J = 4.9 Hz), 3.80 (s, 3H), 3.12 (s, 3H), 2.37 
(s, 3H); 13C NMR (63 MHz, CDCl3): δ 170.9, 157.7, 129.5, 128.5, 121.5, 120.4, 110.3, 86.5, 60.2, 58.5, 
55.4, 21.8. 
 
(±)-(3S,4R)-4-(2-nitrophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (77): yellow solid; 1H NMR 
(250 MHz, CDCl3): δ 8.12 (d, 1H, J = 8.2 Hz), 7.66-7.63 (m, 1H), 7.50-7.41 (m, 2H), 5.49 (d, 1H, J = 5.1 
Hz), 4.93 (d, 1H, J = 5.2 Hz), 3.23 (s, 3H), 2.43 (s, 3H).    
 
(±)-(3S,4R)-4-(4-cyanophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (79): yellow solid; mp 88-90 
°C; 1H NMR (250 MHz, CDCl3): δ 7.64 (d, 2H, J = 8.0 Hz), 7.40 (d, 2H, J = 8.0 Hz), 4.79 (ABm, 2H), 
3.14 (s, 3H), 2.37 (s, 3H). 
 
(±)-(3S,4R)-4-(4-propenoyloxyphenyl)-3-methoxy-1-(methylthio)azetidin-2-one (81): white solid; mp 
87-88 °C; 1H NMR (250 MHz, CDCl3): δ 7.29 (d, 2H, J = 8.4 Hz), 7.08 (d, 2H, J = 8.4 Hz), 6.50 (d, 1H, J 
= 17.3 Hz), 6.21 (dd, 1H, J = 17.1, 10.3 Hz), 5.92 (d, 1H, J = 10.4), 4.75 (d, 1H, J = 4.8 Hz), 4.69 (d, 1H, J 
= 4.8 Hz), 3.05 (s, 3H), 2.26 (s, 3H);13C NMR  (63 MHz, CDCl3): δ 170.3, 164.2, 150.9, 132.9, 131.1, 
129.9, 127.7, 121.4, 86.5, 65.5, 58.3, 22.0. 
 
(±)-(3S,4R)-4-(4-hydroxyphenyl)-3-methoxy-1-(methylthio)azetidin-2-one (83): white solid; mp 119-
123 °C; 1H NMR (250 MHz, CDCl3): δ 7.18 (d, 2H, J = 9.0 Hz), 6.81 (d, 2H, J = 9.0 Hz), 5.73 (bs, 1H), 
4.69 (app s, 2H), 3.11 (s, 3H), 2.28 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 170.9, 168.5, 130.4, 124.9, 
115.4, 65.9, 58.3, 22.1. 
 
(±)-(3S,4R)-4-(2, 3, 4, 5, 6-pentafluorophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (96): white 
solid; mp 72–74 °C; 1H NMR (250 MHz, CDCl3): δ 5.15 (d, 1H, J = 5.1 Hz), 4.81 (d, 1H, J = 5.1 Hz), 3.35 
(s, 3H), 2.35 (s, 3H). 
  
(±)-(3S,4R)-4-(2,4-dichlorophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (97): yellow crystal; mp 
102-105 °C; IR (neat) 1772 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.37 (s, 1H), 7.28 (d, 1H, J = 8.3 
Hz), 7.16 (d, 1H, J = 8.2 Hz), 5.24 (d, 1H, J = 4.6 Hz), 4.79 (d, 1H, J = 4.6 Hz), 3.19 (s, 3H), 2.40 (s, 3H); 
13C NMR (63 MHz, CDCl3): δ 170.5, 135.3, 134.9, 130.6, 130.3, 129.9, 127.7, 87.1, 62.6, 59.4, 22.2. 
 
(±)-(3S,4R)-4-(2,6-dichlorophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (98): pale yellow solid; mp 
77-80 °C; IR (neat) 1771 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.23 (t, 1H, J = 8.1 Hz), 5.72 (d, 1H, 
J = 5.3 Hz), 4.90 (d, 1H, J = 5.1 Hz), 3.30 (s, 3H), 2.44 (s, 3H); 13C NMR (63 MHz, CDCl3,): δ 168.3, 
131.1, 130.1, 128.8, 88.0, 62.9, 59.2, 21.6. 
 
(±)-(3S,4R)-4-(2,3,5-trichlorophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (99):  yellow crystal; mp 
90-94 °C; IR (neat) 1761 cm-1 (C=O); 1H NMR (250 MHz, CDCl3): δ 7.44 (s, 1H), 7.11 (s, 1H), 5.24 (d, 
1H, J = 5.0 Hz), 4.83 (d, 1H, J = 5.0 Hz), 3.26 (s, 3H), 2.45 (s, 3H); 13C NMR (63 MHz, CDCl3,): δ 170.4, 
135.8, 134.4, 133.5, 129, 127.6, 87.2, 63.4, 59.7, 22.2. 
 
(±)-(3S,4R)-4-(phenyl)-3-methoxy-1-(butylthio)azetidin-2-one (108): colorless oil; 1H NMR (250 MHz, 
CDCl3): δ 7.34-7.27 (m, 5H), 4.74-4.71 (m, 2H), 3.09 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 171.0, 133.6, 
128.9, 128.8, 128.3, 86.3, 66.9, 58.3, 38.2, 30.8, 21.5, 13.6. 
 
(±)-(3S,4R)-4-(phenyl)-3-methoxy-1-(phenylthio)azetidin-2-one (109): white solid; mp 58-60 °C 1H 
NMR (250 MHz, CDCl3): δ 7.37-7.23 (m, 8H), 4.88-4.83 (AB m, 2H), 3.18 (s, 3H). 
  
(±)-(3S,4R)-4-(phenyl)-3-methoxy-1-(cyclohexylthio)azetidin-2-one (110): oil; 1H NMR (250 MHz, 
CDCl3): δ 7.38-7.26 (m, 5H), 4.86-4.82 (m, 2H), 3.02 (s, 3H), 2.89-2.85 (m, 1H), 1.98-1.94 (app m, 1H), 
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1.75 (app s, 3H), 1.35-1.19 (m, 6H); 13C NMR (63 MHz, CDCl3): 171.3, 133.5, 128.9, 128.8, 128.3, 86.2, 
67.6, 58.3, 49.5, 32.2, 30.9, 25.6, 25.4.  
 
(±)-(3S,4R)-4-(2-thiophenyl)-3-methoxy-1-(methylthio)azetidin-2-one (127): oil; 1H NMR (250 MHz, 
CDCl3): δ 7.43 (d, 1H, J = 5.0 Hz), 7.21 (d, 1H, J = 2.9 Hz), 7.06 (dd, 1H, J = 5.0, 2.9 Hz), 5.08 (d, 1H, J = 
4.7 Hz), 4.82 (d, 1H, J = 4.8 Hz), 3.32 (s, 3H), 2.30 (s, 3H). 
 
(±)-(3S,4R)-4-(2,6-dichlorophenyl)-3-phenoxy-1-(methylthio)azetidin-2-one (134): white solid; mp 114-
116 °C; 1H NMR (360 MHz, CDCl3): δ 7.39 (d, 1H, J = 7.8 Hz), 7.33-7.23 (m, 7H), 6.92 (t, 1H, J = 7.4 
Hz), 6.79 (d, 2H, J = 7.9 Hz), 5.59 (app s, 2H), 2.49 (s, 3H); 13C NMR (90 MHz, CDCl3): δ 167.0, 140.0, 
133.6, 133.2, 129.7, 129.5, 128.5, 127.0, 122.6, 119.5, 83.9, 55.6. 
 
(±)-(3S,4R)-4-(4-nitrophenyl)-3-acetoxy-1-(methylthio)azetidin-2-one (135): white solid; 1H NMR (360 
MHz, CDCl3): δ 8.26 (d, 2H, J = 8.7 Hz), 7.47 (d, 2H, J = 8.7 Hz), 5.96 (d, 1H, J = 5.0 Hz), 5.15 (d, 1H, J 
= 5.0 Hz), 2.49 (s, 3H), 1.75 (s, 3H); 13C NMR (90 MHz, CDCl3): δ 182.0, 168.9, 167.8, 148.5, 140.3, 
129.7, 123.8, 81.1, 65.1, 22.3, 19.6. 
 
(±)-(3S,4R)-4-(2-chloro-6-fluorophenyl)-3-acetoxy-1-(methylthio)azetidin-2-one (137): yellow solid; 
1787, 1745 cm-1 (C=O); 1H NMR 1H NMR (250 MHz, CDCl3): δ  7.35 (ddd, 1H, J = 8.4, 6.3, 2.1 Hz), 6.91 
(t, 2H, J = 8.7 Hz), 5.95 (d, 1H, J = 5.2 Hz), 5.39 (d, 1H, J = 5.2 Hz), 2.38 (s, 3H), 1.81 (s, 3H); 13C NMR 
(63 MHz, CDCl3): δ 168.9, 167.9, 162.2 (dd, app JC-F = 250, 6.8 Hz), 131.4 (t, app JC-F = 10.7 Hz), 112.0, 
111.7, 108.8 (t, app JC-F = 14 Hz), 77.6, 56.8, 21.7, 19.9. 
 
(±)-(3S,4R)-4-(phenyl)-3-hydroxy-azetidin-2-one (141): brown oil; 1H NMR (250 MHz, CDCl3): δ 7.46-
7.26 (m, 5H), 5.17 (d, 1H, J = 5.3 Hz), 4.96 (d, 1H, J = 5.0 Hz), 2.44 (s, 3H). 
 
6.2 Microbiological Test Procedures 
 
The following bacteria were used for the antimicrobial evaluation of N-thiolated β-lactams: Bacillus 
anthracis (Sterne strain), Bacillus cereus (ATCC 14579), Bacillus coagulans (USF 546), Bacillus globigii 
(Department of Defense Reagents Program), Bacillus megaterium (ATCC 14581), Bacillus subtilis 
(19569), Bacillus thuringensis (ATCC 10792), Bacteroides fragalis (obtained from Smith-Kline 
Laboratory), Candida albicans (clinical isolate), Candida tropicalis (clinical isolate), Enterobacter cloace 
(environmental isolate, USF510), Enterococcus gallinarium (ATCC 49573), Enterococcus faecalis (ATCC 
19433), Enterococcus casseliflavus (ATCC 700327), Enterococcus durans (ATCC 6056), Enterococcus 
avirum (ATCC 14025), Enterococcus saccharolyticus (ATCC 43076), Escherichia coli (ATCC 23590), 
Haemophilus influenzae (USF 561), Klebsiella pneumoniae (USF 512), Lactococcus lactis (ATCC 11454), 
Listeria monocytogenes (ATCC 19115), Micrococcus luteus (environmental isolate, USF681), Niesserria 
gonnorheae (obtained from  the Tampa Branch State Laboratory, β-lactamase positive, USF 662), 
Pseudomonas aeruginosa (ATCC 15442), Salmonella typhimurium (obtained from University of South 
Florida Medical Clinic, USF 515), Serratia marcescens (ATCC 29634), Staphylococcus aureus USF525 
(ATCC 25923) Staphylococcus aureus USF652-658 (obtained from Lakeland Regional Medical Center, β-
lactamase positive), Staphylococcus epidermidis (environmental isolate, USF528), Staphylococcus 
saprophyticus (ATCC 35552), Staphylococcus simulans (ATCC 11631), Staphylococcus capitis (ATCC 
35661), Staphylococcus cohnii (ATCC 35662), Staphylococcus lentus (ATCC 700403), Staphylococcus 
lugdunensis (ATCC 700328), Staphylococcus xylosus (ATCC 29971), Streptococcus pyrogenes, 
Streptococcus agalactiae, Vibrio cholerae (biotype E1 Tor Ogawa, cholera toxin positive, CDC E5906),  
 
6.2.1 Antimicrobial Susceptibility Test  
 
Culture preparation: From a freezer stock in tryptic soy broth  (Difco Laboratories, Detroit, MI) and 20% 
glycerol, a culture of each organism was grown on tryptic soy agar (TSA) plates (Becton-Dickinson 
Laboratories, Cockeysville, MD) at 37°C for 24 hours. A 108 suspension was then made in sterile 
phosphate buffered saline (pH 7.2) and swabbed across fresh TSA plates. 
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Disc method: From each 1mg/ml stock solution in dimethyl sulfoxide (DMSO), sterile 6mm paper discs 
(Becton-Dickinson Laboratories, Cockeysville, MD) were impregnated with 20 µl of the test compounds. 
At this concentration, the microliter quantity is equivalent to the micrograms in solution. The discs were 
allowed to dry in a biohazard safety hood then placed onto the inoculated TSA plates. The plates were 
incubated for 24 hours at 37°C and the antimicrobial susceptibilities were determined by measuring the 
zones of growth inhibition around each disc. 
 
Well method: A 108 standardized cell count suspension was then made in sterile phosphate buffered saline 
(pH 7.2) and swabbed across fresh TSA plates. Circular wells (6 mm in diameter) were cut into the 
inoculated plates and 20 µL of a 1 mg/ml stock solution of the test lactam in dimethylsulfoxide (DMSO) 
was pipetted into the wells. The plates were incubated for 24 hours at 37°C and the antimicrobial 
susceptibilities were determined by measuring the zones of growth inhibition around each well. 
 
6.2.2 MIC Calculations 
 
Media preparation: The minimum inhibitory concentrations were determined by the agar plate dilution 
(need reference).  The test media were prepared in 24 well plates (Costar 3524, Cambridge, MA) by adding 
a known concentration of the test drug in DMSO together with a solution of Mueller-Hinton II agar 
(Becton-Dickinson Laboratories, Cockeysville, MD) for a total volume of 1 ml in each well. Calculations 
of the overall concentration of antibiotic in the wells were standardized by measuring from a 1mg/ml stock 
solution of the test drug. At this concentration, the microliter quantity is equivalent to the micrograms in 
solution. The amount of agar solution added to the wells was determined by subtracting 1000 µl from the 
quantity of test drug in each well to give a combined volume of 1 ml. Following preparation of the well 
plates, the media were allowed to solidify at room temperature for 24 hours before inoculation.  
 
Inoculation: From an 24 hour culture of each organism on tryptic soy agar (TSA) plates (Becton-
Dickinson Laboratories, Cockeysville, MD), the staphylococcal strains were grown overnight in 5 ml of 
tryptic soy broth  (Difco Laboratories, Detroit, MI) at 37°C. One microliter of each culture was then 
applied to the appropriate well of agar and incubated at 37°C overnight. After 24 hr, the MICs were 
determined by examining the wells for growth.   
 
6.2.3 Growth Studies 
 
Overnight cultures of the test strains were grown to logarithmic phase in MHB. An inoculum of 106 cfu/ml 
was added to fresh MHB and grown for 1 hr at 35°C while shaking. The test compounds diluted to 1, 5, or 
10 times the MICs in DMSO was applied to each tube. Viable cell counts were determined by plating 
adequate dilutions of each culture. The plates were incubated and colony counts were taken after 24 hrs. 
Turbidity measurements were determined by transferring 0.2 ml aliquots of culture to a 48-well plate 
(Costar 3524, Cambridge, MA) and optical density readings taken at 630 nm with a Bio-Tek EL800 plate 
reader. 
 
6.2.4 Metabolism studies 
 
To a fresh 106 cfu/ml suspension of S. aureus (ATCC 25923) in 9 ml of sterile saline was added 1 ml of a 
400 µM solution of lactam 68 in DMSO. After 1 hr, 10 ml of dH2O was added and the solution was 
extracted 3 times with 5 ml of ethyl acetate. The organic layers were combined, dried with magnesium 
sulfate, and the solvent was removed under reduced pressure. The residue was dissolved in 500 µl of CDCl3 
and the chemical structure was elucidated by 1H NMR. 
 
6.2.5 Scanning Electron Microscopy (SEM) Experiments 
  
Sample preparation: Samples were prepared from sections of agar taken from the disk-diffusion 
experiment. Sterile 6 mm diameter paper discs (Becton-Dickinson Laboratories, Cockeysville, MD) were 
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impregnated with 20 µg of penicillin-G potassium salt (Sigma Chemical Co, St. Louis, MO) and 68 from 
their 1 mg/ml stock solutions in DMSO. From a 24-hour culture of Staphylococcus aureus USF525 (ATCC 
25923) grown on tryptic soy agar (TSA) plates (Becton-Dickinson Laboratories, Cockeysville, MD), a 108 
suspension was made in sterile phosphate buffered saline (pH 7.2) and swabbed across  two separate TSA 
plates. The discs were placed on the inoculated plates and incubated for 24 hours at 37° C. After 24 hours, 
sections of agar in areas containing the division between the  zones of inhibition and lawn of bacteria were 
cut out and placed into Petri dishes for the  SEM preparation.     
 
SEM preparation: The agar sections were flooded with 10 ml of a pre-made glutaraldehyde-osmium 
fixative. After 1 hour, the sections were removed and washed 3 times with 0.1 M sodium cacodylate. The 
samples were then sequentially submerged in 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, and 100% 
ethanol for periods of 5 minute. Following alcohol treatment, the sections were placed into hexamethyl 
disilazane (HMDS) for chemical drying. The samples were next mounted onto stubs and coated with 
gold/palladium by a Pelco Model 3 Sputter Coater.   
 
Scanning electron microscopy. The morphology of the cells was examined with a Novascan 30 scanning 
electron microscope. 
 
6.2.6 Light Microscopy Experiment 
 
Slide preparation: Sterile 6 mm paper discs (Becton-Dickinson Laboratories, Cockeysville, MD) 
containing 20 ug of B3o-4, penicillin-G potassium salt (Sigma Chemical Co, St. Louis, MO) and 
vancomycin hydrochloride (Abbott Laboratory, Chicago, IL) were placed on TSA plates innoculated by S. 
aureus USF525 (ATCC 25923) from an overnight culture.  The plates were incubated at 37° C for 4-5 
hours or until the zones of inhibition were visible. Glass 24 x 60mm coverslips (Corning Glass works, 
Corning, NY) were then gently pressed across the zones to adhere the bacteria. Following heat fixing over a 
Bunsen burner flame, the coverslips were flooded by Gram crystal violet stain (Becton Dickinson 
Laboratories, Cockeysville, MD) for one minute. The coverslips were rinsed with water and flooded by 
Gram iodine (Difco Laboratories, Detroit, MI) for one minute then decolorized by adding 95% ethanol 
dropwise until the crystal violet no longer flowed off the coverslips. The coverslips were rinsed again with 
water  and counterstained with Gram safranin (Difco Laboratories, Detroit, MI) for one minute. They were 
then thoroughly rinsed with water, blotted dry, and mounted on glass microscope slides (Fisher Scientific, 
Pittsburgh, PA). The slides were view with a Nikon LABPHOT Type: 104 bright-field light microscope. 
 
6.2.7 DNA Cleavage Assay 
 
To 17 µl of sodium phosphate buffer (50 mM, pH 7.4) was added 0.5 µg of pBR322 (ICN Biomedicals Inc, 
Aurora, OH) in 200 µl microfuge tubes. 2 µL of 2a at 5, 10, 25, 50, and 100 µM concentrations in DMSO 
were added and the samples were vortexed then incubated at 37°C. After 24 hrs, 2 µl of Blue/Orange 6X 
Loading Dye (Promega Corp., Madison, WI) were added to 8 µl aliquots of the DNA mixtures. The 
samples were loaded on a 1.2% agarose gel (1.8 g medium EEO agarose; 150 ml TAE; 1 µg/ml ethidium 
bromide) and horizontal electrophoresis was performed at 80 V/10 cm for 2.5 hrs in TAE (40 mM Tris-
acetate, pH 7.8, 1 mM EDTA). The agarose gel was visualized and photographed under UV 
transillumination. The same procedure was used in experiments conducted with glutathione, dithiothreitol 
(DTT), and 2-mercaptoethanol. For the enzyme digest samples, 20 µl of sterile dH2O, 2 µl of 100 µM 2a, 
2 µl of restriction enzyme buffer H (90 mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl, pH 7.5), 1 µg of 
pBR322, and 2 µl EcoR1 were added sequentially to a 1.5 ml microfuge tube and incubated in a 37°C 
water bath for 1 hr. 
 
6.2.8 Determination of Thiol Levels in Bacteria 
 
Preparation of cell extracts: Cells from a culture grown at 37°C in LB broth were harvested by 
centrifugation (3100 rpm for 5 min) once an OD650 of 1.0 to 1.5 nm was achieved. The liquid media  is 
removed and 10 ml of sterile dH2O is added to the pellet. Following centrifugation (3100 rpm for 5 min), 
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the water was then removed. One milliliter of warm (60°C) 50% aqueous acetonitrile containing 25 mM 
methanesulfonic acid is added to the tube and vortexed at maximum speed for 1 min. The foamy cell 
extracts were transferred to a 1.5 ml centrifuge tube and incubated in a 60°C water bath for 15 min. The 
protein and the cellular debris are pelleted by centrifugation for 5 min at 8000 rpms.. The acid supernant 
fraction is then removed and analyzed by thiol titration with Ellman’s reagent. 
 
Reagent preparation: 39.6 mg of DTNB is dissolve in 10 ml of  0.5 M potassium phosphate buffer at pH 
7.2.  
 
Measurement of thiol levels: 0.4 ml of the acid thiol extract is transferred to in a 1 ml cuvette followed by 
the addition of  0.5 ml of DNTB. The absorbance of the bright yellow solution was measured at 412 nm 
after 2 mins using dH2O as a blank. Thiol levels (Co) are then calculated by the following equation: 
 
Co = [∆A412 /13,600]D 
  D = dilution factor 
  ∆A412 =  Acuvette1 - Acuvette2     
  where: Acuvette1 = Absorbance of 0.5 ml of DNTB + 0.4 ml of thiol acid extract 
                                                       Acuvette2 = Absorbance of the 0.5 ml of DNTB + 0.4 ml of dH2O. 
 
6.2.9 Macromolecule Synthesis: 
 
The effects of lactam 68 on DNA, RNA, and protein synthesis in S. aureus ATCC 25923 was determined 
by measuring the respective incorporations of [methyl-3H]thymidine, [5-3H]uridine, or L-[4,5-3H]isoleucine 
(Amersham Life Science). Ciprofloxacin, rifampcin, and chloramphenicol were used as controls for the 
inhibition of DNA, RNA, and protein synthesis, respectively. Radioactive precursors were added to early 
logarithmic-phase S. aureus (3 µCi of [methyl-3H]thymidine, 3 µCi of [5-3H]uridine, or 5 µCi of L-[4,5-
3H]isoleucine) in Luria Broth in the presence or absence of an antibiotic at 2x MIC. 
 
To assess the effect on DNA, RNA, and protein synthesis, 50-µl samples were removed from each reaction 
tube are the designated time intervals (5, 10, 20, 30, 45, and 60 min) and precipitated in 1 ml of ice cold 
10% trichloroacetic acid. After 1 hr, the samples were filtered through glass fiber filters (GF/A; Whatman), 
washed with 2 ml of ice-cold 5% trichloroacetic acid and 2 ml of ice-cold 95% ethanol, and dried at room 
temperature overnight. The dried filters were placed in 10 ml vials containing 7 ml of counting fluid 
(Cytoscint, ICN International). Radioactivity was measured by liquid scintilation (Beckman Instruments).  
 
 
 
 
 
 
CHAPTER VII 
 
1H and 13C NMR SPECTRA 
 
Spectrum 7.01: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 37. 
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Spectrum 7.02: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 38. 
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Spectrum 7.03: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 39. 
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Spectrum 7.04: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 40. 
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Spectrum 7.05: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 41. 
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Spectrum 7.06: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 42. 
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Spectrum 7.07: 1H NMR (250 MHz, CDCl3) of β-lactam 43. 
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Spectrum 7.08: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 45. 
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Spectrum 7.09: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 46. 
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Spectrum 7.10: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 47. 
 
 
N
O PMP
CH3O H H
(±)-47
NO2
 
 
 
 100
Spectrum 7.11: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 48. 
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Spectrum 7.12: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 49. 
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Spectrum 7.13: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 50. 
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Spectrum 7.14: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 51. 
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Spectrum 7.15: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 52. 
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Spectrum 7.16: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 53. 
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Spectrum 7.17: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 54. 
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Spectrum 7.18: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 55. 
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Spectrum 7.19: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 56. 
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Spectrum 7.20: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 57. 
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Spectrum 7.21: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 58. 
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Spectrum 7.22: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 60. 
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Spectrum 7.23: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 61. 
 
 
N
O H
CH3O H H
(±)-61
OCH3
 
 
 
 113
Spectrum 7.24: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 62. 
 
 
N
O H
CH3O H H
(±)-62
NO2
 
 
 114
Spectrum 7.25: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 63. 
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Spectrum 7.26: 1H NMR (250 MHz, CDCl3) of β-lactam 64. 
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Spectrum 7.27: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 65. 
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Spectrum 7.28: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 66. 
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Spectrum 7.29: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 70. 
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Spectrum 2.30: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 71. 
 
 
N
O SCH3
CH3O H H
(±)-71 Br
 
 
 
 
 
 120
Spectrum 7.31: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 72. 
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Spectrum 7.32: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 73. 
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Spectrum 7.33: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 74. 
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Spectrum 7.34: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 75. 
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Spectrum 7.36: 1H NMR (250 MHz, CDCl3) of β-lactam 77. 
 
 
N
O SCH3
CH3O H H
(±)-77
NO2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 125
Spectrum 7.37: 1H NMR (360 MHz, CDCl3) of β-lactam 78. 
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Spectrum 7.38: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 81. 
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Spectrum 7.39: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 82. 
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Spectrum 7.40: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 83. 
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Spectrum 7.41: 1H NMR (250 MHz, CDCl3) of β-lactam 88. 
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Spectrum 7.42: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 89. 
 
 
N
O PMP
CH3O H H
(±)-89
Cl
Cl
 
 
 
 131
Spectrum 7.43: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 90. 
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Spectrum 7.44: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 91. 
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Spectrum 7.45: 1H NMR (250 MHz, CDCl3) of β-lactam 92. 
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Spectrum 7.46: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 94. 
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Spectrum 7.47: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 95. 
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Spectrum 7.48: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 97. 
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Spectrum 7.49: 1H NMR (360 MHz, CDCl3) and 13C NMR (90 MHz, CDCl3) of β-lactam 98. 
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Spectrum 7.50: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 99. 
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Spectrum 7.51: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 108. 
 
 
N
O S
CH3O H H
(±)-108
 
 
 
 140
 
Spectrum 7.52: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 110. 
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Spectrum 7.53: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 117. 
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Spectrum 7.54: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3) of β-lactam 125. 
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Spectrum 7.55: 1H NMR (360 MHz, CDCl3) of β-lactam 133. 
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Spectrum 7.56: 1H NMR (360 MHz, CDCl3) and 13C NMR (90 MHz, CDCl3) of β-lactam 135. 
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Spectrum 7.57: 1H NMR (250 MHz, CDCl3) and 13C NMR (63 MHz, CDCl3)of β-lactam 137. 
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